NZ624072B2 - Combination therapies using anti- pseudomonas psl and pcrv binding molecules - Google Patents
Combination therapies using anti- pseudomonas psl and pcrv binding molecules Download PDFInfo
- Publication number
- NZ624072B2 NZ624072B2 NZ624072A NZ62407212A NZ624072B2 NZ 624072 B2 NZ624072 B2 NZ 624072B2 NZ 624072 A NZ624072 A NZ 624072A NZ 62407212 A NZ62407212 A NZ 62407212A NZ 624072 B2 NZ624072 B2 NZ 624072B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- seq
- antibody
- binding
- amino acid
- pseudomonas
- Prior art date
Links
- 230000027455 binding Effects 0.000 title claims abstract description 530
- 230000000244 anti-pseudomonad Effects 0.000 title description 62
- 238000002648 combination therapy Methods 0.000 title description 4
- 241000589516 Pseudomonas Species 0.000 claims abstract description 142
- 102000004965 antibodies Human genes 0.000 claims description 618
- 108090001123 antibodies Proteins 0.000 claims description 618
- 239000000427 antigen Substances 0.000 claims description 180
- 108091007172 antigens Proteins 0.000 claims description 173
- 102000038129 antigens Human genes 0.000 claims description 173
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 136
- 239000000203 mixture Substances 0.000 claims description 120
- 229920000023 polynucleotide Polymers 0.000 claims description 86
- 239000002157 polynucleotide Substances 0.000 claims description 85
- 102000018358 Immunoglobulins Human genes 0.000 claims description 48
- 108060003951 Immunoglobulins Proteins 0.000 claims description 48
- 150000007523 nucleic acids Chemical group 0.000 claims description 47
- 150000001413 amino acids Chemical class 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 23
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 22
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 206010061471 Pseudomonas infection Diseases 0.000 claims description 10
- ZVNPWFOVUDMGRP-UHFFFAOYSA-N Metol Chemical compound OS(O)(=O)=O.CNC1=CC=C(O)C=C1.CNC1=CC=C(O)C=C1 ZVNPWFOVUDMGRP-UHFFFAOYSA-N 0.000 claims 1
- 235000007959 Psilotum nudum Nutrition 0.000 claims 1
- 229920000591 gum Polymers 0.000 claims 1
- 108010071919 Bispecific Antibodies Proteins 0.000 abstract description 3
- 210000004027 cells Anatomy 0.000 description 145
- 201000009910 diseases by infectious agent Diseases 0.000 description 122
- 229920001184 polypeptide Polymers 0.000 description 118
- 235000001014 amino acid Nutrition 0.000 description 95
- 102000005614 monoclonal antibodies Human genes 0.000 description 73
- 108010045030 monoclonal antibodies Proteins 0.000 description 73
- 230000000694 effects Effects 0.000 description 61
- 238000000034 method Methods 0.000 description 59
- 238000006467 substitution reaction Methods 0.000 description 58
- 230000014509 gene expression Effects 0.000 description 54
- 230000004083 survival Effects 0.000 description 54
- 241001465754 Metazoa Species 0.000 description 52
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 48
- 125000005647 linker group Chemical group 0.000 description 48
- 229960003405 ciprofloxacin Drugs 0.000 description 44
- 238000004166 bioassay Methods 0.000 description 41
- 108020004707 nucleic acids Proteins 0.000 description 41
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 40
- 235000018102 proteins Nutrition 0.000 description 39
- 102000004169 proteins and genes Human genes 0.000 description 39
- 108090000623 proteins and genes Proteins 0.000 description 39
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 35
- 210000004072 Lung Anatomy 0.000 description 34
- DMJNNHOOLUXYBV-PQTSNVLCSA-N Meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 34
- 229960002260 meropenem Drugs 0.000 description 34
- 210000000056 organs Anatomy 0.000 description 33
- 150000002500 ions Chemical class 0.000 description 31
- 229960000060 monoclonal antibodies Drugs 0.000 description 30
- 206010035664 Pneumonia Diseases 0.000 description 29
- 230000001225 therapeutic Effects 0.000 description 28
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 26
- 230000002147 killing Effects 0.000 description 25
- 238000002965 ELISA Methods 0.000 description 24
- 210000000952 Spleen Anatomy 0.000 description 24
- 230000003115 biocidal Effects 0.000 description 24
- 229920001405 Coding region Polymers 0.000 description 23
- 102000004851 Immunoglobulin G Human genes 0.000 description 23
- 230000009089 cytolysis Effects 0.000 description 23
- 230000002934 lysing Effects 0.000 description 23
- 206010022114 Injury Diseases 0.000 description 22
- 210000003734 Kidney Anatomy 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 22
- 238000002560 therapeutic procedure Methods 0.000 description 22
- 210000001519 tissues Anatomy 0.000 description 22
- 210000003324 RBC Anatomy 0.000 description 21
- 230000001580 bacterial Effects 0.000 description 21
- 101700027814 CDR3 Proteins 0.000 description 20
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 20
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 20
- 230000002195 synergetic Effects 0.000 description 20
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 18
- 238000011156 evaluation Methods 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 230000001965 increased Effects 0.000 description 17
- 231100000518 lethal Toxicity 0.000 description 15
- 230000001665 lethal Effects 0.000 description 15
- 230000035772 mutation Effects 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 210000004408 Hybridomas Anatomy 0.000 description 14
- 241000108056 Monas Species 0.000 description 14
- 229940079593 drugs Drugs 0.000 description 14
- 230000004048 modification Effects 0.000 description 14
- 238000006011 modification reaction Methods 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 210000002919 epithelial cells Anatomy 0.000 description 13
- 230000003993 interaction Effects 0.000 description 13
- 230000035897 transcription Effects 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 12
- 210000003743 Erythrocytes Anatomy 0.000 description 12
- 210000001508 Eye Anatomy 0.000 description 12
- 230000003247 decreasing Effects 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 230000001939 inductive effect Effects 0.000 description 12
- 238000002823 phage display Methods 0.000 description 12
- WZPBZJONDBGPKJ-VEHQQRBSSA-N Aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 11
- 229960003644 Aztreonam Drugs 0.000 description 11
- 229920002676 Complementary DNA Polymers 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 11
- NLVFBUXFDBBNBW-PBSUHMDJSA-N Tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 11
- 229960000707 Tobramycin Drugs 0.000 description 11
- 230000001154 acute Effects 0.000 description 11
- 230000000996 additive Effects 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 230000000875 corresponding Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 11
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 10
- 108020004999 Messenger RNA Proteins 0.000 description 10
- 108020004511 Recombinant DNA Proteins 0.000 description 10
- 108091006028 chimera Proteins 0.000 description 10
- 230000000295 complement Effects 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- 108020001507 fusion proteins Proteins 0.000 description 10
- 102000037240 fusion proteins Human genes 0.000 description 10
- 229920002106 messenger RNA Polymers 0.000 description 10
- 230000001603 reducing Effects 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 210000004962 mammalian cells Anatomy 0.000 description 9
- 230000002829 reduced Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 230000035693 Fab Effects 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 210000002966 Serum Anatomy 0.000 description 8
- 206010040872 Skin infection Diseases 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 230000000670 limiting Effects 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 230000000625 opsonophagocytic Effects 0.000 description 8
- 230000002265 prevention Effects 0.000 description 8
- 230000036947 Dissociation constant Effects 0.000 description 7
- 230000036499 Half live Effects 0.000 description 7
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 7
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 7
- 241000229754 Iva xanthiifolia Species 0.000 description 7
- 108010093965 Polymyxin B Proteins 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 230000001419 dependent Effects 0.000 description 7
- 230000001809 detectable Effects 0.000 description 7
- 230000002708 enhancing Effects 0.000 description 7
- 150000004676 glycans Polymers 0.000 description 7
- 230000001404 mediated Effects 0.000 description 7
- 229960005266 polymyxin B Drugs 0.000 description 7
- 229920000024 polymyxin B Polymers 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 150000004804 polysaccharides Polymers 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- 230000000717 retained Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102100008989 IGHV1-2 Human genes 0.000 description 6
- 101710003461 IGHV1-2 Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 6
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 244000052616 bacterial pathogens Species 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 210000003527 eukaryotic cell Anatomy 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000002703 mutagenesis Methods 0.000 description 6
- 231100000350 mutagenesis Toxicity 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 230000001717 pathogenic Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000000159 protein binding assay Methods 0.000 description 6
- 230000003248 secreting Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 238000002741 site-directed mutagenesis Methods 0.000 description 6
- 241000699800 Cricetinae Species 0.000 description 5
- 229940088598 Enzyme Drugs 0.000 description 5
- 206010023332 Keratitis Diseases 0.000 description 5
- 231100000765 Toxin Toxicity 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 230000003042 antagnostic Effects 0.000 description 5
- 230000002587 anti-hemolytic Effects 0.000 description 5
- 230000000890 antigenic Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 230000005714 functional activity Effects 0.000 description 5
- 230000002068 genetic Effects 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000001325 log-rank test Methods 0.000 description 5
- 239000002609 media Substances 0.000 description 5
- 238000010369 molecular cloning Methods 0.000 description 5
- 238000004091 panning Methods 0.000 description 5
- 244000052769 pathogens Species 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 101700047239 pslA Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 108020003112 toxins Proteins 0.000 description 5
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 4
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 4
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 4
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 4
- 206010003997 Bacteraemia Diseases 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 4
- 229940088516 Cipro Drugs 0.000 description 4
- 230000037250 Clearance Effects 0.000 description 4
- 210000004087 Cornea Anatomy 0.000 description 4
- 206010061788 Corneal infection Diseases 0.000 description 4
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 4
- 229920002444 Exopolysaccharide Polymers 0.000 description 4
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 4
- 101710009640 IGKV1D-8 Proteins 0.000 description 4
- 101710024481 IGKV2-29 Proteins 0.000 description 4
- 101710009635 IGKV2D-26 Proteins 0.000 description 4
- 102100005978 IGKV3-20 Human genes 0.000 description 4
- 101710024987 IGKV3-20 Proteins 0.000 description 4
- 101710009651 IGKV3D-15 Proteins 0.000 description 4
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 4
- 210000001672 Ovary Anatomy 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 241000362224 Pseudomonas aeruginosa 6077 Species 0.000 description 4
- 229940035295 Ting Drugs 0.000 description 4
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000035512 clearance Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000001332 colony forming Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000003899 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 230000001976 improved Effects 0.000 description 4
- 229940079866 intestinal antibiotics Drugs 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 230000001264 neutralization Effects 0.000 description 4
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- -1 tides Proteins 0.000 description 4
- 230000000699 topical Effects 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 102000006395 Globulins Human genes 0.000 description 3
- 108010044091 Globulins Proteins 0.000 description 3
- 102000005720 Glutathione Transferase family Human genes 0.000 description 3
- 108010070675 Glutathione Transferase family Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 229920000272 Oligonucleotide Polymers 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 210000001747 Pupil Anatomy 0.000 description 3
- IUHPMMLFTNIXHM-UHFFFAOYSA-N [5-(2-amino-6-oxo-3H-purin-9-yl)-2-[[[5-(2-amino-6-oxo-3H-purin-9-yl)-2-[[[5-(2-amino-6-oxo-3H-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl]oxy-hydroxyphosphoryl]oxymethyl]oxolan-3-yl] [5-(2-amino-6-oxo-3H-purin-9-y Chemical compound C1=NC(C(N=C(N)N2)=O)=C2N1C(OC1COP(O)(=O)OC2C(OC(C2)N2C3=C(C(N=C(N)N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(N=C(N)N3)=O)N=C2)CO)CC1OP(O)(=O)OCC(O1)C(O)CC1N1C=NC2=C1NC(N)=NC2=O IUHPMMLFTNIXHM-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000240 adjuvant Effects 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 102000024070 binding proteins Human genes 0.000 description 3
- 108091007650 binding proteins Proteins 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 230000001413 cellular Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002224 dissection Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 101700055141 exoU Proteins 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 238000002825 functional assay Methods 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 230000002757 inflammatory Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000036961 partial Effects 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000003389 potentiating Effects 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrugs Drugs 0.000 description 3
- 230000001737 promoting Effects 0.000 description 3
- 230000002633 protecting Effects 0.000 description 3
- 230000001681 protective Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000001105 regulatory Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000002103 transcriptional Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 101710027066 ALB Proteins 0.000 description 2
- 210000003719 B-Lymphocytes Anatomy 0.000 description 2
- 210000000988 Bone and Bones Anatomy 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010051548 Burn infection Diseases 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 210000000349 Chromosomes Anatomy 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 2
- 101710007887 DHFR Proteins 0.000 description 2
- 201000005804 Eastern equine encephalitis Diseases 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 210000003608 Feces Anatomy 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 229960001031 Glucose Drugs 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 210000000224 Granular leucocyte Anatomy 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282619 Hylobates lar Species 0.000 description 2
- 229960000310 ISOLEUCINE Drugs 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
- 229920002459 Intron Polymers 0.000 description 2
- 210000003127 Knee Anatomy 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 102000003855 L-lactate dehydrogenases Human genes 0.000 description 2
- 108091000084 L-lactate dehydrogenases Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 101700026702 LE10 Proteins 0.000 description 2
- AAXCQFOXUJMCCW-PETQGJDISA-N LPS core Chemical compound O([C@H]1[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]([C@@H](CO[C@]2(O[C@@H]([C@@H](OC3[C@H]([C@@H](OC4[C@H]([C@@H](OC5[C@@H]([C@@H](O[C@@H]6[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O6)OC6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O6)NC(C)=O)[C@H](O)[C@@H](CO[C@@H]6[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O6)O)O5)O)[C@H](O)[C@@H]([C@@H](O)COC5[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O5)O)O4)O)[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)O3)O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](O[C@]4(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C4)[C@@H](O)CO)C(O)=O)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)O1)OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C[C@H]1O[C@H](OP(O)(O)=O)[C@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H]1O AAXCQFOXUJMCCW-PETQGJDISA-N 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 108060004843 Mical Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000000440 Neutrophils Anatomy 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 229960005190 Phenylalanine Drugs 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 241000168225 Pseudomonas alcaligenes Species 0.000 description 2
- 210000004915 Pus Anatomy 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000235070 Saccharomyces Species 0.000 description 2
- 210000003491 Skin Anatomy 0.000 description 2
- 210000003802 Sputum Anatomy 0.000 description 2
- 235000019892 Stellar Nutrition 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 2
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 101710042194 Trpgamma Proteins 0.000 description 2
- 210000002700 Urine Anatomy 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000037348 biosynthesis Effects 0.000 description 2
- 230000000903 blocking Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000002860 competitive Effects 0.000 description 2
- 230000001010 compromised Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 201000003883 cystic fibrosis Diseases 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000003292 diminished Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000001747 exhibiting Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002458 infectious Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000977 initiatory Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000000051 modifying Effects 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- 230000001402 polyadenylating Effects 0.000 description 2
- 108091008117 polyclonal antibodies Proteins 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- 230000002797 proteolythic Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002285 radioactive Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 102220222936 rs1060502586 Human genes 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000002194 synthesizing Effects 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- YMXHPSHLTSZXKH-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanoate Chemical compound S1CC2NC(=O)NC2C1CCCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-UHFFFAOYSA-N 0.000 description 1
- NKCXQMYPWXSLIZ-PSRDDEIFSA-N (2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-m Chemical compound O=C([C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O NKCXQMYPWXSLIZ-PSRDDEIFSA-N 0.000 description 1
- OWFJMIVZYSDULZ-PXOLEDIWSA-N (4S,4aR,5S,5aR,6S,12aR)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O OWFJMIVZYSDULZ-PXOLEDIWSA-N 0.000 description 1
- MHKBMNACOMRIAW-UHFFFAOYSA-N 2,3-dinitrophenol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O MHKBMNACOMRIAW-UHFFFAOYSA-N 0.000 description 1
- ZPZDIFSPRVHGIF-UHFFFAOYSA-N 3-aminopropylsilicon Chemical compound NCCC[Si] ZPZDIFSPRVHGIF-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 101710006746 7.5K Proteins 0.000 description 1
- 102100007409 APRT Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010069351 Acute lung injury Diseases 0.000 description 1
- 108010024223 Adenine Phosphoribosyltransferase Proteins 0.000 description 1
- 208000009956 Adenocarcinoma Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 244000303258 Annona diversifolia Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 1
- 241001550224 Apha Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241001112741 Bacillaceae Species 0.000 description 1
- 240000008371 Bacillus subtilis Species 0.000 description 1
- 229940075615 Bacillus subtilis Drugs 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 230000037177 Biodistribution Effects 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000310637 Capillipedium spicigerum Species 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 102100005838 DHFR Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 101700011961 DPOM Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 108020004461 Double-Stranded RNA Proteins 0.000 description 1
- 108010091358 EC 2.4.2.8 Proteins 0.000 description 1
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 1
- 210000001671 Embryonic Stem Cells Anatomy 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 210000003935 Endoplasmic Reticulum, Rough Anatomy 0.000 description 1
- 210000002889 Endothelial Cells Anatomy 0.000 description 1
- 206010067410 Endotoxaemia Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 206010016334 Feeling hot Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 101700014779 GLB1 Proteins 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N Guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 102100016790 HPRT1 Human genes 0.000 description 1
- 229940047650 Haemophilus influenzae Drugs 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 1
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 1
- 229960002591 Hydroxyproline Drugs 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 210000001822 Immobilized Cells Anatomy 0.000 description 1
- 108090000745 Immune Sera Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 210000003000 Inclusion Bodies Anatomy 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KMPDEGCQSA-N Inosine Natural products O[C@H]1[C@H](O)[C@@H](CO)O[C@@H]1N1C(N=CNC2=O)=C2N=C1 UGQMRVRMYYASKQ-KMPDEGCQSA-N 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229940047124 Interferons Drugs 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229940047122 Interleukins Drugs 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 229940065638 Intron A Drugs 0.000 description 1
- 108020004391 Introns Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine zwitterion Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108060001084 Luciferase family Proteins 0.000 description 1
- 206010061229 Lung infection Diseases 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 210000003563 Lymphoid Tissue Anatomy 0.000 description 1
- 101710029649 MDV043 Proteins 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 101710017500 MitHPPK/DHPS Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 229960000951 Mycophenolic Acid Drugs 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- 101710004953 NGR_a03520 Proteins 0.000 description 1
- 210000001331 Nose Anatomy 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 229960003104 Ornithine Drugs 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 101700040790 PH Proteins 0.000 description 1
- 101700061424 POLB Proteins 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 241001272996 Polyphylla fullo Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 101700054624 RF1 Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010033725 Recombinant Proteins Proteins 0.000 description 1
- 102000007312 Recombinant Proteins Human genes 0.000 description 1
- 210000003705 Ribosomes Anatomy 0.000 description 1
- 241000724205 Rice stripe tenuivirus Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039447 Salmonellosis Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine Kinase Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 108010069584 Type III Secretion Systems Proteins 0.000 description 1
- 230000036462 Unbound Effects 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 240000000038 Ziziphus mauritiana Species 0.000 description 1
- 235000006545 Ziziphus mauritiana Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000003314 affinity selection Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000024126 agglutination involved in conjugation with cellular fusion Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 101700064588 algD Proteins 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000001178 bacterial pneumonia Diseases 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 201000009030 carcinoma Diseases 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000023298 conjugation with cellular fusion Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 108010002591 epsilon receptor Proteins 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 101700037230 galU Proteins 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 101700046795 gtaB Proteins 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 108060003552 hemocyanin family Proteins 0.000 description 1
- 230000002949 hemolytic Effects 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000984 immunochemical Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 101700049451 lppL Proteins 0.000 description 1
- 230000002101 lytic Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 101700077224 mom-2 Proteins 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 230000003472 neutralizing Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000036963 noncompetitive Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 244000039328 opportunistic pathogens Species 0.000 description 1
- 230000001662 opsonic Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000003169 placental Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional Effects 0.000 description 1
- 230000001323 posttranslational Effects 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000770 pro-inflamatory Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 230000036678 protein binding Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001718 repressive Effects 0.000 description 1
- 238000004805 robotic Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 125000003616 serine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- KISFEBPWFCGRGN-UHFFFAOYSA-M sodium;2-(2,4-dichlorophenoxy)ethyl sulfate Chemical compound [Na+].[O-]S(=O)(=O)OCCOC1=CC=C(Cl)C=C1Cl KISFEBPWFCGRGN-UHFFFAOYSA-M 0.000 description 1
- 230000000392 somatic Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atoms Chemical group 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 230000005700 syncytium formation by plasma membrane fusion Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N trans-L-hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000001296 transplacental Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
- 102000037275 μ-opioid receptors Human genes 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Disclosed are bispecific antibodies comprising a binding domain that binds to Pseudomonas Psl and a binding domain that binds to Pseudomonas PcrV.
Description
COMBINATION THERAPIES USING ANTI— PSEUDOMONAS PSL AND PCRV BINDING
MOLECULES
REFERENCE TO CE LISTING SUBMITTED ONICALLY
The t of the electronically submitted sequence listing in ASCII text file
entitled sequencelisting_PCTascii.txt created on November 6, 2012 and having a size of
382 kilobytes filed with the application is incorporated herein by reference in its entirety.
BACKGROUND
Field of the Disclosure
This disclosure relates to combination therapies using seudomonas Psl and
Pch binding domains for use in the prevention and treatment of Pseudomonas infection.
Furthermore, the disclosure provides compositions useful in such ies.
Background of the Disclosure
Pseudomonas aeruginosa (P. aeruginosa) is a gram—negative opportunistic
pathogen that causes both acute and chronic infections in compromised individuals (Ma et
al., Journal of iology 189(22):8353—8356 (2007)). This is partly due to the high
innate resistance of the bacterium to clinically used antibiotics, and partly due to the
formation of highly antibiotic-resistant biofilms (Drenkard E., Microbes Infect 531213—
1219 (2003); Hancokc & Speert, Drug Resist Update 3247—255 ).
P. aeruginosa is a common cause of hospital—acquired infections in the Western
world. It is a frequent causative agent of bacteremia in burn victims and immune
compromised individuals (Lyczak et al., Microbes Infect 231051—1060 (2000)). It is also
the most common cause of nosocomial gram—negative pneumonia (Craven et al., Semin
Respir Infect 11:32—53 ), especially in mechanically ated patients, and is the
most prevalent pathogen in the lungs of individuals with cystic fibrosis (Pier et al., ASM
News 6:339—347 (1998)).
Pseudomonas Ps1 exopolysaccharide is reported to be anchored to the e of
P. nosa and is thought to be important in facilitating colonization of host tissues
and in establishing/maintaining biofilm formation (Jackson, K.D., et al., J Bacteriol 186,
4466—4475 (2004)). Its structure comprises mannose-rich repeating pentasaccharide
(Byrd, M.S., et al., Mol Microbiol 73, 622—638 (2009)).
Pch is a relatively conserved component of the type III secretion . Pch
appears to be an integral component of the translocation apparatus of the type III
secretion system mediating the ry of the type III secretory toxins into target
eukaryotic cells (Sawa T., et al. Nat. Med. 5, 392—398 ). Active and passive
immunization against Pch improved acute lung injury and mortality of mice ed
with cytotoxic P. aeruginosa (Sawa et a]. 2009). The major effect of zation
t Pch was due to the blockade of translocation of the type III secretory toxins into
eukaryotic cells.
Due to increasing rug resistance, there remains a need in the art for the
development of novel strategies for the identification of new Pseudomonas-specific
prophylactic and therapeutic agents.
BRIEF SUMMARY
The disclosure provides a binding molecule or antigen binding fragment f
that specifically binds Pseudomonas Pch, which comprises: (a) a heavy chain CDRl
comprising SYAMN (SEQ ID NO:218), or a variant thereof comprising 1, 2, 3, or 4
conservative amino acid substitutions; a heavy chain CDR2 comprising
AITISGITAYYTDSVKG (SEQ ID NO: 219), or a variant thereof comprising 1, 2, 3, or 4
conservative amino acid substitutions; and a heavy chain CDR3 comprising
EEFLPGTHYYYGMDV (SEQ ID NO: 220), or a t thereof comprising 1, 2, 3, or 4
conservative amino acid substitutions; (b) a light chain CDRl comprising
RASQGIRNDLG (SEQ ID NO: 221), or a variant thereof comprising 1, 2, 3, or 4
conservative amino acid substitutions; a light chain CDR2 comprising SASTLQS (SEQ
ID NO: 222), or a variant thereof comprising 1, 2, 3, or 4 conservative amino acid
substitutions; and a light chain CDR3 comprising LQDYNYPWT (SEQ ID NO: 223), or
a variant thereof comprising 1, 2, 3, or 4 conservative amino acid substitutions; or
combinations of (a) and (b). In one embodiment, the binding molecule or antigen binding
fragment thereof specifically binds Pseudomonas Pch, and comprises: (a) a heavy chain
CDRl comprising SYAMN (SEQ ID NO: 218), a heavy chain CDR2 comprising
AITISGITAYYTDSVKG (SEQ ID NO: 219), and a heavy chain CDR3 comprising
EEFLPGTHYYYGMDV (SEQ ID NO: 220); and (b) a light chain CDRl comprising
RNDLG (SEQ ID NO: 221), a light chain CDR2 comprising S (SEQ
ID NO: 222), and a light chain CDR3 comprising LQDYNYPWT (SEQ ID NO: 223). In
one embodiment, the isolated binding le or antigen binding fragment thereof
specifically binds Pseudomonas Pch and comprises (a) a heavy chain variable region
having at least 90% sequence identity to SEQ ID NO: 216; (b) a light chain le
region having at least 90% sequence identity to SEQ ID NO: 217; or combinations of (a)
and (b). In another embodiment, the binding molecule or fragment f comprises: (a)
a heavy chain variable region having at least 95% sequence identity to SEQ ID NO: 216;
(b) a light chain variable region having at least 95% sequence identity to SEQ ID NO:
217; or combinations of (a) and (b). In another embodiment, the binding molecule or
fragment thereof is V2L2 and comprises: (a) a heavy chain variable region comprising
SEQ ID NO: 216; and (b) a light chain variable region comprising SEQ ID NO: 217.
In one ment, the disclosure provides an isolated binding molecule or
antigen binding fragment thereof that specifically binds to the same Pseudomonas Pch
epitope as an antibody or antigen-binding fragment f comprising the VH and VL
region of V2L2. In another embodiment, the disclosure provides an ed binding
molecule or antigen binding fragment thereof that specifically binds to Pseudomonas
Pch, and competitively inhibits Pseudomonas Pch g by an antibody or antigen-
binding fragment thereof comprising the VH and VL of V2L2. In one embodiment, the
binding le or fragment thereof is a recombinant antibody. In one ment, the
binding molecule or fragment thereof is a monoclonal antibody. In one embodiment, the
binding molecule or fragment thereof is a chimeric antibody. In one embodiment, the
binding molecule or nt thereof is a humanized antibody. In one embodiment, the
g molecule or fragment thereof is a human antibody. In one embodiment, the
binding molecule or fragment thereof is a bispeciflc antibody.
In one embodiment, the g molecule or fragment thereof inhibits delivery of
type III secretory toxins into target cells.
In one embodiment, the sure provides a bispecif1c antibody comprising a
binding domain that binds to Pseudomonas Psl and a binding domain that binds to
Pseudomonas Pch. In one embodiment, the Ps1 binding domain comprises a scFv
nt and the Pch binding domain comprises an intact immunoglobulin. In one
embodiment, the Psl binding domain comprises an intact immunoglobulin and said Pch
g domain comprises a scFv nt. In one embodiment, the scFv is fused to the
amino-terminus of the VH region of the intact immunoglobulin. In one embodiment, the
scFv is fused to the carboxy—terminus of the CH3 region of the intact immunoglobulin. In
one embodiment, the scFV is inserted in the hinge region of the intact immunoglobulin.
In one embodiment, the anti-Psl binding domain cally binds to the same
Pseudomonas Psl epitope as an antibody or antigen-binding fragment f comprising
the heavy chain variable region (VH) and light chain le region (VL) region at least
90% identical to the ponding region of WapR—004. In one embodiment, the anti—Psl
binding domain specifically binds to Pseudomonas Psl, and competitively inhibits
Pseudomonas Psl binding by an antibody or antigen-binding nt thereof comprising
a VH and VL region at least 90% identical to the corresponding region of WapR—004. In
one embodiment, the VH and VL of WapR—004 se SEQ ID NO:11 and SEQ ID
NO:12, respectively. In one embodiment, the WapR—004 sequence is selected from the
group consisting of: SEQ ID NO:228, SEQ ID NO:229, and SEQ ID NO:235. In one
embodiment, the anti-Pch binding domain specifically binds to the same Pseudomonas
Pch epitope as an antibody or antigen-binding fragment thereof comprising the VH and
VL region of V2L2. In one embodiment, the anti-Pch binding domain specifically binds
to Pseudomonas Pch, and competitively inhibits Pseudomonas Pch binding by an
antibody or antigen-binding fragment thereof comprising the VH and VL of V2L2. In
another embodiment, the anti-Pch binding domain specifically binds to the same
Pseudomonas Pch epitope as an antibody or antigen-binding fragment thereof
comprising a VH and VL region at least 90% identical to the corresponding region of
V2L2. In one embodiment, the VH and VL of V2L2 comprise SEQ ID NO:216 and SEQ
ID NO:217, respectively. In one embodiment, the VH and VL of WapR—004 (SEQ ID
NOs:11 and 12, respectively) and the VH and VL of V2L2 (SEQ ID NOs: 216 and 217,
respectively). In one embodiment, the bispecific antibody comprises an amino acid
sequence selected from the group consisting of: SEQ ID , SEQ ID NO:229, and
SEQ ID NO:235.
In one embodiment, the sure provides a polypeptide comprising an amino
acid sequence of SEQ ID NO:216 or SEQ ID . In one embodiment, the
polypeptide is an antibody.
In one embodiment, the disclosure es a cell comprising or producing the
binding le or polypeptide sed herein.
In one embodiment, the disclosure provides an isolated polynucleotide molecule
sing a cleotide that encodes a binding molecule or polypeptide described
herein. In one embodiment, the polynucleotide le comprises a polynucleotide
sequence selected from the group consisting of: SEQ ID NO:238 and SEQ ID NO:239.
In another embodiment, the disclosure provides a vector comprising a polynucleotide
described herein. In another embodiment, the disclosure provides a cell sing a
polynucleotide or vector.
In one embodiment, the disclosure provides a ition comprising a binding
le, bispecif1c antibody, or polypeptide described herein and a pharmaceutically
acceptable carrier.
In one embodiment, the disclosure provides a composition comprising a binding
domain that binds to Pseudomonas Psl and a binding domain that binds to Pseudomonas
Pch. In one embodiment, the anti-Psl binding domain specifically binds to the same
Pseudomonas Psl epitope as an dy or antigen-binding fragment thereof comprising
the heavy chain variable region (VH) and light chain variable region (VL) region at least
90% identical to the corresponding region of WapR—004, Cam—003, Cam—004, Cam—005,
WapR—OOl, WapR—OOZ, WapR—003, or WapR—Ol6. In one embodiment, the anti-Psl
binding domain specifically binds to Pseudomonas Psl, and competitively inhibits
Pseudomonas Psl binding by an antibody or antigen-binding fragment thereof comprising
a VH and VL region at least 90% identical to the corresponding region of WapR—004,
Cam—003, Cam—004, Cam—005, WapR—OOl, WapR—002, WapR—003, or WapR—Ol6. In one
embodiment, the VH and VL of WapR-004 comprise SEQ ID NO: 11 and SEQ ID I\O: 12,
tively, the VH and VL of Cam—003 comprise SEQ ID NO:1 and SEQ ID \IO:2,
respectively, the VH and VL of Cam—004 comprise SEQ ID NO:3 and SEQ ID \IO:2,
respectively, the VH and VL of Cam—005 comprise SEQ ID NO:4 and SEQ ID \IO:2,
respectively, the VH and VL of WapR—OOl se SEQ ID NO:5 and SEQ ID \IO:6,
respectively, the VH and VL of WapR—002 se SEQ ID NO:7 and SEQ ID \IO:8,
respectively, the VH and VL of WapR—003 comprise SEQ ID N09 and SEQ ID l\O:lO,
respectively, and the VH and VL of WapR—Ol6 se SEQ ID NO: 15 and SEQ ID
NO: 16, respectively. In one embodiment, the anti-Pch binding domain specifically
binds to the same Pseudomonas Pch epitope as an antibody or antigen-binding nt
thereof comprising the VH and VL region of V2L2. In one ment, the anti-Pch
binding domain specifically binds to Pseudomonas Pch, and competitively inhibits
Pseudomonas Pch binding by an antibody or antigen-binding fragment thereof
comprising the VH and VL of V2L2. In one ment, the anti-Pch binding domain
specif1cally binds to the same Pseudomonas Pch e as an antibody or antigenbinding
fragment thereof comprising a VH and VL region at least 90% identical to the
corresponding region of V2L2. In one embodiment, the VH and VL of V2L2 comprise
SEQ ID NO:2l6 and SEQ ID NO:217, respectively. In one embodiment, the anti-Psl
binding domain comprises the VH and VL region of WapR-004, and said anti-Pch
binding domain comprises the VH and VL region of V2L2, or antigen-binding fragments
thereof
In one embodiment, the composition comprises a first binding molecule
comprising said anti Psl-binding domain, and a second binding molecule comprising a
Pch-binding domain. In one embodiment, the first g molecule is an antibody or
antigen binding fragment f, and said second binding molecule is an antibody or
antigen g fragment thereof. In one embodiment, the antibodies or antigen binding
fragments are independently ed from the group consisting of: monoclonal,
humanized, ic, human, Fab fragment, Fab' fragment, F(ab)2 fragment, and scFv
fragment. In one embodiment, the binding s, binding molecules or fragments
thereof, bind to two or more, three or more, four or more, or five or more different P.
aeruginosa serotypes. In one embodiment, the binding domains, binding molecules or
fragments thereof, bind to at least 80%, at least 85%, at least 90% or at least 95% of P.
aeruginosa strains isolated from infected patients. In one embodiment, the P. aeruginosa
strains are isolated from one or more of lung, sputum, eye, pus, feces, urine, sinus, a
wound, skin, blood, bone, or knee fluid. In one embodiment, the antibody or antigen
g fragment thereof is conjugated to an agent selected from the group consisting of
antimicrobial agent, a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a
lipid, a biological response modifier, ceutical agent, a lymphokine, a heterologous
antibody or nt thereof, a detectable label, hylene glycol (PEG), and a
combination of two or more of any said . In one embodiment, the detectable label
is selected from the group consisting of an enzyme, a fluorescent label, a
chemiluminescent label, a bioluminescent label, a radioactive label, or a combination of
two or more of any said detectable labels.
(Followed by page 7A)
] In one embodiment the disclosure provides for the use of the binding molecule
or fragment thereof, a bispecific antibody, a polypeptide, or a composition thereof as
described herein in the manufacture of a ment for preventing or treating a
Pseudomonas infection in a subject in need thereof.
[0020b] In a preferred embodiment, the sure provides for the use of a
composition comprising a bispecific antibody comprising a binding domain that binds
to monas Psl and a binding domain that binds to Pseudomonas PcrV in the
manufacture of a medicament for preventing or treating a Pseudomonas infection in a
subject in need thereof.
-7A-
wed by page 8)
aeruginosa 3064 A WapR (1) or P. aeruginosa PAOl MexAB OprM A WapR (2) in
suspension. Bars te the output titers (in CPU) at each round of selection, and circles
indicate the proportion of duplicated VH CDR3 sequences, an indication of clonal
ment. (E) ELISA screen of scFv from phage display to test binding to multiple
strains of P. aeruginosa. ELISA data (absorbance at 450 nm) are shown for eight
individual phage-scFvs from selections and one irrelevant phage-scFv. (F) FACS binding
of P. nosa c antibodies with representative s from unique P.
aeruginosa serotypes. For each antibody tested a human IgG negative control antibody is
shown as a shaded peak.
Figure 2 (A-B): Evaluation of mAbs promoting OPK of P. aeruginosa (A)
Opsonophagocytosis assay with luminescent P. aeruginosa serogroup 05 strain
(PAOl.lux), with dilutions of purified monoclonal antibodies derived from phage
panning. (B) phagocytosis assay with luminescent P. nosa serogroup Oll
strain (9882-80.lux), with dilutions of purified WapR-004 and Cam-003 monoclonal
antibodies derived from phage panning. In both A and B, R347, an isotype matched
human monoclonal antibody that does not bind P. nosa antigens, was used as a
negative control.
Figure 3 (A—I): Identification of the P. aeruginosa Psl exopolysaccharide target of
antibodies derived from phenotypic screening. Reactivity of dies was determined
by indirect ELISA on plates coated with indicated P. aeruginosa strains: (A) wild type
PAOl, PAOlAwpr, PAOlArmZC and PAOlAgaZU. (B) PAOlApslA. The Genway
antibody is specific to a P. aeruginosa outer ne protein and was used as a positive
control. (C) FACS binding analysis of Cam-003 to PAOl and PAOlApSZA. Cam—003 is
indicated by a solid black line and clear peak; an isotype matched non—P. aeruginosa—
specific human IgG1 dy was used as a negative control and is indicated by a gray
line and shaded peak. (D) LPS purified from PAOl and PAOlApsZA was resolved by
SDS-PAGE and bloted with antisera derived from mice vaccinated with
PAOlAwapRAaZgD, a mutant strain deficient in O-antigen transport to the outer
membrane and alginate production. (E) Cam-003 ELISA binding data with isogenic
mutants of PAOl. Cam-003 is only capable of binding to strains expressing Psl.
pPWl45 is a pUCP expression vector containing psZA. (F and G) phagocytosis
assays indicating that Cam-003 only es killing of strains capable of producing Psl
(wild type PAOl and PAOlApslA complemented in trans with the pslA gene). (H and I)
ELISA data indicating reactivity of anti-Psl antibodies WapR—OOl, WapR—004, and
WapR—Ol6 with PAOl AwprAaZgD and PAOl AwprAalgDApslA. R347 was used as
a negative control in all experiments.
Figure 4: Anti-Psl mAbs inhibit cell ment of luminescent P. aeruginosa
strain PAOl.lux to A549 cells. ase PAOl.lux were added to a confluent
monolayer of A549 cells at an MOI of 10 followed by analysis of RLU after repeated
washing to remove unbound P. aeruginosa. Results are representative of three
independent experiments performed in duplicate for each antibody concentration.
Figure 5 (A—C): In vivo passaged P. aeruginosa strains maintain/increase
expression of Psl. The Cam—003 antibody is shown by a solid black line and a clear peak;
the human IgG negative control antibody is shown as a gray line and a shaded peak. (A)
For the positive control, Cam-003 was assayed for binding to strains grown to log phase
from an ght culture (~5 x lOS/ml). (B) The a for each strain were prepared
to 5 x 108 CFU/ml from an overnight TSA plate grown to lawn and tested for reactivity to
Cam—003 by flow cytometry. (C) Four hours post intraperitoneal challenge, bacteria was
harvested from mice by peritoneal lavage and d for the presence of Psl with Cam-
003 by flow cytometry.
Figure 6 (A-F): Survival rates for animals treated with anti-Psl monoclonal
antibodies Cam—003 or WapR—004 in a P. nosa acute pneumonia model. (A—D)
Animals were d with Cam-003 at 45, 15, and 5mg/kg and R347 at 45mg/kg or PBS
24 hours prior to intranasal ion with (A) PAOl (1.6 x 107 CPU), (B) 33356 (3 x 107
CFU), (C) 6294 (7 x 106 CFU), (D) 6077 (l x 106 CFU). (E-F) Animals were treated
with 04 at 5 and lmg/kg as indicated followed by infection with 6077 at (E) (8 x
105 CFU), or (F) (6 x 105 CFU). Animals were carefully monitored for survival up to 72
hours (A-D) or for 120 hours (E-F). In all experiments, PBS and R347 served as negative
controls. Results are represented as Kaplan—Meier survival curves; differences in survival
were calculated by the nk test for Cam—003 vs. R347. (A) Cam—003 kg —
P<0.0001; 15mg/kg — 03; 5mg/kg — P=0.0033). (B) 3 (45mg/kg —
P=0.0012; 15mg/kg — P=0.0012; 5mg/kg — P=0.0373). (C) Cam—003 (45mg/kg —
P=0.0007; 15mg/kg — P=0.0019; 5mg/kg — P=0.0212). (D) Cam—003 (45mg/kg —
P<0.0001; 15mg/kg — P<0.0001; 5mg/kg — P=0.0001). Results are representative of at
least two independent experiments. (E) [Cam—003 (5mg/kg) vs. R347 (5mg/kg): P=0.02;
Cam—003 (lmg/kg) vs. R347 (5mg/kg): 48; WapR—004 (5mg/kg) vs. R347
(5mg/kg): P<0.0001; WapR—004 (lmg/kg) vs. R347 (5mg/kg): P=0.0886; 04
(5mg/kg) vs. Cam—003 (5mg/kg): P=0.0017; WapR—004 (lmg/kg) vs. Cam—003 (lmg/kg):
P=0.2468; R347 g) vs. PBS: P=0.6676] (F) [Cam—003 (5mg/kg) vs. R347
(5mg/kg): P=0.0004; Cam—003 g) vs. R347 (5mg/kg): P<0.0001; WapR—004
g) vs. R347 (5mg/kg): P<0.0001; WapR-004 (lmg/kg) vs. R347 (5mg/kg):
01; WapR—004 (5mg/kg) vs. Cam—003 (5mg/kg): P=0.0002; WapR—004 (lmg/kg)
vs. Cam—003 (lmg/kg): P=0.2628; R347 (5mg/kg) vs. PBS: 76]. Results are
representative of five independent experiments.
Figure 7 (A—F): Anti—Ps1 monoclonal antibodies, Cam—003 and WapR—004, reduce
organ burden after induction of acute pneumonia. Mice were treated with Cam—003
antibody 24 hours prior to infection with (A) PAOl (1.1 x 107 CFU), (B) 33356 (1 X 107
CFU), (C) 6294 (6.25 x 106 CFU) (D) 6077 (l x 106 CFU), and WapR-004 antibody 24
hours prior to infection with (E) 6294 (~1 x 107 CFU), and (F) 6206 (~1 x 106 CFU). 24
hours post-infection, animals were euthanized ed by harvesting or organs for
identification of viable CFU. Differences in viable CFU were determined by the Mann-
Whitney U—test for Cam—003 or WapR—004 vs. R347. (A) Lung: Cam—003 (45mg/kg —
; lSmg/kg — P=0.0021; 5mg/kg — 15); Spleen: Cam—003 (45mg/kg —
P=0.0120; lSmg/kg — P=0.0367); s: Cam—003 (45mg/kg — P=0.0092; lSmg/kg —
P=0.0056); (B) Lung: Cam—003 (45mg/kg — P=0.0010; lSmg/kg — P<0.0001; 5mg/kg —
P=0.0045); (C) Lung: 3 kg — P=0.0003; lSmg/kg — P=0.0039; 5mg/kg —
P=0.0068); Spleen: Cam—003 (45mg/kg — P=0.0057; lSmg/kg — 30; 5mg/kg —
P=0.0012); (D) Lung: Cam—003 (45mg/kg — P=0.0005; lSmg/kg — P=0.0003; 5mg/kg —
P=0.0007); Spleen: Cam—003 (45mg/kg — P=0.0015; lSmg/kg — P=0.0089; 5mg/kg —
89); Kidneys: Cam—003 (45mg/kg — P=0.019l; lSmg/kg — P=0.0355; 5mg/kg —
P=0.002l). (E) Lung: WapR—004 (lSmg/kg — P=0.0011; 5mg/kg — 04; lmg/kg —
P=0.0002); Spleen: WapR—004 (lSmg/kg — P<0.0001; 5mg/kg — P=0.0014; lmg/kg —
P<0.0001); F) Lung: WapR—004 (lSmg/kg — P<0.0001; 5mg/kg — P=0.0006; lmg/kg —
P=0.0079); Spleen: WapR—004 (lSmg/kg — P=0.0059; 5mg/kg — P=0.026l; lmg/kg —
P=0.0047); Kidney: WapR—004 (lSmg/kg — P=0.0208; 5mg/kg — P=0.0268.
Figure 8 (A-G): Anti-Psl monoclonal antibodies Cam-003 and WapR—004 are
active in a P. aeruginosa keratitis model and l injury model. Mice were treated
with a control IgGl antibody or Cam-003 at 45mg/kg (A, B) or lSmg/kg (C, D) or PBS
or a control IgGl antibody or Cam-003 at 45mg/kg or WapR—004 at 45mg/kg or lSmg/kg
or 5mg/kg (F, G) 24 hours prior to infection with 6077 (Oll-cytotoxic — 2XlO6 CFU).
Immediately before infection, three 1 mm scratches were made on the left cornea of each
animal followed by topical application of P. aeruginosa in a 5 ul inoculum. 24 hours
after infection, the corneal pathology scores were calculated followed by l of the
eye for determination of viable CFU. Differences in pathology scores and viable CFU
were determined by the Mann—Whitney U—test. (A) P=0.0001, (B) P<0.0001, (C)
P=0.0003, (D) P=0.0015. (F) and (G) Cam—003 (45mg/kg) vs. WapR—004 (45mg/kg):
P=0.018; 3 (45mg/kg) vs. WapR—004 kg): P=0.0025; WapR—004
(45mg/kg) vs. WapR—004 (lSmg/kg): 3l; WapR—004 (5mg/kg) vs. Ctrl: P<0.0001.
Results are representative of five ndent experiments. (E) Survival analysis from
Cam—003 and R347 treated CF—l mice in a P. aeruginosa thermal injury model after 6077
infection (2 x 105 CFU) ank: R347 vs. Cam—003 lSmg/kg, P=0.0094; R347 vs.
Cam—003 5mg/kg, P=0.0017). Results are representative of at least three independent
experiments. (n) refers to number of animals in each group. Figure 8 (H): Anti-Psl and
anti-Pch monoclonal antibodies are active in a P. aeruginosa mouse ocular keratitis
model. Mice were injected intraperitoneally (IP) with PBS or a control IgGl antibody
(R347) at 45mg/kg or 04 (ct-Ps1) at 5mg/kg or V2L2 (oc-Pch) at 5mg/kg, 16
hours prior to infection with 6077 (Oll-cytotoxic — 1x106 CFU). Immediately before
infection, mice were anesthetized followed by initiation of three 1 mm scratches on the
cornea and superficial stroma of one eye of each mouse using a ge needle under a
dissection microscope, followed by topical ation of P. aeruginosa 6077 strain in a 5
ul inoculum.
Figure 9 (A—C): A Cam—003 Fc mutant dy, CamTM, has diminished
OPK and in viva efficacy but maintains anti-cell attachment activity. (A) PAOl.lux OPK
assay with Cam-003 and CamTM, which harbors ons in the Fc domain that
prevents Fc interactions with Fcy ors (Oganesyan, V., et al., Acta Crystallogr D
Biol Crystallogr 64, 4 (2008)). R347 was used as a negative control. (B) PAOl
cell attachment assay with 3 and Cam-003—TM. (C) Acute pneumonia model
comparing efficacy of Cam—003 vs. Cam—003—TM.
Figure 10 (A-C): A: Epitope mapping and fication of the relative binding
affinity for anti-Psl monoclonal antibodies. Epitope mapping was performed by
competition ELISA and confirmed using an OCTET® flow system with Psl derived from
the supernatant of an overnight culture of P. aeruginosa strain PAOl. Relative binding
affinities were measured on a FORTEBIO® OCTET® 384 instrument. Also shown are
antibody concentrations where cell attachment was maximally inhibited and OPK EC50
values for each dy. B, C. Relative binding affinities of various WapR—004 mutants
%nwfimwonaFmUEmO®OCUH®3Mdmmmwm.AbommmamCWKECw
values for the various mutants.
Figure 11 (A-M): Evaluation of WapR-004 (W4) mutants clones in the P.
aeruginosa opsonophagocytic killing (OPK) assay (A—M) OPK assay with luminescent P.
nosa serogroup 05 strain (PAOl.luX), with dilutions of different W4 mutant clones
in scFv-Fc format. In some instances, W4 IgGl was included in the assay and is
indicated as W4-IgGl. W4-RAD-Cam and W4-RAD-GB represent the same WapR-
004RAD sequence described . "W4-RAD" is a shorthand name for WapR-
004RAD, and W4-RAD-Cam and W4-RAD-GB designations in panels D through M
ent two ent preparations of WapR-004RAD. (N—Q): Evaluation of the
optimized anti-Psl mAbs derived from lead (WapR-004) zation in the P.
aeruginosa OPK assay. (N—O) OPK assay with luminescent PAOl.lux using dilutions of
purified lead zed monoclonal antibodies. (P-Q) Repeat OPK assay with PAOl.lux
with dilutions of ed mAbs to confirm results. (N—Q): W4—RAD was used as a
ative positive control. In all experiments, R347, a human IgG1 monoclonal
antibody that does not bind P. aeruginosa ns, was used as a negative control.
Figure 12 (A-H): (A) The Pch epitope diversity. . (B) Percent inhibition of
cytotoxicity analysis for the parental V2L2 mAb, mAbl66 (positive control) and R347
(negative control). (C) Evaluation of the V2L2 mAb, mAbl66 (positive control) and
R347 (negative control) ability to prevent lysis of RBCs. (D) Evaluation of the V2L2-
germlined mAb (V2L2-GL) and optimized V2L2-GL mAbs (V2L2—P4M, V2L2-MFS,
V2L2-MD and V2L2-MR) to prevent lysis of RBCs. (E) tion of mAbs 1E6, lF3,
llA6, 29D2, PCRV02 and V2L7 to prevent lysis of RBCs (F) Evaluation of mAbs V2L2
2012/063722
and 29D2 to prevent lysis of RBCs. (G-H) Relative binding ties of L and
V2L2—MD antibodies.
Figure 13 (A—I): In vivo survival study of anti-Pch antibody treated mice. (A)
Mice were treated 24 hours prior to infection with: 1.03 X 106 CFU 6077 (exoU+) with 45
mg/kg R347 (negative control), 45 mg/kg, 15.0 mg/kg, 5.0 mg/kg, or 1.0 mg/kg mAb166
(positive control), or 15 mg/kg, 5.0 mg/kg, 1.0 mg/kg, or 0.2 mg/kg V2L2. Survival was
monitored for 96 hours. (B) Mice were treated 24 hours prior to infection with: 2.1 x 107
CPU 6294 (exoSl) with 15 mg/kg R347 (negative control), 15.0 mg/kg, 5.0 mg/kg, or 1.0
mg/kg mAb166 (positive control), or 15 mg/kg, 5.0 mg/kg, or 1.0 mg/kg V2L2. Survival
was monitored for 168 hours. Mice were d 24 hours prior to infection with: (C)
6294 (06) or (D) PA103A with R347 (negative control), 5mg/kg of the Pch antibody
Pch—02, or 5mg/kg, 1.0mg/kg, 0.2mg/kg, or 0.04mg/kg V2L2. Mice were treated 24
hours prior to infection with strain 6077 with R347 (negative control), 5mg/kg of the
Pch antibody Pch-02, V2L7 (5mg/kg or 1mg/kg), 3G5 (5mg/kg or 1mg/kg), or 11A6
(5mg/kg or ) (E), or 25mg/kg of the V2L7, 1E6, 1F3, 29D2, R347 or 1mg/kg of
the Pch antibody Pch-01 (F), or 25mg/kg of the 21F1, V2L2, 2H3, 4A8, SH3, LE10,
R347 or 1mg/kg of the Pch-02 (G), or the 29D2 (1 mg/kg, 3mg/kg or 10 mg/kg), the
V2L2 (1 mg/kg, 3mg/kg or 10 mg/kg) R347 or 1mg/kg of the Pch—02 (H). Mice were
treated 24 hours prior to ion with: 6294 (06) or PA103A with the V2L2
(0.04mg/kg, 0.2mg/kg, 1 mg/kg or 5 mg/kg), R347 or 5mg/kg of the Pch-02. Percent
survival was assayed in an acute pneumonia model.
Figure 14: Organ burden analysis of V2L2 treated mice. Mice were treated 24
hours prior to infection with 6206 with (A) R347 (negative control), 1 mg/kg, 0.2 mg/kg,
or 0.07 mg/kg V2L2 and (B) 15 mg/kg R347 (negative l); 15.0 mg/kg, 5.0 mg/kg,
or 1.0 mg/kg mAb166 (positive control); or 5.0 mg/kg, 1.0 mg/kg, or 0.2 mg/kg V2L2.
Colony forming units were identified per gram of tissue in lung, spleen, and kidney.
Figure 15: Organ burden analysis of V2L2 and WapR—004 (W4) treated mice.
Mice were treated 24 hours prior to infection with 6206 (Oll-ExoU+) with R347
(negative control), V2L2 alone, or V2L2 (0.1mg/kg) in ation with increasing
concentrations of W4 (0.1, 0.5, 1.0, or 2.0 mg/kg). Colony g units were identified
per gram of tissue in lung, spleen, and kidney. .
Figure 16 (A—G): Survival rates for animals treated with ch monoclonal
antibody V2L2 in a P. aeruginosa acute pneumonia model. V2L2-GL, V2L2-MD,
V2L2-PM4, V2L2-A and V2L2-MFS designations in panels A through G represent
different ations of V2L2. (A-C) Animals were treated with V2L2 at lmg/kg,
0.5mg/kg or R347 at 0.5mg/kg prior to asal infection with (A) 6077 (9.75 x 105
CFU), (B, C) 6077 (9.5 X 105 CFU). (D—F) Animals were treated with V2L2 at 0.5mg/kg,
0.1mg/kg or R347 at 0.5mg/kg followed by infection with 6077 (D) (l x 106 CFU), (E)
(9.5 x 105 CPU) or F (1.026 x 106 CPU). (G) Animals were treated with V2L2—MD at
(0.04mg/kg, 0.2mg/kg, lmg/kg or 5mg/kg), mAbl66 (positive control) at (0.2mg/kg,
lmg/kg, 5mg/kg or lSmg/kg), or R347 at 0.5mg/kg followed by infection with 6206 (2 x
107+ CFU).
Figure 17 (A—B): Schematic representation of (A) oc/W4, Bs2—TNFOt/W4,
BS3-TNFOt/W4 and (B) Bs2-V2L2/W4-RAD, Bs3-V2L2/W4-RAD, and Bs4-V2L2-W4-
RAD Psl/Pch bispeciflc antibodies. (A) For oc/W4, the W4 scFv is fused to the
amino-terminus of TNFoc VL through a (G4S)2 linker. For BS2—TNFOL/W4, the W4 scFv
is fused to the amino-terminus of TNFoc VH through a (G4S)2 . For Bs3-
TNFOL/W4, the W4 scFv is fused to the carboxy—terminus of CH3 through a (G4S)2
linker. (B) For Bs2—V2L2-2C, the W4-RAD scFv is fused to the amino-terminus of
V2L2 VH through a (G4S)2 linker. For Bs2-W4-RAD-2C, the V2L2 scFv is fused to the
amino-terminus of W4-RAD VH through a (G4S)2 linker. For Bs3-V2L2-2C, the W4-
RAD scFv is fused to the carboxy-terminus of CH3 through a (G4S)2 . For Bs4-
V2L2-2C, the W4-RAD scFv is inserted in the hinge region, linked by (G4S)2 linker on
the N—terminal and C-terminal of the scFv.
Figure 18: Evaluation of WapR—004 (W4) scFv activity in a bispeciflc constructs
depicted in Figure 17A. The W4 scFv was ligated onto two different ific constructs
(in alternating N— or C—terminal orientations) having a TNFoc binding arm. Each W4-
TNFOL bispecific construct (le—TNFoc/W4, FOL/W4 and Bs3—TNF0t/W4) retained
the ability to inhibit cell ment similarly as W4 using the ux (05) assay
indicating that the W4 scFv retains its activity in a bispecif1c format. R347 was used as a
negative control.
Figure 19 (A-C): Anti-Psl and anti-Pch binding domains were combined in the
bispecif1c format by replacing the TNFoc antibody of Figure 17B with V2L2. These
constructs are identical to those depicted in Figure 17B with the exception of using the
non-stabilized W4-scFv in place of the ized W4-RAD scFv. Both W4 and W4-RAD
target identical epitopes and have identical onal activities. Percent inhibition of
cytotoxicity was analysed for both BS2-V2L2 and BS3-V2L2 using both (A) 6206 and
(B) SZA treated A549 cells. (C) L2, BS3-V2L2, and Bs4-V2L2 were
evaluated for their ability to t lysis of RBCs compared to the parental control. All
bi—specif1c constructs retained anti—cytotoxicity activity similar to the parental V2L2
antibody using 6206 and 6206ApslA infected cells and prevented lysis of RBCs similar to
the parental control (V2L2). R347 was used as a negative control in all ments.
Figure 20 (A-C): Evaluation of sl/anti-Pch bispecif1c ucts for
promoting OPK of P. aeruginosa. Opsonophagocytosis assay is shown with luminescent
P. aeruginosa serogroup 05 strain (PAOl.lux), with dilutions of purified Psl/TNFoc
bispeciflc dies (BS2-TNFOL and Bs3-TNFoc); the W4-RAD or V2L2-IgGl parental
antibodies; the Psl/Pch bispecif1c antibodies Bs2- V2L2 or Bs3-V2L2, or the Bs2-V2L2-
2C, Bs3-V2L2-2C, Bs4-V2L2-2C or the Bs4-V2L2-2C antibody harboring a YTE
mutation (Bs4-V2L2-2C-YTE). (A) While the Bs2-V2L2 antibody showed similar killing
compared to the parental W4-RAD antibody, the killing for the L2 antibody was
sed. (B) While the Bs2—V2L2—2C and Bs4—V2L2—2C antibodies showed similar
killing compared to the parental W4-RAD antibody, the killing for the Bs3-V2L2-2C
antibody was decreased. (C) W4—RAD and W4-RAD-YTE designations represent
different ations of W4-RAD. Bs4-V2L2-2C (old lot) and Bs4-V2L2-2C (new lot),
designations represent different preparations of Bs4-V2L2-2C. The YTE modification in
Bs4-V2L2-2C-YTE is a modification made to dies that increases the half-life of
antibodies. Different preparations of Bs4 antibodies (old lot vs. new lot) showed similar
killing compared to the parental W4-RAD antibody, r the Bs4-V2L2-2C—YTE
antibodies had a 3-fold drop in OPK activity when compared to Bs4—V2L2—2C (See EC50
table). R347 was used as a negative control in all experiments.
Figure 21 (A-I): In vivo survival study of anti-Psl/anti-Pch bispecif1c antibodies
Bs2-V2L2, Bs3-V2L2, Bs4-V2L2-2C and Bs4-V2L2-2C-YTE-treated mice in a 6206
acute pneumonia model system. Mice (n=10) were treated with (A): R347 (negative
control, 0.2 mg/kg), Bs2-V2L2 (0.28 mg/kg), Bs3-V2L2 (0.28 mg/kg), V2L2 (0.2 mg/kg)
or W4-RAD (0.2 mg/kg); (B-C): R347 (negative control, 1 mg/kg), Bs2-V2L2 (0.5 mg/kg
or 1 mg/kg), or Bs4-V2L2-2C (0.5 mg/kg or 1 mg/kg); (D): R347 (negative control, 1
mg/kg), L2 (0.5 mg/kg or 1 mg/kg), or Bs4-V2L2-2C (0.5 mg/kg or 1 mg/kg);
(E): R347 (negative control, 2 mg/kg), a combination of the individual W4 and V2L2
antibodies (0.5 mg/kg or 1 mg/kg each) or Bs4-V2L2-2C (1 mg/kg or 2 mg/kg); (F):
R347 (negative l, 1 , a mixture of the individual W4 and V2L2 antibodies
(0.5 mg/kg or 1 mg/kg each) or Bs4-V2L2-2C (1 mg/kg or 0.5 mg/kg). Twenty-four
hours post-treatment, all mice were infected with ~ (6.25x105-1x106 CFU/animal) 6206
(Oll-ExoU+). All mice were monitored for 120 hours. (A): All of the control mice
succumbed to ion by approximately 30 hours post—infection. All of the Bs3—V2L2
animals survived, along with those which received the V2L2 control. Approximately
90% of the W4-RAD immunized animals survived. In contrast, approximately 50% of
the Bs2-V2L2 animals succumbed to infection by 120 hours. (B-F): All of the control
mice succumbed to infection by approximately 48 hours post—infection. (B): L2—
2C had greater activity in comparison to Bs2-V2L2 at both 1.0 and 0.5 mg/kg. (C): Bs4—
V2L2-2C appeared to have r activity in comparison to Bs2-V2L2 at 1.0 mg/kg
(results are not statistically significant). (D): Bs4-V2L2-2C had greater activity in
comparison to L2 at 0.5 mg/kg. (E): Bs4-V2L2-2C at both 2 mg/kg and 1 mg/kg
had greater activity in comparison to the antibody mixture at both 1.0 and 0.5 mg/kg. (F):
Bs4-V2L2 (1 mg/kg) has similar activity at both 1.0 and 0.5 mg/kg. (G-H): Both Bs4—
V2L2-2C and Bs4-V2L2-2C—YTE had similar activity at both 1.0 and 0.5 mg/kg. Results
are represented as Kaplan—Meier survival curves; ences in al were calculated
by the Log-rank test for (B) Bs4-V2L2-2C vs. Bs2-V2L2 (1 mg/kg — P=0.034; 0.5mg/kg
— P=0.0002); (D) L2—2C vs. Bs3—V2L2 (0.5 mg/kg — P<0.0001); (E): L2—
2C (2 mg/kg) vs. antibody e (1 mg/kg each)-P=0.0012; Bs4-V2L2-2C (1 mg/kg)
vs. antibody mixture (0.5 mg/kg each)—P=0.0002. (G—H): Mice (n=8) were treated with:
R347 (negative control, 1 mg/kg), Bs4-V2L2-2C (1 and 0.5 mg/kg), and Bs4-V2L2-2C—
YTE (1 and 0.5 mg/kg) and 6206 (9e5 CFU). No difference in al between Bs4—
V2L2—2C and Bs4—V2L2—2C—YTE at either dose were observed by Log—Rank. (I): To
analyze the cy of each antibody construct, mice were treated with 0.1 mg/kg, 0.2
mg/kg, 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 5 mg/kg, 10 mg/kg or 15 mg/kg and analyzed for
survival in a 6206 lethal pneumonia model. The percent survival is indicated in the table
with the number of animals for each comparison indicated in parentheses.
Figure 22: Organ burden analysis of anti-Psl/Pch bispecific antibody-treated
s using the 6206 acute pneumonia model. Mice were treated 24 hours prior to
infection with 6206 (01 l-ExoU+) with R347 (negative control), V2L2 or W4-RAD alone
(0.2 mg/kg), Bs2-V2L2 (0.28 , or BS3-V2L2 (0.28 . Colony forming units
were identified per gram of tissue in lung, , and kidney. At the concentration
tested, both Bs2-V2L2 and Bs3-V2L2 significantly decreased organ burden in lung.
However, neither of the bispeciflc constructs was able to significantly affect organ burden
in spleen or kidney compared to the parental antibodies.
Figure 23 (A-B): Organ burden analysis of anti-Psl/Pch bispecif1c antibody-
treated animals using a 6294 model system. Mice were d 24 hours prior to infection
with 6294 with R347 (negative control), V2L2 or W4-RAD alone (0.5 mg/kg), Bs2-V2L2
(0.7 mg/kg), or Bs3—V2L2 (0.7 mg/kg) (A), or V2L2 or W4-RAD alone (0.2 , Bs2-
V2L2 (0.2 mg/kg), L2 (0.2 mg/kg) or a combination of the individual W4-RAD
and V2L2 antibodies (0.1 mg/kg each) (B). Twenty-four hours post-administration of
antibody, all mice were infected with an inoculum containing 2.5 x 107 CFU 6294 (A) or
1.72 x 107 CFU 6294 (B). Colony forming units were identified per gram of tissue in
lung, spleen, and kidney. Using the 6294 model system, (A) both the BS2-V2L2 and
BS3-V2L2 significantly decreased organ burden in all of the tissues to a level comparable
to that of the V2L2 parental dy. The W4-RAD parental antibody had no effect on
decreasing organ burden. (B) Bs2—V2L2, Bs3—V2L2, and +V2L2 combination
significantly decreased organ burden in all of the tissues to a level comparable to that of
the V2L2 parental antibody.
Figure 24: In vivo survival study of Bs2—W4/V2L2 and Bs3-W4/V2L2-treated
mice in a 6294 model system. Mice were treated with R347 (negative control, 0.2
mg/kg), Bs2-V2L2 (0.28 mg/kg), Bs3-V2L2 (0.28 mg/kg), V2L2 (0.2 mg/kg) or W4-
RAD (0.2 . Twenty-four hours post-treatment, all mice were infected with 6294.
All mice were monitored for 120 hours. All of the control mice succumbed to ion
by approximately 75 hours post-infection. Sixty percent of the Bs3-V2L2 and 50% of the
Bs2-V2L2 animals survived after 120 hours post-inoculation. As was seen in the organ
burden studies, W4-RAD immunization did not affect al with all mice succumbing
to infection at approximately the same time as the controls.
Figure 25 (A-D): Organ burden analysis of anti-Psl/Pch bispecific antibody or
W4 + V2L2 combination therapy in the 6206 model system. Suboptimal concentrations
of antibody were used (A—C) to enable the ability to decipher dy activity. (D) High
concentrations of Bs4 were used. Mice were treated 24 hours prior to infection with 6206
with R347 (negative control), V2L2 or W4-RAD alone (0.2 mg/kg), L2 (0.2
mg/kg), Bs3—V2L2 (0.2 , Bs4 (15.0, 5.0 and 1.0 mg/kg) or a combination of the
individual W4 and V2L2 dies (0.1 mg/kg each). Twenty—four hours post—
administration of antibody, all mice were infected with an um containing (A), (B)
4.75 x 105 CPU 6206 (Oll—ExoU+), or (C) 7.75 x 105 CPU 6206 (Oll—ExoU+) or (D)
9.5 X 105 CPU 6206 (Oll—ExoU+). Colony g units were identified per gram of
tissue in lung, spleen, and kidney. Using the 6206 model system, both the BS2-V2L2 and
BS3—V2L2 decreased organ burden in the lung, spleen and kidneys to a level comparable
to that of the W4 + V2L2 combination. In the lung, the combination significantly
reduced bacterial CFUs Bs2- and Bs3—V2L2 and V2L2 using the Kruskal-Wallis with
Dunn’s post test. Significant differences in bacterial burden in the spleen and kidney
were not observed, although a trend towards reduction was noted. (D) When optimal
concentrations of Bs4—V2L2—2C were used (15.0, 5.0, and 1.0), rapid and efficient
bacterial nce was observed from the lung. In on, bacterial dissemination to
the spleen and s were also ablated. Asterisks indicate statistical significance when
compared to the R347 control using the Kruskal-Wallis with Dunn’s post test.
Figure 26 (A—J): Therapeutic adjunctive therapy: Bs4-V2L2—2C + antibiotic. (A)—
(B) Mice were treated 24 hours prior to infection with 1 x 106 CPU 6206 with 0.5 mg/kg
R347 (negative control) or Bs4-V2L2-2C (0.2 mg/kg or 0.5 mg/kg) or Ciprofloxacin
(CIP) (20 mg/kg or 6.7 mg/kg) 1 hour post infection, or a combination of the Bs4-V2L2-
2C 24 hours prior to infection and CIP 1 hour post infection (0.5 mg/kg + 20 mg/kg or 0.5
mg/kg + 6.7 mg/kg or 0.2 mg/kg + 20 mg/kg or 0.2 mg/kg + 6.7 mg/kg, respectively). (C)
Mice were treated 1 hour post infection with 9.5 x 105 CPU 6206 with 5 mg/kg R347 or
CIP (20 mg/kg or 6.7 mg/kg) or Bs4-V2L2-2C (1 mg/kg or 5 mg/kg), or a combination of
the Bs4-V2L2-2C and CIP (5 mg/kg + 20 mg/kg or 5 mg/kg + 6.7 mg/kg or 1 mg/kg + 20
mg/kg or 1 mg/kg + 6.7 mg/kg, respectively). (D) Mice were treated 2 hours post
infection with 9.5 X 105 CPU 6206 with 5 mg/kg R347 or CIP (20 mg/kg or 6.7 mg/kg) or
Bs4-V2L2-2C (1 mg/kg or 5 mg/kg), or a combination of the Bs4-V2L2-2C and Cipro (5
2012/063722
mg/kg + 20 mg/kg or 5 mg/kg + 6.7 mg/kg or 1 mg/kg + 20 mg/kg or 1 mg/kg + 6.7
mg/kg, respectively). (E) Mice were treated 2 hours post ion with 9.75 x 105 CPU
6206 with 5 mg/kg R347or Bs4-V2L2-2C (1 mg/kg or 5 mg/kg) or CIP (20 mg/kg or 6.7
mg/kg) 1 hour post infection, or a combination of the Bs4-V2L2-2C 2 hours post
ion and CIP 1 hour post infection (5 mg/kg + 20 mg/kg or 5 mg/kg + 6.7 mg/kg or 1
mg/kg + 20 mg/kg or 1 mg/kg + 6.7 mg/kg, respectively). (F) Mice were treated 1 hour
post infection with 9.5 x 105 CPU 6206 with 5 mg/kg R347 or Meropenem (MEM) (0.75
mg/kg or 2.3 mg/kg) or Bs4-V2L2-2C (1 mg/kg or 5 mg/kg), or a combination of the
Bs4—V2L2—2C and MEM (5 mg/kg + 2.3 mg/kg or 5 mg/kg + 0.75 mg/kg or 1 mg/kg +
2.3 mg/kg or 1 mg/kg + 0.75 mg/kg, respectively). (G) Mice were treated 2 hours post
infection with 9.75 x 105 CPU 6206 with 5 mg/kg R347 or Bs4-V2L2-2C (1 mg/kg or 5
mg/kg) or MEM (0.75 mg/kg or 2.3 mg/kg) 1 hour post infection, or a combination of the
Bs4-V2L2-2C 2 hours post infection and MEM 1 hour post ion (5 mg/kg + 2.3
mg/kg or 5 mg/kg + 0.75 mg/kg or 1 mg/kg + 2.3 mg/kg or 1 mg/kg + 0.75 mg/kg,
respectively). (H) Mice were treated 2 hours post infection with l x 106 CPU 6206 with 5
mg/kg R347 or Bs4-V2L2-2C (1 mg/kg or 5 mg/kg) or MEM (0.75 mg/kg or 2.3 mg/kg),
or a combination of the Bs4-V2L2-2C 2 and MEM (5 mg/kg + 2.3 mg/kg or 5 mg/kg +
0.75 mg/kg or 1 mg/kg + 2.3 mg/kg or 1 mg/kg + 0.75 mg/kg, respectively). (I) Mice
were treated 4 hour post infection with 9.25 x 105 CPU 6206 with 5 mg/kg R347 or CIP
(6.7 mg/kg) or Bs4-V2L2-2C (1 mg/kg or 5 mg/kg) or a combination of the Bs4-V2L2-
2C and CIP (5 mg/kg + 6.7 mg/kg or 1 mg/kg + 6.7 mg/kg, respectively) Mice were
, (J)
treated 4 hour post infection with 1.2 x 106 CPU 6206 with 5 mg/kg R347 + CIP (6.7
, CIP (6.7 mg/kg), or Bs4-V2L2-2C (1 mg/kg or 5 mg/kg) or a ation of the
Bs4—V2L2—2C and CIP (5 mg/kg + 6.7 mg/kg or 1 mg/kg + 6.7 mg/kg, respectively). (A—
J) Bs4 antibody combined with either CIP or MEM increases efficacy of antibiotic
therapy, indicating synergistic protection when the molecules are combined. In addition,
gh antibiotic delivered by itself or in combination with a P. aeruginosa non—
specific antibody can reduce or control bacterial CFU in the lung, antibiotic alone does
not protect mice from lethality in this setting. Optimal protection in this setting requires
including L2-2C in combination with antibiotic.
Figure 27 (A-C): Difference in onal activity of bi-specific antibodies BS4-
WT, BS4—GL and BS4-GLO: opsonophagocytic killing assay (A), anti-cell attachment
assay (B), and a RBC lysis anti-cytotoxicity assay (C).
Figure 28 (A-B): Percent protection against lethal pneumonia in mice challenged
in lactic (A) or therapeutic (B) settings with P. aeruginosa strains. The t
survival is indicated in the table with the number of animals for each comparison
indicated in parentheses. The dashes indicate not tested.
Figure 29 (A—B): Survival rates for animals treated with bispecif1c antibody Bs4-
GLO in a P. aeruginosa lethal emia model. (A) Animals were treated with Bs4-
GLO at 15mg/kg, 5mg/kg, lmg/kg or R347 at g 24 hours prior to intraperitoneal
ion with 6294 (06) (5.58 x 107 CFU). (B) Animals were treated with Bs4-GLO at 5
mg/kg, 1 mg/kg, 0.2 mg/kg or R347 at 5mg/kg 24 hours prior to intraperitoneal infection
with 6206 (Oll—ExoU+) (6.48 X 106 CFU). Results are represented as Kaplan-Meier
survival curves; differences in survival were calculated by the Log—rank test for BS4—
GLO at each concentration vs. R347. (A) Bs4-GLO at all concentrations vs. R347
P<0.0001. (B) Bs4—GLO at all concentrations vs. R347 P=0.0003. Results are
representative of three independent experiments.
Figure 30 (A—C): Survival rates for s prophylactically treated (prevention)
with Bs4-GLO in a P. aeruginosa thermal injury model. (A) Animals were treated with
Bs4-GLO at 15mg/kg, 5mg/kg or R347 at 15mg/kg 24 hours prior to induction of thermal
injury and subcutaneous infection with P. aeruginosa strain 6077 (01 l-ExoU+) with 1.4 x
105 CFU directly under the wound. (B) Animals were treated with Bs4-GLO at 15mg/kg
or R347 at 15mg/kg 24 hours prior to induction of thermal injury and subcutaneous
infection with P. aeruginosa strain 6206 xoU+) with 4.15 x 104 CFU ly
under the wound. (C) Animals were treated with O at 15mg/kg, 5mg/kg or R347
at 15mg/kg 24 hours prior to induction of thermal injury and subcutaneous infection with
P. aeruginosa strain 6294 (06) with 7.5 x 101 CFU directly under the wound. Results are
represented as Kaplan—Meier survival curves; differences in survival were calculated by
the Log-rank test for Bs4-GLO at each tration vs. R347. (A-C) Bs4-GLO at all
trations vs. R347 — P<0.0001. Results are representative of two independent
experiments for each P. aeruginosa strain.
Figure 31 (A-B): Survival rates for animals therapeutically treated (treatment))
with Bs4-GLO in a P. aeruginosa thermal injury model. (A) Animals were treated with
Bs4-GLO at 42.6mg/kg, 15 mg/kg or R347 at 45mg/kg 4h hours after ion of
thermal injury and subcutaneous infection with P. aeruginosa strain 6077 (Oll—EXOU+)
with 1.6 x 105 CFU directly under the wound. (B) Animals were d with Bs4-GLO
at 15mg/kg, 5 mg/kg or R347 at 15mg/kg 12h hours after induction of thermal injury and
subcutaneous infection with P. nosa strain 6077 (01 l—ExoUT) with 1.0 x 105 CFU
directly under the wound. s are represented as Kaplan—Meier survival curves;
differences in survival were ated by the Log—rank test for BS4-GLO at each
concentration vs. R347. (A) Bs4—GLO at both concentrations vs. R347 — P=0.0004. (B)
Bs4—GLO at 5mg/kg vs. R347 — P=0.048. Results are entative of two independent
experiments.
Figure 32 (A—B): Therapeutic tive therapy: Bs4GLO + ciprofloxacin (CIP):
(A) Mice were treated 4 hour post infection with 9.5 x 105 CFU 6206 with 5 mg/kg R347
+ CIP (6.7 mg/kg) or Bs4-WT (1 mg/kg or 5 mg/kg) or a combination of the Bs4-WT and
CIP (5 mg/kg + 6.7 mg/kg or 1 mg/kg + 6.7 mg/kg, respectively). (B) Mice were treated
4 hour post infection with 9.5 x 105 CFU 6206 with 5 mg/kg R347 + CIP (6.7 mg/kg) or
Bs4-GLO (1 mg/kg or 5 mg/kg) or a combination of the Bs4-GLO and CIP (5 mg/kg +
6.7 mg/kg or 1 mg/kg + 6.7 mg/kg, respectively
Figure 33 (A—B): Therapeutic adjunctive therapy: Bs4-GLO + meropenem
(MEM): (A) Mice were treated 4 hour post infection with 9.5 X 105 CFU 6206 with 5
mg/kg R347 + MEM (0.75 mg/kg) or Bs4-WT (1 mg/kg or 5 mg/kg) or a combination of
the Bs4-WT and MEM (5 mg/kg + 0.75 mg/kg or 1 mg/kg + 0.75 mg/kg, respectively).
(B) Mice were treated 4 hour post ion with 9.5 x 105 CFU 6206 with 5 mg/kg R347
+ MEM (0.75 mg/kg) or Bs4-GLO (1 mg/kg or 5 mg/kg) or a combination of the Bs4-
GLO and MEM (5 mg/kg + 0.75 mg/kg or 1 mg/kg + 0.75 mg/kg, tively).
Figure 34 (A—C): Therapeutic adjunctive therapy: Bs4—GLO + antibiotic in a lethal
bacteremia model. Mice were treated 24 hours prior to eritoneal infection with P.
aeruginosa strain 6294 (06) 9.3 x 107 with Bs4—GLO at (0.25mg/kg or 0.5mg/kg) or
R347 (negative control). One hour post infection, mice were treated subcutaneously with
(A) 1mg/kg CIP, (B) 2.5mg/kg MEM or (C) 2.5mg/kg TOB. Results are represented as
Kaplan-Meier survival curves; differences in survival were calculated by the Log-rank
test for Bs4-GLO at each concentration vs. R347.
Figure 35 (A-B) Schematic representation of alternative s for Bs4
constructs (A) anti-Pch variable regions are present separately on the heavy and light
chains while the anti-Psl variable regions are present as an scFv within the hinge region
of the heavy chain and (B) anti-Psl variable regions are present separately on the heavy
and light chains while the anti-Pch variable regions are present as an scFv within the
hinge region of the heavy chain.
DETAILED DESCRIPTION
I. DEFINITIONS
It is to be noted that the term "a" or "an" entity refers to one or more of that entity;
for example, "a binding molecule which specifically binds to Pseudomonas Ps1 and/or
Pcr ," is understood to represent one or more binding molecules which specifically bind
to Pseudomonas Psl and/or Pch. As such, the terms "a" (or "an"), "one or more," and "at
least one" can be used interchangeably herein.
As used herein, the term “polypeptide” is intended to encompass a singular
“polypeptide” 3
as well as plural “polypeptides,’ and refers to a molecule composed of
monomers (amino acids) linearly linked by amide bonds (also known as peptide bonds).
The term "polypeptide" refers to any chain or chains of two or more amino acids, and
does not refer to a specific length of the t. Thus, peptides, dipeptides, tides,
oligopeptides, “protein,3’ “amino acid chain,” or any other term used to refer to a chain or
chains of two or more amino acids are included within the definition of "polypeptide,”
and the term “polypeptide” can be used d of, or interchangeably with any of these
terms. The term "polypeptide" is also intended to refer to the products of post—expression
modifications of the polypeptide, including t limitation glycosylation, ation,
phosphorylation, ion, derivatization by known ting/blocking ,
proteolytic cleavage, or modification by non-naturally occurring amino acids. A
polypeptide can be derived from a natural biological source or produced by inant
technology, but is not necessarily translated from a designated nucleic acid sequence. It
can be generated in any manner, including by chemical synthesis.
A ptide as disclosed herein can be of a size of about 3 or more, 5 or more,
or more, 20 or more, 25 or more, 50 or more, 75 or more, 100 or more, 200 or more,
500 or more, 1,000 or more, or 2,000 or more amino acids. Polypeptides can have a
defined three—dimensional ure, although they do not necessarily have such structure.
Polypeptides with a defined three—dimensional structure are referred to as folded, and
polypeptides which do not possess a defined three—dimensional structure, but rather can
adopt a large number of different conformations, and are referred to as ed. As used
herein, the term glycoprotein refers to a protein coupled to at least one ydrate
moiety that is attached to the protein via an oxygen-containing or a nitrogen-containing
side chain of an amino acid residue, e. g., a serine residue or an asparagine residue.
By an "isolated" polypeptide or a fragment, variant, or derivative f is
intended a polypeptide that is not in its natural milieu. No particular level of purification
is required. For example, an ed polypeptide can be removed from its native or
natural environment. Recombinantly produced polypeptides and proteins expressed in
host cells are considered isolated as sed herein, as are native or recombinant
polypeptides which have been ted, fractionated, or partially or ntially purified
by any suitable technique.
Other polypeptides disclosed herein are fragments, derivatives, analogs, or
variants of the foregoing polypeptides, and any combination thereof. The terms
"fragment," nt," "derivative" and "analog" when referring to a binding molecule
such as an dy which specifically binds to Pseudomonas Psl and/or Pch as
disclosed herein e any polypeptides which retain at least some of the antigenbinding
properties of the corresponding native antibody or polypeptide. Fragments of
polypeptides include, for example, proteolytic fragments, as well as deletion fragments, in
addition to specific antibody fragments discussed elsewhere herein. Variants of a binding
molecule, e.g., an antibody which specifically binds to Pseudomonas Psl and/or Pch as
disclosed herein include fragments as bed above, and also polypeptides with altered
amino acid sequences due to amino acid substitutions, deletions, or insertions. Variants
can occur naturally or be non-naturally occurring. Non-naturally occurring variants can
be produced using art—known mutagenesis techniques. Variant polypeptides can comprise
conservative or non—conservative amino acid substitutions, deletions or additions.
Derivatives of a binding le, e.g., an antibody which specifically binds to
Pseudomonas Psl and/or Pch as disclosed herein are polypeptides which have been
altered so as to exhibit additional es not found on the native polypeptide. Examples
include fusion proteins. t polypeptides can also be referred to herein as
"polypeptide analogs. H As used herein a "derivative" of a binding molecule, e.g., an
antibody which specifically binds to Pseudomonas Psl and/or Pch refers to a subject
polypeptide having one or more residues chemically tized by reaction of a
functional side group. Also included as "derivatives" are those peptides which contain one
or more naturally occurring amino acid derivatives of the twenty rd amino acids.
For example, 4-hydroxyproline can be substituted for proline; 5-hydroxylysine can be
substituted for lysine; 3-methylhistidine can be substituted for histidine; homoserine can
be substituted for serine; and ornithine can be substituted for lysine.
The term ucleotide" is intended to encompass a singular nucleic acid as
well as plural nucleic acids, and refers to an isolated nucleic acid molecule or construct,
e.g., messenger RNA (mRNA) or plasmid DNA (pDNA). A polynucleotide can comprise
a conventional phosphodiester bond or a non—conventional bond (e.g., an amide bond,
such as found in peptide nucleic acids (PNA)). The term "nucleic acid" refers to any one
or more nucleic acid segments, e.g., DNA or RNA fragments, present in a polynucleotide.
By "isolated" nucleic acid or polynucleotide is ed a nucleic acid molecule, DNA or
RNA, which has been removed from its native environment. For example, a recombinant
polynucleotide encoding a binding molecule, e.g., an dy which ically binds to
Pseudomonas Psl and/or Pch contained in a vector is considered ed as disclosed
herein. Further examples of an isolated polynucleotide include recombinant
polynucleotides maintained in heterologous host cells or ed (partially or
substantially) polynucleotides in solution. Isolated RNA molecules include in vivo or in
vitro RNA transcripts of polynucleotides. Isolated polynucleotides or nucleic acids
further e such molecules produced synthetically. In on, polynucleotide or a
nucleic acid can be or can include a regulatory element such as a promoter, ribosome
binding site, or a ription terminator.
As used herein, a "coding " is a portion of nucleic acid which consists of
codons translated into amino acids. Although a "stop codon" (TAG, TGA, or TAA) is not
translated into an amino acid, it can be considered to be part of a coding region, but any
flanking sequences, for example promoters, ribosome binding sites, transcriptional
2012/063722
terminators, introns, and the like, are not part of a coding region. Two or more coding
regions can be present in a single cleotide construct, e.g., on a single vector, or in
te polynucleotide constructs, e.g., on separate (different) vectors. rmore, any
vector can contain a single coding region, or can comprise two or more coding regions,
e.g., a single vector can separately encode an globulin heavy chain variable
region and an immunoglobulin light chain variable region. In addition, a vector,
polynucleotide, or c acid can encode heterologous coding regions, either fused or
unfused to a nucleic acid encoding an a binding molecule which specifically binds to
Pseudomonas Psl and/or Pch, e.g., an antibody, or antigen-binding fragment, variant, or
derivative thereof. Heterologous coding regions include without limitation specialized
elements or motifs, such as a secretory signal peptide or a heterologous onal
domain.
In n embodiments, the polynucleotide or nucleic acid is DNA. In the case of
DNA, a polynucleotide comprising a nucleic acid which encodes a polypeptide normally
can include a promoter and/or other ription or translation control elements operably
associated with one or more coding regions. An operable association is when a coding
region for a gene product, e.g., a polypeptide, is associated with one or more regulatory
sequences in such a way as to place expression of the gene product under the influence or
control of the tory sequence(s). Two DNA fragments (such as a polypeptide coding
region and a promoter associated therewith) are "operably associated" if induction of
promoter function results in the transcription of mRNA encoding the desired gene product
and if the nature of the e between the two DNA fragments does not interfere with
the ability of the expression regulatory sequences to direct the expression of the gene
product or interfere with the y of the DNA template to be ribed. Thus, a
promoter region would be operably associated with a nucleic acid encoding a polypeptide
if the promoter was capable of effecting transcription of that nucleic acid. The promoter
can be a cell—specific promoter that directs substantial transcription of the DNA only in
predetermined cells. Other transcription l elements, besides a promoter, for
example enhancers, ors, repressors, and transcription termination signals, can be
operably ated with the polynucleotide to direct cell-specific transcription. Suitable
promoters and other transcription control regions are disclosed herein.
A variety of transcription control regions are known to those skilled in the art.
These include, without limitation, transcription control regions which on in
vertebrate cells, such as, but not limited to, promoter and er segments from
galoviruses (the immediate early promoter, in conjunction with intron-A), simian
virus 40 (the early promoter), and retroviruses (such as Rous sarcoma virus). Other
transcription l regions e those derived from vertebrate genes such as actin,
heat shock protein, bovine growth hormone and rabbit B-globin, as well as other
sequences capable of controlling gene expression in eukaryotic cells. Additional suitable
transcription control regions include tissue—specific promoters and enhancers as well as
lymphokine—inducible promoters (e.g., promoters inducible by interferons or
interleukins).
Similarly, a variety of ation control ts are known to those of ry
skill in the art. These include, but are not limited to ribosome binding sites, translation
initiation and termination codons, and elements derived from picornaviruses (particularly
an internal ribosome entry site, or IRES, also referred to as a CITE sequence).
In other embodiments, a polynucleotide can be RNA, for example, in the form of
messenger RNA (mRNA).
cleotide and c acid coding regions can be associated with additional
coding regions which encode secretory or signal peptides, which direct the ion of a
polypeptide encoded by a polynucleotide as disclosed herein, e.g., a polynucleotide
encoding a binding molecule which specifically binds to Pseudomonas Ps1 and/or Pch,
e. g., an antibody, or antigen-binding fragment, variant, or derivative thereof. According
to the signal hypothesis, proteins secreted by mammalian cells have a signal peptide or
secretory leader sequence which is cleaved from the mature protein once export of the
growing protein chain across the rough endoplasmic reticulum has been initiated. Those
of ordinary skill in the art are aware that polypeptides secreted by vertebrate cells
generally have a signal peptide fused to the inus of the polypeptide, which is
cleaved from the complete or "full length" polypeptide to produce a secreted or "mature"
form of the polypeptide. In certain embodiments, the native signal peptide, e.g., an
immunoglobulin heavy chain or light chain signal peptide is used, or a functional
derivative of that sequence that retains the ability to direct the secretion of the polypeptide
that is ly associated with it. Alternatively, a heterologous mammalian signal
peptide, or a functional derivative thereof, can be used. For example, the wild—type leader
sequence can be substituted with the leader sequence of human tissue plasminogen
activator (TPA) or mouse B—glucuronidase.
Disclosed herein are certain binding molecules, or antigen—binding fragments,
variants, or derivatives thereof. Unless ically referring to full—sized antibodies such
as naturally—occurring antibodies, the term "binding molecule" encompasses full—sized
antibodies as well as antigen-binding fragments, variants, analogs, or derivatives of such
antibodies, e.g., naturally occurring antibody or immunoglobulin molecules or engineered
antibody les or fragments that bind antigen in a manner similar to dy
molecules.
As used herein, the term “binding molecule” refers in its broadest sense to a
molecule that specifically binds an antigenic determinant. As described further herein, a
binding molecule can comprise one of more of the binding domains bed herein. As
used herein, a ng " includes a site that specifically binds the antigenic
determinant. A non-limiting example of an antigen g molecule is an antibody or
nt thereof that retains antigen-specific binding.
The terms "antibody" and "immunoglobulin" can be used interchangeably herein.
An antibody (or a fragment, variant, or derivative thereof as disclosed herein comprises at
least the variable domain of a heavy chain and at least the variable s of a heavy
chain and a light chain. Basic immunoglobulin structures in vertebrate s are
relatively well understood. See, e.g., Harlow et al., Antibodies: A Laboratory Manual,
(Cold Spring Harbor Laboratory Press, 2nd ed. 1988).
As will be discussed in more detail below, the term oglobulin” comprises
various broad classes of polypeptides that can be guished biochemically. Those
skilled in the art will appreciate that heavy chains are classified as gamma, mu, alpha,
delta, or epsilon, (y, u, 0L, 8, a) with some subclasses among them (e. g., yl—y4). It is the
nature of this chain that ines the "class" of the dy as IgG, IgM, IgA IgG, or
IgE, respectively. The immunoglobulin subclasses (isotypes) e.g., IgGl, Ing, IgG3, IgG4,
IgA1, etc. are well characterized and are known to confer functional specialization.
Modified versions of each of these classes and isotypes are readily discernible to the
skilled artisan in view of the instant disclosure and, accordingly, are within the scope of
this disclosure.
WO 70615
Light chains are classified as either kappa or lambda (K, 9»). Each heavy chain
class can be bound with either a kappa or lambda light chain. In general, the light and
heavy chains are covalently bonded to each other, and the "tail" portions of the two heavy
chains are bonded to each other by covalent disulflde linkages or non—covalent linkages
when the immunoglobulins are generated either by hybridomas, B cells or genetically
engineered host cells. In the heavy chain, the amino acid sequences run from an N-
terminus at the forked ends of the Y configuration to the C-terminus at the bottom of each
chain.
Both the light and heavy chains are diVided into regions of structural and
functional homology. The terms "constant" and "variable" are used functionally. In this
regard, it will be appreciated that the variable domains of both the light (VL) and heavy
(VH) chain portions determine antigen recognition and specificity. Conversely, the
nt domains of the light chain (CL) and the heavy chain (CH1, CH2 or CH3) confer
important biological ties such as secretion, transplacental mobility, Fc receptor
binding, complement binding, and the like. By convention the numbering of the constant
region s increases as they become more distal from the antigen g site or
amino-terminus of the antibody. The N—terminal portion is a variable region and at the C-
terminal portion is a constant region; the CH3 and CL domains actually se the
carboxy-terminus of the heavy and light chain, respectively.
As indicated above, the variable region allows the binding molecule to selectively
recognize and specifically bind epitopes on antigens. That is, the VL domain and VH
, or subset of the complementarity determining regions (CDRs), of a binding
molecule, e.g., an antibody combine to form the variable region that s a three
dimensional antigen binding site. This quaternary binding le structure forms the
antigen binding site present at the end of each arm of the Y. More ically, the
antigen binding site is defined by three CDRs on each of the VH and VL chains.
In naturally occurring antibodies, the six “complementarity ining regions”
or “CDRs” present in each antigen binding domain are short, non—contiguous sequences
of amino acids that are specifically positioned to form the antigen binding domain as the
antibody assumes its three dimensional configuration in an aqueous environment. The
remainder of the amino acids in the n binding s, referred to as "framework"
regions, show less inter-molecular variability. The framework regions largely adopt a [3-
sheet conformation and the CDRs form loops which connect, and in some cases form part
of, the B—sheet ure. Thus, framework regions act to form a scaffold that provides for
positioning the CDRs in correct orientation by inter-chain, non-covalent interactions. The
antigen binding domain formed by the positioned CDRs defines a surface complementary
to the epitope on the immunoreactive antigen. This complementary e promotes the
valent binding of the antibody to its cognate epitope. The amino acids comprising
the CDRs and the framework regions, respectively, can be readily identified for any given
heavy or light chain variable region by one of ordinary skill in the art, since they have
been precisely defined (see, "Sequences of Proteins of Immunological Interest," Kabat,
E., et al., U.S. Department of Health and Human Services, (1983); and Chothia and Lesk,
J. M01. Biol., [96:901—917 (1987), which are incorporated herein by reference in their
entireties).
In the case where there are two or more definitions of a term which is used and/or
accepted within the art, the definition of the term as used herein is intended to include all
such meanings unless explicitly stated to the contrary. A specific example is the use of the
term "complementarity determining region" ("CDR") to describe the non—contiguous
n ing sites found within the variable region of both heavy and light chain
polypeptides. This particular region has been bed by Kabat et al., U.S. Dept. of
Health and Human Services, "Sequences of Proteins of Immunological Interest" (1983)
and by Chothia et al., J. M01. Biol. 196:901—917 (1987), which are incorporated herein by
nce, where the definitions include overlapping or subsets of amino acid residues
when ed against each other. Nevertheless, application of either definition to refer
to a CDR of an dy or ts thereof is intended to be within the scope of the term
as defined and used herein. The riate amino acid residues which encompass the
CDRs as defined by each of the above cited references are set forth below in Table I as a
comparison. The exact residue numbers which encompass a ular CDR will vary
depending on the sequence and size of the CDR. Those skilled in the art can routinely
determine which residues comprise a particular CDR given the variable region amino acid
sequence of the antibody.
:CDR[mfimfimm1
Kabat Chothia
VH CDRl
VH CDR2
VH CDR3
VL CDRl
VL CDR2 50—56 50—52
VL CDR3 89—97 91—96
1Numbering of all CDR definitions in Table l is ing to the
numbering conventions set forth by Kabat et all. (see below).
Kabat et al. also defined a numbering system for variable domain sequences that
is applicable to any antibody. One of ordinary skill in the art can unambiguously assign
this system of "Kabat numbering" to any variable domain sequence, without ce on
any experimental data beyond the sequence . As used herein, "Kabat numbering"
refers to the numbering system set forth by Kabat et al., US. Dept. of Health and Human
Services, "Sequence of Proteins of Immunological Interest" (1983). Unless otherwise
specified, references to the numbering of specific amino acid residue positions in a
binding le which specifically binds to Pseudomonas Ps1 and/or Pch, e.g, an
dy, or antigen-binding fragment, variant, or derivative thereof as disclosed herein
are according to the Kabat numbering system.
Binding molecules, e.g., antibodies or antigen-binding nts, ts, or
derivatives thereof include, but are not limited to, polyclonal, monoclonal, human,
humanized, or chimeric antibodies, single chain antibodies, e-binding fragments,
e.g., Fab, Fab' and F(ab')2, Fd, Fvs, single-chain Fvs (scFv), single-chain antibodies,
disulflde—linked Fvs (dev), fragments comprising either a VL or VH domain, fragments
produced by a Fab expression y. ScFv molecules are known in the art and are
described, e.g., in US patent 5,892,019. Immunoglobulin or antibody molecules
encompassed by this disclosure can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and
IgY), class (e.g., IgGl, IgG2, IgG3, IgG4, IgAl and IgA2) or subclass of
immunoglobulin molecule.
By "specifically binds," it is lly meant that a binding molecule, e.g., an
antibody or fragment, variant, or derivative thereof binds to an epitope via its antigen
binding , and that the binding entails some complementarity between the antigen
binding domain and the epitope. According to this definition, a binding molecule is said
to "specifically bind" to an e when it binds to that e, via its antigen binding
domain more y than it would bind to a random, unrelated epitope. The term
"specificity" is used herein to qualify the relative affinity by which a certain binding
molecule binds to a certain epitope. For example, binding molecule "A" may be deemed
to have a higher specificity for a given epitope than binding molecule "B," or binding
molecule "A" may be said to bind to epitope "C" with a higher specificity than it has for
related epitope "D."
By "preferentially binds," it is meant that the antibody specifically binds to an
epitope more y than it would bind to a d, similar, homologous, or analogous
epitope. Thus, an antibody which "preferentially binds" to a given epitope would more
likely bind to that epitope than to a related epitope, even though such an antibody can
cross—react with the related epitope.
By way of non-limiting example, a binding molecule, e.g., an dy can be
considered to bind a first epitope preferentially if it binds said first epitope with a
dissociation constant (KD) that is less than the antibody’s KD for the second epitope. In
another non-limiting example, a binding le such as an antibody can be considered
to bind a first antigen preferentially if it binds the first epitope with an affinity that is at
least one order of magnitudeless than the dy’s KD for the second epitope. In another
non-limiting example, a binding molecule can be considered to bind a first e
preferentially if it binds the first epitope with an affinity that is at least two orders of
magnitude less than the antibody’s KD for the second epitope.
In r non-limiting example, a binding molecule, e. g., an antibody or
fragment, variant, or derivative thereof can be considered to bind a first epitope
preferentially if it binds the first epitope with an off rate (k(off)) that is less than the
antibody’s k(off) for the second epitope. In another non-limiting example, a g
molecule can be considered to bind a first epitope preferentially if it binds the first
epitope with an ty that is at least one order of magnitude less than the antibody’s
k(off) for the second epitope. In another non-limiting example, a binding molecule can be
considered to bind a first epitope preferentially if it binds the first epitope with an affinity
that is at least two orders of magnitude less than the antibody’s k(off) for the second
epitope.
A binding molecule, e. g., an antibody or nt, variant, or derivative thereof
disclosed herein can be said to bind a target antigen, e.g., a polysaccharide disclosed
herein or a fragment or variant thereof with an off rate (k(off)) of less than or equal to 5 X
'2 sec'l, 10'2 sec'l, 5 X 10'3 sec'1 or 10'3 sec'l. A binding molecule as disclosed herein
can be said to bind a target antigen, e. g., a polysaccharide with an off rate (k(off)) less
than or equal to 5 X 10'4 sec'l, 10'4 sec'l, 5 X 10'5 sec'l, or 10'5 sec'1 5 X 10'6 sec'l, 10'6
sec'l, 5 X 10'7 sec"1 or 10'7 sec'l.
A binding molecule, e.g., an antibody or antigen-binding nt, variant, or
derivative disclosed herein can be said to bind a target antigen, e. g., a polysaccharide with
an on rate (k(on)) of greater than or equal to 103 M"1 sec'l, 5 X 103 M'1 sec'l, 104 M'1 sec'1
or 5 X 104 M'1 sec'l. A binding molecule as disclosed herein can be said to bind a target
antigen, e. g., a polysaccharide with an on rate (k(on)) greater than or equal to 105 M"1 sec'
1, 5 X 105 M'1 sec'l, 106 M'1 sec'l, or 5 X 106 M'1 sec'1 or 107 M'1 sec'l.
A binding molecule, e.g., an antibody or fragment, variant, or derivative thereof is
said to competitively inhibit binding of a reference antibody or antigen binding fragment
to a given epitope if it preferentially binds to that epitope to the extent that it blocks, to
some degree, binding of the reference antibody or antigen binding fragment to the
epitope. Competitive inhibition can be determined by any method known in the art, for
example, competition ELISA assays. A g molecule can be said to competitively
t binding of the reference antibody or n binding fragment to a given epitope
by at least 90%, at least 80%, at least 70%, at least 60%, or at least 50%.
As used , the term "affinity" refers to a e of the strength of the
g of an individual epitope with the CDR of an immunoglobulin molecule. See, e.g.,
Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press,
2nd ed. 1988) at pages 27—28. As used herein, the term "avidity" refers to the overall
stability of the complex n a population of globulins and an antigen, that is,
the functional combining strength of an immunoglobulin mixture with the antigen. See,
e. g. Harlow at pages 29-34.
, Avidity is related to both the affinity of individual
immunoglobulin molecules in the population with specific epitopes, and also the
valencies of the immunoglobulins and the antigen. For example, the interaction n
a bivalent monoclonal antibody and an antigen with a highly repeating epitope structure,
such as a polymer, would be one of high avidity.
Binding molecules or antigen-binding fragments, variants or derivatives thereof as
disclosed herein can also be described or specified in terms of their cross—reactivity. As
used herein, the term "cross-reactivity" refers to the ability of a g molecule, e. g., an
antibody or fragment, variant, or derivative f, specific for one antigen, to react with
a second antigen; a measure of relatedness between two ent antigenic substances.
Thus, a binding molecule is cross ve if it binds to an epitope other than the one that
induced its formation. The cross reactive epitope generally contains many of the same
complementary structural features as the inducing epitope, and in some cases, can
actually fit better than the original.
A g molecule, e. g., an antibody or fragment, variant, or derivative thereof
can also be described or specified in terms of their binding ty to an n. For
example, a binding molecule can bind to an n with a dissociation constant or KD no
greater than 5 x 10'2 M, 10'2 M, 5 x 10'3 M, 10'3 M, 5 x 10'4 M, 10'4 M, 5 x 10'5 M, 10'5 M,
x 10‘6 M, 10‘6 M, 5 x 10‘7 M, 10‘7 M, 5 x 10‘8 M, 10‘8 M, 5 x 10‘9 M, 10‘9 M, 5 x 10'10M,
'10M, 5 x 10'11M, , 5 x 10'12M, , 5 x 10‘13 M, 10‘13 M, 5 x 10'14M, 10‘14
M, 5 x 10'15 M, or 10'15 M.
Antibody fragments including single-chain dies can se the variable
region(s) alone or in combination with the entirety or a portion of the following: hinge
region, CH1, CH2, and CH3 domains. Also included are antigen-binding fragments also
comprising any combination of variable (s) with a hinge region, CH1, CH2, and
CH3 domains. Binding molecules, e. g., antibodies, or antigen-binding fragments thereof
disclosed herein can be from any animal origin including birds and mammals. The
antibodies can be human, , donkey, rabbit, goat, guinea pig, camel, llama, horse, or
chicken antibodies. In another embodiment, the variable region can be condricthoid in
origin (e. g., from sharks). As used herein, "human" antibodies include antibodies having
the amino acid sequence of a human immunoglobulin and include antibodies isolated
from human immunoglobulin libraries or from animals transgenic for one or more human
immunoglobulins and that do not express endogenous immunoglobulins, as described
infra and, for example in, US. Pat. No. 5,939,598 by Kucherlapati et a1.
As used herein, the term “heavy chain portion” includes amino acid sequences
derived from an immunoglobulin heavy chain. a binding molecule, e.g., an antibody
comprising a heavy chain portion comprises at least one of: a CHl domain, a hinge (e.g.,
upper, middle, and/or lower hinge region) domain, a CH2 domain, a CH3 domain, or a
variant or fragment f. For example, a binding molecule, e.g., an dy or
fragment, variant, or derivative thereof can comprise a ptide chain comprising a
CHl domain; a polypeptide chain comprising a CHl domain, at least a portion of a hinge
domain, and a CH2 domain; a polypeptide chain comprising a CHl domain and a CH3
domain; a ptide chain comprising a CHl domain, at least a portion of a hinge
domain, and a CH3 domain, or a polypeptide chain comprising a CHl domain, at least a
portion of a hinge , a CH2 domain, and a CH3 domain. In another ment, a
binding molecule, e.g., an antibody or nt, variant, or derivative thereof comprises a
polypeptide chain comprising a CH3 domain. Further, a binding molecule for use in the
disclosure can lack at least a portion of a CH2 domain (e.g., all or part of a CH2 domain).
As set forth above, it Will be understood by one of ordinary skill in the art that these
domains (e.g., the heavy chain portions) can be modified such that they vary in amino
acid sequence from the lly occurring immunoglobulin molecule.
The heavy chain portions of a binding molecule, e.g., an antibody as disclosed
herein can be derived from different immunoglobulin molecules. For example, a heavy
chain portion of a polypeptide can comprise a CHl domain derived from an IgGl
molecule and a hinge region derived from an IgG3 molecule. In another example, a
heavy chain portion can comprise a hinge region derived, in part, from an IgGl molecule
and, in part, from an IgG3 le. In another example, a heavy chain portion can
comprise a chimeric hinge derived, in part, from an IgGl molecule and, in part, from an
IgG4 molecule.
As used herein, the term “light chain portion” includes amino acid sequences
d from an immunoglobulin light chain. The light chain portion comprises at least
one of a VL or CL domain.
Binding molecules, e.g., antibodies or antigen-binding fragments, variants, or
derivatives thereof disclosed herein can be described or specified in terms of the
epitope(s) or portion(s) of an antigen, e. g., a target ccharide that they recognize or
specifically bind. The portion of a target polysaccharide which specifically cts with
the n binding domain of an antibody is an "epitope," or an "antigenic determinant."
A target antigen, e.g., a polysaccharide can comprise a single e, but typically
ses at least two epitopes, and can include any number of epitopes, ing on
the size, conformation, and type of antigen.
As previously indicated, the subunit ures and three dimensional
configuration of the constant regions of the various immunoglobulin s are well
known. As used herein, the term “VH domain” includes the amino terminal variable
domain of an immunoglobulin heavy chain and the term “CHl domain” includes the first
(most amino terminal) constant region domain of an immunoglobulin heavy chain. The
CHl domain is adjacent to the VH domain and is amino terminal to the hinge region of an
immunoglobulin heavy chain molecule.
As used herein the term “CH2 domain” includes the portion of a heavy chain
molecule that s, e.g., from about residue 244 to residue 360 of an antibody using
conventional numbering schemes ues 244 to 360, Kabat numbering system; and
residues 231—340, EU numbering system; see Kabat EA et a1. op. cit. The CH2 domain is
unique in that it is not closely paired with another domain. Rather, two N—linked
branched carbohydrate chains are interposed n the two CH2 domains of an intact
native IgG molecule. It is also well documented that the CH3 domain s from the
CH2 domain to the C-terminal of the IgG molecule and comprises approximately 108
residues.
As used herein, the term “hinge region” includes the portion of a heavy chain
molecule that joins the CH1 domain to the CH2 domain. This hinge region comprises
approximately 25 residues and is flexible, thus allowing the two N—terminal antigen
binding regions to move independently. Hinge regions can be subdivided into three
distinct s: upper, middle, and lower hinge domains (Roux et al., J. Immunol.
[61:4083 (1998)).
As used herein the term “disulfide bond” includes the covalent bond formed
n two sulfur atoms. The amino acid cysteine comprises a thiol group that can form
a disulfide bond or bridge with a second thiol group. In most naturally occurring IgG
les, the CH1 and CL regions are linked by a disulfide bond and the two heavy
chains are linked by two disulfide bonds at positions corresponding to 239 and 242 using
the Kabat numbering system ion 226 or 229, EU numbering system).
As used herein, the term “chimeric antibody” will be held to mean any antibody
wherein the immunoreactive region or site is obtained or derived from a first species and
WO 70615
the constant region (which can be intact, partial or modified) is ed from a second
species. In some embodiments the target binding region or site will be from a non—human
source (6. g. mouse or primate) and the constant region is human.
The term "bispecific antibody" as used herein refers to an antibody that has
binding sites for two different antigens within a single antibody molecule. It will be
appreciated that other molecules in addition to the canonical antibody structure can be
constructed with two g speciflcities. It will further be appreciated that antigen
binding by bispeciflc antibodies can be simultaneous or sequential. Triomas and hybrid
hybridomas are two examples of cell lines that can secrete bispeciflc antibodies.
Bispeciflc antibodies can also be constructed by recombinant means. (Strohlein and
Heiss, Future Oncol. 6:1387—94 ; Mabry and Snavely, [Drugs. 13 :543—9 (2010)).
As used herein, the term "engineered antibody" refers to an antibody in which the
variable domain in either the heavy and light chain or both is altered by at least partial
replacement of one or more CDRs from an antibody of known specificity and, if
necessary, by l ork region replacement and sequence ng. gh
the CDRs can be derived from an antibody of the same class or even subclass as the
antibody from which the framework regions are derived, it is envisaged that the CDRs
will be derived from an antibody of different class and preferably from an antibody from
a different species. An engineered antibody in which one or more "donor" CDRs from a
non-human dy of known specificity is d into a human heavy or light chain
framework region is referred to herein as a "humanized dy." It may not be
necessary to replace all of the CDRs with the complete CDRs from the donor variable
region to transfer the antigen binding capacity of one variable domain to another. Rather,
it may only be necessary to transfer those residues that are necessary to maintain the
activity of the target g site. Given the explanations set forth in, e. g., U. S. Pat. Nos.
,585,089, 5,693,761, 5,693,762, and 6,180,370, it will be well within the competence of
those d in the art, either by carrying out routine experimentation or by trial and error
testing to obtain a functional engineered or humanized antibody.
As used herein the term “properly folded polypeptide” includes polypeptides (e.g.,
anti—Pseudomonas Ps1 and Pch antibodies) in which all of the functional domains
comprising the polypeptide are distinctly active. As used herein, the term “improperly
folded polypeptide” includes ptides in which at least one of the functional domains
of the ptide is not active. In one embodiment, a properly folded polypeptide
comprises polypeptide chains linked by at least one disulfide bond and, conversely, an
improperly folded polypeptide comprises polypeptide chains not linked by at least one
disulfide bond.
As used herein the term “engineered” includes manipulation of nucleic acid or
polypeptide molecules by synthetic means (e.g. by recombinant techniques, in vitro
peptide synthesis, by enzymatic or chemical coupling of es or some combination of
these techniques).
As used herein, the terms "linked," "fused" or "fusion" are used interchangeably.
These terms refer to the joining er of two more elements or ents, by
whatever means including chemical conjugation or recombinant means. An "in-frame
fusion" refers to the joining of two or more polynucleotide open reading frames (ORFs)
to form a continuous longer ORF, in a manner that maintains the correct translational
reading frame of the original ORFs. Thus, a inant fusion protein is a single protein
ning two or more segments that correspond to polypeptides encoded by the original
ORFs (which ts are not normally so joined in .) Although the reading frame
is thus made continuous throughout the fused segments, the segments can be physically or
spatially separated by, for example, in-frame linker ce. For example,
polynucleotides encoding the CDRs of an immunoglobulin variable region can be fused,
in-frame, but be separated by a polynucleotide encoding at least one immunoglobulin
framework region or additional CDR regions, as long as the "fused" CDRs are co—
translated as part of a continuous polypeptide.
In the context of polypeptides, a "linear ce" or a nce" is an order of
amino acids in a polypeptide in an amino to carboxyl terminal direction in which residues
that neighbor each other in the sequence are contiguous in the primary structure of the
polypeptide.
The term “expression” as used herein refers to a process by which a gene produces
a biochemical, for example, a polypeptide. The process includes any manifestation of the
functional presence of the gene within the cell including, without tion, gene
knockdown as well as both transient expression and stable expression. It includes without
limitation transcription of the gene into ger RNA (mRNA), and the translation of
such mRNA into polypeptide(s). If the final desired product is a biochemical, expression
includes the creation of that biochemical and any precursors. Expression of a gene
produces a "gene t." As used herein, a gene product can be either a nucleic acid,
e.g., a messenger RNA produced by ription of a gene, or a polypeptide which is
translated from a transcript. Gene products described herein further include nucleic acids
with post transcriptional modifications, e.g., polyadenylation, or polypeptides with post
translational modifications, e. g., ation, glycosylation, the addition of lipids,
association with other protein subunits, lytic cleavage, and the like.
As used herein, the terms "treat" or "treatment" refer to both therapeutic treatment
and prophylactic or preventative measures, wherein the object is to prevent or slow down
(lessen) an undesired physiological change, infection, or disorder. cial or desired
al results include, but are not limited to, alleviation of symptoms, shment of
extent of disease, stabilized (i.e., not ing) state of disease, clearance or reduction of
an infectious agent such as P. aeruginosa in a subject, a delay or slowing of disease
ssion, amelioration or palliation of the disease state, and remission (whether partial
or total), whether detectable or undetectable. "Treatment" can also mean prolonging
survival as compared to expected al if not receiving treatment. Those in need of
ent include those y with the infection, condition, or disorder as well as those
prone to have the condition or disorder or those in which the condition or disorder is to be
prevented, e.g., in burn patients or immunosuppressed patients susceptible to P.
aeruginosa infection.
By "subject" or "individual" or "animal" or "patient" or “mammal,” is meant any
t, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is
desired. Mammalian subjects include humans, domestic animals, farm animals, and zoo,
sports, or pet animals such as dogs, cats, guinea pigs, s, rats, mice, horses, cattle,
cows, bears, and so on.
As used herein, phrases such as “a subject that would benefit from administration
of anti—Pseudomonas Psl and Pch binding domains or binding molecules” and “an
animal in need of treatment” includes subjects, such as mammalian subjects, that would
benefit from administration of anti-Pseudomonas Psl and Pch binding domains or a
binding molecule, such as an antibody, comprising one or more of the binding s.
Such binding s, or binding molecules can be used, e.g., for detection of
Pseudomonas Psl or Pch (e.g., for a diagnostic procedure) and/or for treatment, i.e.,
palliation or prevention of a disease, with seudomonas PSI and Pch binding
molecules. As described in more detail herein, the seudomonas Ps1 and Pch
binding molecules can be used in unconjugated form or can be conjugated, e.g., to a drug,
prodrug, or an e.
The term "synergistic effect", as used herein, refers to a greater-than-additive
therapeutic effect produced by a combination of compounds wherein the therapeutic
effect obtained with the combination s the additive s that would otherwise
result from individual administration the compounds alone. Certain embodiments include
methods of producing a synergistic effect in the treatment of Pseudomonas infections,
wherein said effect is at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at
least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least
200%, at least 500%, or at least 1000% greater than the corresponding additive .
ministration" refers to the administration of different nds, such as
an anti-Psl and an anti-Pch binding domain, or binding molecule comprising one or both
an anti-Ps1 and anti-Pch binding domain, such that the compounds elicit a synergistic
effect on anti—Pseudomonas immunity. The compounds can be administered in the same
or different compositions which if separate are administered proximate to one another,
generally within 24 hours of each other and more typically within about 1-8 hours of one
another, and even more typically within 1-4 hours of each other or close to simultaneous
administration. The relative amounts are s that achieve the desired synergism.
II. BINDING DOMAINS AND BINDING MOLECULES
dies that bind Ps1 and formats for using these antibodies have been
described in the art. See, for example, International Application Nos.
2012/041538, filed June 8, 2012, and , filed November 6,
2012 (attorney docket no. AEMS-115WOl, entitled “MULTISPECIFIC AND
MULTIVALENT BINDING PROTEINS AND USES THEREOF”), which are herein
incorporated in their entireties by reference.
One embodiment is directed to binding domains that specifically bind to
Pseudomonas Pch, n binding can t the activity of the type III toxin
secretion system. In certain embodiments, the binding domains have the same
Pseudomonas binding specificity as the antibody V2L2.
2012/063722
r embodiment is directed to binding domains that specifically bind to
Pseudomonas Psl or Pch, wherein administration of both binding domains results in
synergistic effects against Pseudomonas infections by (a) inhibiting attachment of
Pseudomonas aeruginosa to epithelial cells, (b) promoting, mediating, or enhancing
opsonophagocytic killing (OPK) of P. nosa, (c) inhibiting ment of P.
aeruginosa to epithelial cells, or (d) disrupting the ty of the type III toxin secretion
system. In certain ments, the binding domains have the same Pseudomonas
binding specificity as the antibodies 3, WapR-004, V2L2, or 29D2.
Other embodiments are directed to an isolated binding molecule(s) comprising
one or both g domains that specifically bind to Pseudomonas Psl and/or Pch,
wherein administration of the binding molecule results in synergistic effects t
Pseudomonas infections. In certain embodiments, the binding molecule can comprise a
binding domain from the antibodies or fragments thereof that include, but are not limited
to Cam—003,WapR—004, V2L2, or 29D22.
As used herein, the terms "binding domain" or "antigen binding " includes
a site that specifically binds an epitope on an antigen (e.g., an epitope of Pseudomonas
Psl or Pch). The antigen binding domain of an antibody typically includes at least a
portion of an immunoglobulin heavy chain variable region and at least a portion of an
immunoglobulin light chain variable region. The binding site formed by these variable
regions ines the specificity of the antibody.
The disclosure is more specifically directed to a composition comprising at least
two anti—Pseudomonas binding s, wherein one binding domain specifically binds
Psl and the other binding domain ically binds Pch. In one embodiment, the
composition comprises one binding domain that specifically binds to the same
Pseudomonas Psl e as an antibody or antigen-binding fragment thereof comprising
the heavy chain variable region (VH) and light chain variable region (VL) region of
WapR—004, Cam—003, Cam—004, Cam—005, WapR—OOl, WapR—002, WapR—003, or
WapR—Ol6. In certain embodiments, the second binding domain specifically binds to the
same Pseudomonas Pch epitope as an antibody or antigen binding fragment thereof
comprising the heavy chain variable region (VH) and light chain variable region (VL) of
V2L2 or 29D2.
In one embodiment, the composition ses one binding domain that
specifically binds to Pseudomonas Psl and/or competitively inhibits Pseudomonas Psl
binding by an antibody or antigen-binding fragment thereof comprising the VH and VL
of WapR—004, Cam—003, Cam—004, Cam—005, WapR—OOl, WapR—002, WapR—003, or
WapR—Ol6. In certain embodiments, the second binding domain specifically binds to the
same Pseudomonas Pch epitope and/or competitively inhibits Pseudomonas Pch
g by an antibody or antigen g fragment thereof comprising the heavy chain
variable region (VH) and light chain variable region (VL) of V2L2 or 29D2.
r embodiment is directed to an isolated g molecule, e.g., an antibody
or antigen-binding fragment thereof which specifically binds to the same Pseudomonas
Pch epitope as an antibody or antigen-binding fragment thereof comprising the VH and
VL region ofV2L2 or 29D2.
Also included is an isolated binding molecule, e. g., an antibody or fragment
thereof which specifically binds to Pseudomonas Pch and itively ts
Pseudomonas Pch binding by an antibody or antigen-binding fragment thereof
comprising the VH and VL ofV2L2 or 29D2.
One embodiment is directed to an isolated binding molecule, e.g., an dy or
antigen-binding fragment thereof which specifically binds to the same Pseudomonas Psl
e as an antibody or antigen-binding fragment thereof comprising the VH and VL
region of WapR—OOl, WapR—002, or WapR—003.
Also ed is an isolated binding molecule, e. g., an antibody or fragment
f which specifically binds to Pseudomonas Psl and competitively inhibits
monas Psl binding by an dy or antigen-binding fragment thereof comprising
the VH and VL of WapR—OOl, WapR—002, or WapR—003.
Further included is an isolated binding molecule, e.g., an antibody or fragment
thereof which specifically binds to the same monas Psl epitope as an antibody or
antigen-binding fragment thereof comprising the VH and VL of WapR—Ol6.
Also included is an isolated binding molecule, e. g., an antibody or fragment
thereof which specifically binds to Pseudomonas Psl and competitively inhibits
Pseudomonas Psl binding by an antibody or antigen-binding fragment thereof comprising
the VH and VL of WapR—Ol6.
Methods of making dies are well known in the art and described .
Once antibodies to various fragments of, or to the full—length Pseudomonas Psl or Pch
without the signal sequence, have been produced, determining which amino acids, or
epitope, of Pseudomonas Psl or Pch to which the antibody or antigen binding nt
binds can be determined by epitope mapping ols as described herein as well as
methods known in the art (e. g. double antibody—sandwich ELISA as described in
er 11 - Immunology," Current Protocols in Molecular Biology, Ed. Ausubel et al.,
v.2, John Wiley & Sons, Inc. (1996)). Additional epitope mapping protocols can be
found in Morris, G. Epitope Mapping Protocols, New Jersey: Humana Press (1996),
which are both orated herein by reference in their entireties. Epitope mapping can
also be performed by commercially available means (i.e. ProtoPROBE, Inc. (Milwaukee,
Wisconsin)).
In certain aspects, the disclosure is directed to a binding molecule, e.g., an
dy or fragment, variant, or derivative thereof which specifically binds to
Pseudomonas Psl and/or Pch with an affinity characterized by a dissociation nt
(KD) which is less than the KD for said reference monoclonal antibody.
In certain embodiments an anti—Pseudomonas Psl and/or Pch binding molecule,
e. g., an antibody or antigen-binding fragment, variant or derivative thereof as disclosed
herein binds specifically to at least one epitope of Psl or Pch, i.e., binds to such an
epitope more readily than it would bind to an unrelated, or random epitope; binds
preferentially to at least one e of Psl or Pch, i.e., binds to such an epitope more
y than it would bind to a related, similar, homologous, or analogous epitope;
competitively inhibits binding of a reference antibody which itself binds specifically or
preferentially to a certain epitope of Psl or Pch; or binds to at least one epitope of Psl or
Pch with an affinity characterized by a iation constant KD of less than about 5 X
‘2 M, about 10‘2 M, about 5 x 10‘3 M, about 10‘3 M, about 5 x 10‘4 M, about 10‘4 M,
about 5 x 10'5 M, about 10'5 M, about 5 x 10'6 M, about 10'6 M, about 5 x 10'7 M, about 10'
M, about 5 x 10‘8 M, about 10‘8 M, about 5 x 10‘9 M, about 10‘9 M, about 5 x 10‘10 M,
about 10'10 M, about 5 x 10'11 M, about 10'11 M, about 5 x 10'12 M, about 10'12 M, about 5
x 10-13 M, about 10-13 M, about 5 x 10-14 M, about 10-14 M, about 5 x 10‘15 M, or about 10‘
WO 70615
As used in the context of binding dissociation constants, the term " allows
for the degree of variation inherent in the methods utilized for measuring antibody
affinity. For example, depending on the level of precision of the instrumentation used,
standard error based on the number of samples measured, and rounding error, the term
“about 10‘2 M” might e, for example, from 0.05 M to 0.005 M.
In specific embodiments a binding molecule, e. g., an antibody, or antigen-binding
fragment, variant, or derivative thereof binds Pseudomonas Psl and/or Pch with an off
rate (k(off)) of less than or equal to 5 X 10'2 sec'l, 10'2 sec'l, 5 X 10'3 sec"1 or 10'3 sec'l.
Alternatively, an antibody, or antigen-binding fragment, variant, or derivative thereof
binds Pseudomonas Psl and/or Pch with an off rate (k(off)) of less than or equal to 5 X
'4 sec'l, 10'4 sec'l, 5 X 10'5 sec'l, or 10'5 sec'1 5 X 10'6 sec'l, 10'6 sec'l, 5 X 10'7 sec'1 or
'7 sec'l.
In other embodiments, a binding molecule, e. g., an antibody, or antigen-binding
fragment, variant, or derivative thereof as disclosed herein binds monas Psl and/or
Pch with an on rate (k(on)) of greater than or equal to 103 M"1 sec'l, 5 X 103 M"1 sec'l,
104 M'1 sec'1 or 5 X 104 M'1 sec'l. Alternatively, a binding molecule, e.g., an antibody, or
antigen—binding fragment, variant, or derivative thereof as disclosed herein binds
Pseudomonas Psl and/or Pch with an on rate (k(on)) r than or equal to 105 M"1 sec'
1, 5 X 105 M'1 sec'l, 106 M'1 sec'l, or 5 X 106 M'1 sec'1 or 107 M'1 sec'l.
In various embodiments, an seudomonas Psl and/or Pch binding molecule,
e. g., an antibody, or antigen-binding fragment, variant, or derivative thereof as described
herein promotes opsonophagocytic killing of Pseudomonas, or ts Pseudomonas
binding to epithelial cells. In certain embodiments described herein, the Pseudomonas
Psl or Pch target is Pseudomonas aeruginosa Psl or Pch. In other embodiments,
certain binding molecules bed herein can bind to structurally related polysaccharide
molecules regardless of their source. Such Psl—like les would be expected to be
identical to or have sufficient structural relatedness to P. aeruginosa Psl to permit specif1c
recognition by one or more of the binding molecules disclosed. In other embodiments,
certain binding molecules described herein can bind to structurally related polypeptide
molecules regardless of their source. Such ke molecules would be expected to be
cal to or have sufficient structural relatedness to P. aeruginosa Pch to permit
specific recognition by one or more of the g les disclosed. Therefore, for
example, certain binding molecules described herein can bind to Psl-like and/or Pch-like
molecules produced by other bacterial species, for example, Psl—like or Pch—like
molecules produced by other Pseudomonas species, e.g., monas fluorescens,
Pseudomonas putida, 0r Pseudomonas alcaligenes. Alternatively, certain binding
molecules as described herein can bind to Psl—like and/or Pch—like molecules ed
synthetically or by host cells genetically modified to produce Psl-like or Pch-like
molecules.
Unless it is ically noted, as used herein a "fragment thereof' in reference to a
binding molecule, e. g., an antibody refers to an antigen-binding fragment, i.e., a portion
of the antibody which ically binds to the antigen.
Anti—Pseudomonas Psl and/or Pch g molecules, e.g., antibodies or antigen-
binding fragments, variants, or derivatives f can comprise a constant region which
mediates one or more effector functions. For example, binding of the Cl component of
complement to an antibody constant region can activate the complement .
Activation of complement is important in the zation and lysis of pathogens. The
activation of complement also ates the inflammatory se and can also be
involved in autoimmune hypersensitivity. Further, antibodies bind to receptors on
various cells via the Fc region, with a PC receptor binding site on the antibody Fc region
binding to a PC receptor (FcR) on a cell. There are a number of Fc receptors which are
ic for different classes of antibody, ing IgG (gamma receptors), IgE (epsilon
receptors), IgA (alpha receptors) and IgM (mu receptors). Binding of antibody to Fc
ors on cell surfaces rs a number of important and diverse biological responses
including ment and destruction of antibody-coated particles, clearance of immune
complexes, lysis of antibody—coated target cells by killer cells (called antibody—dependent
cell—mediated cytotoxicity, or ADCC), release of inflammatory mediators, placental
transfer and control of immunoglobulin production.
Accordingly, certain embodiments disclosed herein include an anti—Pseudomonas
Psl and/or Pch binding molecule, e.g., an antibody, or antigen-binding fragment, variant,
or derivative thereof, in which at least a fraction of one or more of the nt region
domains has been deleted or ise altered so as to provide desired biochemical
characteristics such as reduced effector functions, the ability to non—covalently dimerize,
increased ability to localize at the site of a tumor, reduced serum half-life, or increased
serum half-life when compared with a whole, unaltered antibody of imately the
same immunogenicity. For example, certain binding molecules bed herein are
domain deleted antibodies which comprise a polypeptide chain similar to an
immunoglobulin heavy chain, but which lack at least a portion of one or more heavy
chain domains. For instance, in certain antibodies, one entire domain of the constant
region of the modified antibody will be deleted, for example, all or part of the CH2
domain will be deleted.
Modified forms of anti—Pseudomonas Psl and/or Pch binding molecules, e.g.,
antibodies or antigen-binding fragments, variants, or derivatives thereof can be made
from whole precursor or parent antibodies using techniques known in the art. Exemplary
techniques are discussed elsewhere herein.
In certain embodiments both the variable and constant regions of anti-
Pseudomonas Psl and/or Pch binding molecules, e.g., dies or n—binding
nts are fully human. Fully human antibodies can be made using techniques that
are known in the art and as described herein. For example, fully human antibodies
against a specific antigen can be prepared by administering the antigen to a transgenic
animal which has been modified to produce such antibodies in response to antigenic
nge, but whose nous loci have been disabled. Exemplary techniques that can
be used to make such antibodies are described in US patents: 6,150,584; 6,458,592;
6,420,140. Other techniques are known in the art. Fully human anti bodies can likewise
be produced by various display technologies, e.g., phage display or other viral display
systems, as described in more detail elsewhere herein.
Anti—Pseudomonas Psl and/or Pch binding molecules, e.g., antibodies or antigen-
binding fragments, variants, or derivatives thereof as disclosed herein can be made or
manufactured using techniques that are known in the art. In certain ments,
binding molecules or fragments thereof are “recombinantly ed,” i.e., are produced
using recombinant DNA technology. Exemplary techniques for making antibody
molecules or fragments thereof are discussed in more detail elsewhere herein.
In certain anti—Pseudomonas Ps1 and/or Pch binding les, e.g., antibodies
or antigen-binding fragments, variants, or tives thereof bed herein, the Fc
portion can be mutated to decrease effector function using ques known in the art.
For e, the deletion or inactivation (through point mutations or other means) of a
constant region domain can reduce Fc receptor binding of the circulating modified
antibody y increasing tumor localization. In other cases it can be that constant
region modifications te complement binding and thus reduce the serum half-life
and nonspecific association of a conjugated xin. Yet other modifications of the
constant region can be used to modify disulf1de linkages or oligosaccharide moieties that
allow for enhanced localization due to increased antigen specificity or antibody
lity. The resulting physiological profile, bioavailability and other mical
effects of the modifications, such as localization, biodistribution and serum half-life, can
easily be measured and quantified using well known immunological techniques without
undue experimentation.
In certain embodiments, anti—Pseudomonas Ps1 and/or Pch binding molecules,
e.g., antibodies or antigen-binding nts, variants, or derivatives thereof will not
elicit a deleterious immune response in the animal to be treated, e. g., in a human. In one
ment, anti—Pseudomonas Ps1 and/or Pch binding molecules, e.g., antibodies or
antigen-binding fragments, ts, or derivatives thereof are modified to reduce their
immunogenicity using art-recognized techniques. For example, antibodies can be
humanized, de—immunized, or chimeric antibodies can be made. These types of
dies are derived from a non-human antibody, typically a murine or primate
antibody, that s or substantially retains the antigen-binding properties of the parent
antibody, but which is less immunogenic in humans. This can be achieved by various
methods, including (a) grafting the entire non-human variable domains onto human
constant s to generate chimeric antibodies; (b) grafting at least a part of one or
more of the non-human complementarity determining regions (CDRs) into a human
framework and constant s with or without retention of critical framework residues;
or (c) transplanting the entire non-human variable domains, but "cloaking" them with a
like section by replacement of surface residues. Such s are disclosed in
Morrison et al., Proc. Natl. Acad. Sci. 81:6851—6855 (1984); Morrison et al., Adv.
Immunol. 92 (1988); Verhoeyen et al., Science 239:1534—1536 (1988); Padlan,
Molec. Immun. 28:489—498 (1991); Padlan, Molec. Immun. 31:169—217 , and US.
Pat. Nos. 5,585,089, 5,693,761, 5,693,762, and 6,190,370, all of which are hereby
incorporated by reference in their entirety.
De-immunization can also be used to decrease the immunogenicity of an dy.
As used herein, the term “de-immunization” includes tion of an antibody to modify
T cell epitopes (see, e.g., WO9852976A1, WOOO34317A2). For example, VH and VL
sequences from the starting antibody are analyzed and a human T cell epitope "map" from
each V region g the location of epitopes in relation to mentarity-
determining regions (CDRs) and other key residues within the sequence. Individual T cell
epitopes from the T cell epitope map are analyzed in order to identify alternative amino
acid substitutions with a low risk of altering activity of the final antibody. A range of
alternative VH and VL sequences are designed comprising combinations of amino acid
substitutions and these sequences are subsequently incorporated into a range of binding
polypeptides, e.g., Pseudomonas Psl— and/or eciflc antibodies or antigen—binding
fragments thereof disclosed herein, which are then tested for function. Complete heavy
and light chain genes comprising modified V and human C s are then cloned into
expression vectors and the subsequent plasmids introduced into cell lines for the
production of whole antibody. The antibodies are then compared in riate
mical and biological , and the optimal variant is identified.
Anti—Pseudomonas Psl and/or Pch binding molecules, e.g., antibodies or antigen—
binding fragments, variants, or derivatives thereof can be generated by any suitable
method known in the art. Polyclonal antibodies to an antigen of interest can be produced
by various procedures well known in the art. For example, an anti—Pseudomonas Ps1
and/or Pch antibody or n-binding nt thereof can be administered to various
host animals including, but not limited to, rabbits, mice, rats, chickens, hamsters, goats,
donkeys, etc., to induce the production of sera containing polyclonal antibodies specific
for the antigen. s adjuvants can be used to se the immunological response,
depending on the host species, and include but are not d to, Freund's (complete and
incomplete), l gels such as aluminum hydroxide, surface active substances such as
cithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet
hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille
Calmette—Guerin) and Corynebacterium parvum. Such adjuvants are also well known in
the art.
Monoclonal antibodies can be prepared using a wide variety of techniques known
in the art including the use of hybridoma, recombinant, and phage display technologies,
or a combination thereof. For example, monoclonal antibodies can be produced using
hybridoma techniques including those known in the art and taught, for example, in
Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press,
2nd ed. (1988)
DNA encoding dies or antibody fragments (e. g., antigen binding sites) can
also be derived from antibody libraries, such as phage display libraries. In a particular,
such phage can be utilized to display antigen-binding domains expressed from a
repertoire or combinatorial antibody library (e. g., human or murine). Phage expressing an
antigen binding domain that binds the antigen of interest can be selected or fied with
n, e.g., using labeled antigen or antigen bound or captured to a solid surface or
bead. Phage used in these methods are typically filamentous phage including fd and M13
g s expressed from phage with scFv, Fab, Fv OE DAB idual Fv
region from light or heavy ) or disulf1de stabilized Fv antibody domains
inantly fused to either the phage gene III or gene VIII protein. Exemplary
s are set forth, for example, in EP 368 684 B1; US. patent. 5,969,108,
Hoogenboom, HR. and Chames, Immunol. Today 21:371 (2000); Nagy et al. Nat. Med.
8:801 (2002); Huie et al., Proc. Natl. Acad. Sci. USA 982682 (2001); Lui et al., J. Mol.
Biol. 315:1063 (2002), each of which is incorporated herein by reference. Several
publications (e.g., Marks et al., chnology 10:779—783 (1992)) have described the
production of high affinity human antibodies by chain shuffling, as well as combinatorial
infection and in vivo recombination as a strategy for constructing large phage libraries. In
another embodiment, Ribosomal display can be used to replace bacteriophage as the
display rm (see, e.g., Hanes et al., Nat. Biotechnol. 18:1287 (2000); Wilson et al.,
Proc. Natl. Acad. Sci. USA 98:3750 (2001); or Irving et al., J. Immunol. s 248:31
(2001)). In yet another embodiment, cell surface libraries can be screened for antibodies
(Boder et al., Proc. Natl. Acad. Sci. USA 97:10701 ; Daugherty et al., J. Immunol.
Methods 243:211 (2000)). Such procedures provide alternatives to traditional hybridoma
techniques for the isolation and uent cloning of monoclonal antibodies.
In phage display s, functional antibody domains are displayed on the
surface of phage particles which carry the polynucleotide sequences encoding them. For
example, DNA sequences encoding VH and VL regions are amplified from animal cDNA
libraries (e. g., human or murine cDNA libraries of lymphoid tissues) or synthetic cDNA
ies. In certain embodiments, the DNA encoding the VH and VL regions are joined
together by an scFv linker by PCR and cloned into a phagemid vector (e.g., p CANTAB 6
or pComb 3 HSS). The vector is oporated in E. coli and the E. coli is ed with
helper phage. Phage used in these methods are typically ntous phage including fd
and M13 and the VH or VL regions are usually recombinantly fused to either the phage
gene III or gene VIII. Phage expressing an antigen binding domain that binds to an
antigen of st (i.e., Pseudomonas Ps1 or Pch) can be selected or identified with
antigen, e.g., using labeled antigen or antigen bound or captured to a solid e or
bead.
Additional examples of phage display methods that can be used to make the
antibodies include those sed in Brinkman et al., J. Immunol. Methods [82:41—50
(1995); Ames et al., J. Immunol. Methods 184: 177—186 (1995); Kettleborough et al., Eur.
J. Immunol. 24:952—958 (1994); Persic et al., Gene 187:9—18 (1997); Burton et al.,
Advances in logy 57:191—280 (1994); PCT Application No. PCT/GB91/01134;
PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO
93/11236; WO 95/15982; WO 95/20401; and US. Pat. Nos. 5,698,426; 5,223,409;
484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637;
,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by
reference in its entirety.
As described in the above references and in the examples below, after phage
selection, the dy coding regions from the phage can be isolated and used to
generate whole antibodies, including human antibodies, or any other desired antigen
binding fragment, and expressed in any desired host, including mammalian cells, insect
cells, plant cells, yeast, and bacteria. For example, techniques to recombinantly e
Fab, Fab' and F(ab')2 fragments can also be employed using methods known in the art
such as those disclosed in PCT publication WO 92/22324; Mullinax et al., BioTechniques
12(6):864—869 (1992); and Sawai et al., AJRI 34:26—34 (1995); and Better et al., Science
240: 1041—1043 (1988) (said references incorporated by reference in their entireties).
Examples of ques which can be used to e single—chain Fvs and
antibodies include those described in US. Pat. Nos. 4,946,778 and 5,258,498; Huston et
al., Methods in Enzymology 203:46—88 (1991); Shu et al., PNAS 90:7995—7999 (1993);
and Skerra et al., e 240:1038—1040 (1988). In certain embodiments such as
eutic administration, chimeric, humanized, or human antibodies can be used. A
chimeric antibody is a molecule in which different portions of the antibody are derived
from different animal species, such as antibodies having a variable region derived from a
murine onal antibody and a human immunoglobulin nt region. Methods for
producing chimeric antibodies are known in the art. See, e. g., Morrison, Science 229: 1202
(1985); Oi et al., BioTechniques 4:214 ; s et al., J. Immunol. Methods
1—202 (1989); US. Pat. Nos. 5,807,715; 4,816,567; and 4,816397, which are
incorporated herein by reference in their entireties. Humanized antibodies are antibody
molecules from non-human species antibody that binds the desired antigen having one or
more complementarity determining regions (CDRs) from the non-human s and
framework regions from a human immunoglobulin molecule. Often, framework residues
in the human framework regions will be substituted with the corresponding residue from
the CDR donor antibody to alter, preferably e, antigen binding. These framework
tutions are identified by methods well known in the art, e. g., by modeling of the
interactions of the CDR and framework residues to identify framework residues ant
for antigen binding and sequence comparison to identify unusual framework residues at
particular positions. (See, e.g., Queen et al., US. Pat. No. 5,585,089; Riechmann et al.,
Nature 332:323 (1988), which are incorporated herein by reference in their entireties.)
Antibodies can be humanized using a variety of techniques known in the art including, for
example, CDR—grafting (EP 239,400; PCT publication WO 91/09967; US. Pat. Nos.
,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 6; EP 6;
Padlan, Molecular Immunology 28(4/5):489—498 (1991); Studnicka et al., Protein
Engineering 7(6):805—814 (1994); Roguska. et al., PNAS 91:969—973 (1994)), and chain
shuffling (U.S. Pat. No. 5,565,332).
Fully human dies are particularly desirable for therapeutic treatment of
human patients. Human antibodies can be made by a variety of methods known in the art
including phage display methods described above using dy libraries derived from
human immunoglobulin sequences. See also, US. Pat. Nos. 4,444,887 and 4,716,111; and
PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 54, WO
96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by
reference in its entirety.
Human antibodies can also be produced using transgenic mice which are
incapable of expressing functional nous globulins, but which can express
human immunoglobulin genes. For example, the human heavy and light chain
immunoglobulin gene complexes can be introduced randomly or by homologous
recombination into mouse embryonic stem cells. In on, various ies can be
engaged to provide human antibodies produced in transgenic mice ed against a
selected antigen using technology similar to that described above.
Fully human antibodies which recognize a selected epitope can be generated using
a que referred to as "guided selection." In this approach a selected non-human
onal dy, e.g., a mouse antibody, is used to guide the selection of a
completely human antibody recognizing the same epitope. (Jespers et al., Bio/Technology
12:899-903 (1988). See also, U.S. Patent No. 5,565,332.)
In another embodiment, DNA encoding desired monoclonal antibodies can be
readily isolated and sequenced using conventional procedures (e.g., by using
oligonucleotide probes that are capable of binding specifically to genes encoding the
heavy and light chains of murine antibodies). Isolated and subcloned hybridoma cells or
isolated phage, for example, can serve as a source of such DNA. Once isolated, the DNA
can be placed into expression vectors, which are then transfected into prokaryotic or
eukaryotic host cells such as E. coli cells, simian COS cells, e Hamster Ovary
(CHO) cells or myeloma cells that do not otherwise produce globulins. More
particularly, the isolated DNA (which can be synthetic as described herein) can be used to
clone constant and variable region sequences for the manufacture antibodies as described
in Newman et al., U.S. Pat. No. 5,658,570, filed January 25, 1995, which is incorporated
by reference herein. Transformed cells expressing the d antibody can be grown up
in relatively large quantities to provide clinical and commercial supplies of the
globulin.
In one ment, an isolated binding molecule, e.g., an antibody ses at
least one heavy or light chain CDR of an antibody molecule. In another embodiment, an
isolated binding molecule comprises at least two CDRs from one or more antibody
molecules. In another embodiment, an ed binding molecule comprises at least three
CDRs from one or more antibody molecules. In another embodiment, an isolated binding
molecule comprises at least four CDRs from one or more antibody molecules. In another
2012/063722
embodiment, an ed binding le comprises at least five CDRs from one or
more antibody molecules. In another embodiment, an isolated g molecule of the
ption comprises at least six CDRs from one or more antibody molecules.
In a specific embodiment, the amino acid ce of the heavy and/or light chain
variable domains can be ted to identify the sequences of the complementarity
determining s (CDRs) by methods that are well-known in the art, e.g., by
comparison to known amino acid sequences of other heavy and light chain variable
regions to determine the regions of sequence hypervariability. Using routine recombinant
DNA techniques, one or more of the CDRs can be inserted within framework regions,
e. g., into human framework regions to humanize a non-human antibody. The framework
regions can be lly occurring or consensus framework regions, and preferably
human ork regions (see, e.g., Chothia et al., J. M01. Biol. 278:457—479 (1998) for
a listing of human framework regions). The polynucleotide generated by the ation
of the framework regions and CDRs encodes an antibody that specifically binds to at least
one epitope of a desired antigen, e.g., Psl or Pch. One or more amino acid substitutions
can be made within the framework regions, and, the amino acid substitutions improve
binding of the antibody to its antigen. Additionally, such s can be used to make
amino acid substitutions or ons of one or more variable region cysteine residues
participating in an intrachain disulfide bond to generate antibody molecules lacking one
or more intrachain disulfide bonds. Other alterations to the polynucleotide are
encompassed by the present disclosure and are within the capabilities of a person of skill
of the art.
Also ed are binding molecules that comprise, consist essentially of, or
consist of, variants (including derivatives) of antibody molecules (e.g., the VH regions
and/or VL regions) described herein, which binding molecules or fragments thereof
specifically bind to Pseudomonas Psl or Pch. Standard techniques known to those of
skill in the art can be used to introduce mutations in the nucleotide sequence encoding a
binding molecule or fragment thereof which specifically binds to Pseudomonas Psl and/or
Pch, including, but not limited to, site-directed mutagenesis and PCR-mediated
mutagenesis which result in amino acid substitutions. The variants ding
derivatives) encode polypeptides comprising less than 50 amino acid substitutions, less
than 40 amino acid substitutions, less than 30 amino acid substitutions, less than 25 amino
acid substitutions, less than 20 amino acid substitutions, less than 15 amino acid
substitutions, less than 10 amino acid substitutions, less than 5 amino acid substitutions,
less than 4 amino acid substitutions, less than 3 amino acid substitutions, or less than 2
amino acid substitutions relative to the reference VH , VHCDRl, VHCDRZ,
VHCDR3, VL region, VLCDRl, VLCDRZ, or . A "conservative amino acid
substitution" is one in which the amino acid residue is replaced with an amino acid
residue having a side chain with a similar charge. es of amino acid residues having
side chains with r charges have been defined in the art. These families include
amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains
(e.g., aspartic acid, ic acid), uncharged polar side chains (e. g., glycine, asparagine,
ine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e. g., alanine,
valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-
branched side chains (e. g., threonine, valine, isoleucine) and aromatic side chains (e. g.,
tyrosine, phenylalanine, tryptophan, histidine). atively, mutations can be
introduced randomly along all or part of the coding sequence, such as by saturation
mutagenesis, and the resultant s can be screened for ical activity to identify
mutants that retain activity (e. g., the ability to bind an Pseudomonas Psl or Pch).
For example, it is possible to introduce mutations only in framework regions or
only in CDR s of an antibody molecule. Introduced mutations can be silent or
neutral missense mutations, i.e., have no, or little, effect on an dy’s ability to bind
antigen. These types of mutations can be useful to optimize codon usage, or e a
hybridoma’s dy production. Alternatively, non-neutral missense mutations can alter
an antibody’s y to bind n. The location of most silent and neutral missense
mutations is likely to be in the framework regions, while the location of most non-neutral
missense mutations is likely to be in CDR, though this is not an absolute requirement.
One of skill in the art would be able to design and test mutant molecules with desired
properties such as no alteration in antigen binding activity or alteration in binding activity
(e. g., improvements in antigen binding activity or change in antibody specificity).
Following mutagenesis, the encoded protein can routinely be expressed and the functional
and/or biological activity of the encoded protein, (e.g., ability to bind at least one e
of Pseudomonas Psl or Pch) can be determined using techniques described herein or by
routinely modifying techniques known in the art.
WO 70615
One embodiment provides a bispecif1c antibody comprising an anti—Pseudomonas
Psl and Pch binding domain disclosed herein. In n embodiments, the bispecific
antibody contains a first Psl binding domain, and the second Pch binding domain.
Bispeciflc antibodies with more than two ies are plated. For example,
trispecific antibodies can also be prepared using the methods described herein. (Tutt et al.,
J. Immunol., 147:60 (1991)).
One embodiment provides a method of producing a bispecif1c antibody, that
utilizes a single light chain that can pair with both heavy chain variable domains t
in the bispecif1c molecule. To fy this light chain, various strategies can be
employed. In one embodiment, a series of monoclonal antibodies are identified to each
antigen that can be targeted with the bispecif1c antibody, followed by a determination of
which of the light chains utilized in these antibodies is able to function when paired with
the heavy chain of any of the antibodies identified to the second target. In this manner a
light chain that can function with two heavy chains to enable binding to both antigens can
be fied. In another embodiment, display techniques, such as phage display, can
enable the identification of a light chain that can function with two or more heavy chains.
In one embodiment, a phage library is ucted which comprises a diverse repertoire of
heavy chain variable s and a single light chain variable . This library can
further be utilized to identify antibodies that bind to various antigens of interest. Thus, in
certain embodiments, the antibodies identif1ed will share a common light chain.
In certain embodiments, the bispecif1c antibody comprises at least one single
chain Fv (scFv). In n embodiments the bispecif1c antibody comprises two scFvs.
For example, a scFv can be fused to one or both of a CH3 domain-containing polypeptide
contained within an antibody. Some methods comprise producing a bispecif1c molecule
wherein one or both of the heavy chain constant regions comprising at least a CH3
domain is ed in conjunction with a single chain Fv domain to provide antigen
binding.
III. DY POLYPEPTIDES
The disclosure is further directed to isolated polypeptides which make up binding
molecules, e.g., antibodies or antigen-binding fragments thereof, which specifically bind
to Pseudomonas Ps1 and/or Pch and polynucleotides encoding such polypeptides.
Binding molecules, e.g., antibodies or fragments thereof as disclosed herein, comprise
polypeptides, e.g., amino acid sequences encoding, for example, Psl—specific and/or Pch—
specific n binding regions derived from immunoglobulin molecules. A polypeptide
or amino acid sequence "derived from" a designated protein refers to the origin of the
polypeptide. In certain cases, the polypeptide or amino acid sequence which is derived
from a particular starting polypeptide or amino acid sequence has an amino acid sequence
that is essentially identical to that of the starting sequence, or a portion thereof, wherein
the n consists of at least 10-20 amino acids, at least 20-30 amino acids, at least 30-
50 amino acids, or which is otherwise identifiable to one of ordinary skill in the art as
having its origin in the starting ce.
Also disclosed is an ed binding molecule, e.g., an antibody or antigen-
binding fragment thereof which specifically binds to Pseudomonas Psl comprising an
immunoglobulin heavy chain variable region (VH) amino acid sequence at least 80%,
85%, 90% 95% or 100% identical to one or more of: SEQ ID NO: 1, SEQ ID NO: 3, SEQ
ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO:
13, SEQ ID NO: 15, or SEQ ID NO: 74 as shown in Table 2.
Further disclosed is an isolated binding molecule, e.g., an antibody or antigen-
binding fragment thereof which specifically binds to Pseudomonas Psl comprising a VH
amino acid ce identical to, or identical except for one, two, three, four, five, or
more amino acid substitutions to one or more of: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID
NO: 4, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13,
SEQ ID NO: 15, or SEQ ID NO: 74 as shown in Table 2.
Some embodiments include an isolated g molecule, e.g., an antibody or
antigen-binding fragment thereof which ically binds to Pseudomonas Psl
comprising a VH, where one or more of the VHCDRl, VHCDR2 or VHCDR3 regions of
the VH are at least 80%, 85%, 90%, 95% or 100% identical to one or more reference
heavy chain VHCDRl, VHCDR2 or VHCDR3 amino acid sequences of one or more of:
SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID
NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, or SEQ ID NO: 74 as shown
in Table 2.
Further disclosed is an ed binding molecule, e.g., an antibody or n-
binding fragment thereof which specifically binds to Pseudomonas Psl comprising a VH,
2012/063722
—56—
where one or more of the VHCDRl, VHCDR2 or VHCDR3 regions of the VH are
identical to, or identical except for four, three, two, or one amino acid substitutions, to
one or more reference heavy chain VHCDRl, VHCDR2 and/or VHCDR3 amino acid
sequences of one or more of: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID
NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO:
, or SEQ ID NO: 74 as shown in Table 2. Thus, according to this embodiment the VH
comprises one or more of a VHCDRl, VHCDR2, or VHCDR3 identical to or identical
except for four, three, two, or one amino acid substitutions, to one or more of the
VHCDRl, , or VHCDR3 amino acid sequences shown in Table 3.
Also disclosed is an isolated binding molecule, e.g., an antibody or antigenbinding
fragment thereof which specifically binds to Pseudomonas Psl comprising an
globulin light chain variable region (VL) amino acid sequence at least 80%, 85%,
90% 95% or 100% identical to one or more of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID
NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID
NO: 16 as shown in Table 2.
Some embodiments se an isolated binding le, e.g., an antibody or
antigen-binding fragment thereof which specifically binds to Pseudomonas Psl
comprising a VL amino acid sequence identical to, or identical except for one, two, three,
four, five, or more amino acid substitutions, to one or more of SEQ ID NO: 2, SEQ ID
NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO:
14, or SEQ ID NO: 16 as shown in Table 2.
Also provided is an isolated binding molecule, e.g., an antibody or antigenbinding
fragment thereof which specifically binds to Pseudomonas Psl comprising a VL,
where one or more of the VLCDRl, VLCDR2 or VLCDR3 regions of the VL are at least
80%, 85%, 90%, 95% or 100% identical to one or more reference light chain VLCDRl,
VLCDR2 or VLCDR3 amino acid sequences of one or more of: SEQ ID NO: 2, SEQ ID
NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO:
14, or SEQ ID NO: 16 as shown in Table 2.
Further provided is an isolated binding molecule, e.g., an antibody or antigen-
binding fragment thereof which ically binds to Pseudomonas Psl comprising a VL,
where one or more of the VLCDRl, VLCDR2 or VLCDR3 s of the VL are
identical to, or identical except for four, three, two, or one amino acid substitutions, to
one or more reference heavy chain VLCDRl, VLCDR2 and/or VLCDR3 amino acid
ces of one or more of: SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID
NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16 as shown
in Table 2. Thus, according to this embodiment the VL comprises one or more of a
VLCDRl, VLCDR2, or VLCDR3 identical to or identical except for four, three, two, or
one amino acid substitutions, to one or more of the VLCDRl, VLCDR2, or VLCDR3
amino acid sequences shown in Table 3.
In other embodiments, an isolated antibody or antigen-binding fragment thereof
which specifically binds to Pseudomonas Psl, comprises, consists essentially of, or
consists of VH and VL amino acid sequences at least 80%, 85%, 90% 95% or 100%
identical to:
(a) SEQ ID NO: 1 and SEQ ID NO: 2, respectively,(b) SEQ ID NO: 3 and SEQ
ID NO:2, respectively,(c) SEQ ID NO: 4 and SEQ ID NO: 2
, respectively, (d)
SEQ ID NO: 5 and SEQ ID NO: 6, respectively,(e) SEQ ID NO: 7 and SEQ ID
NO: 8, tively,(f) SEQ ID NO: 9 and SEQ ID NO: 10, respectively,(g) SEQ
ID NO: 11 and SEQ ID NO: 12, respectively,(h) SEQ ID NO: 13 and SEQ ID
NO: 14, tively; (i) SEQ ID NO: 15 and SEQ ID NO: 16, respectively; or (j)
SEQ ID NO: 74 and SEQ ID NO: 12, respectively. In certain embodiments, the
above—described antibody or antigen-binding fragment thereof comprises a VH
with the amino acid sequence SEQ ID NO: 11 and a VL with the amino acid
sequence of SEQ ID NO: 12. In some embodiments, the above—described
antibody or antigen-binding nt thereof comprises a VH with the amino acid
sequence SEQ ID NO: 1 and a VL with the amino acid ce of SEQ ID NO:
2. In other embodiments, the above—described antibody or antigen—binding
fragment thereof comprises a VH with the amino acid sequence SEQ ID NO: 11
and a VL with the amino acid ce of SEQ ID NO: 12.
Certain embodiments provide an isolated binding molecule, e.g, an antibody, or
antigen-binding fragment thereof which ically binds to monas Psl,
comprising an immunoglobulin VH and an immunoglobulin VL, each comprising a
mentarity determining region 1 (CDRl), CDR2, and CDR3, wherein the VH
CDRl is PYYWT (SEQ ID NO:47), the VH CDR2 is YIHSSGYTDYNPSLKS (SEQ ID
NO: 48), the VH CDR3 is selected from the group consisting of ADWDRLRALDI
2012/063722
—58—
(P510096, SEQ ID NO:258), AMDIEPHALDI (P510225, SEQ ID NO:267),
ADDPFPGYLDI (P510588, SEQ ID NO:268), ADWNEGRKLDI 67, SEQ ID
), ADWDHKHALDI (P510337, SEQ ID NO:270), ATDEADHALDI (P510170,
SEQ ID NO:271), ADWSGTRALDI (P510304, SEQ ID NO:272), GLPEKPHALDI
(P510348, SEQ ID NO:273), SLFTDDHALDI (P510573, SEQ ID NO:274),
ASPGVVHALDI 74, SEQ ID NO:275), AHIESHHALDI (P510582, SEQ ID
NO:276), ATQAPAHALDI (P510584, SEQ ID NO:277), SQHDLEHALDI (P510585,
SEQ ID ), and AMPDMPHALDI (P510589, SEQ ID NO:279), the VL CDR1 is
RASQSIRSHLN (SEQ ID , the VL CDR2 is GASNLQS (SEQ ID NO:51), and
the VL CDR3 is selected from the group consisting of QQSTGAWNW (P510096, SEQ ID
NO:280), QQDFFHGPN (P510225, SEQ ID NO:281), QQSDTFPLK (P510588, SEQ ID
NO:282), QQSYSFPLT (WapR0004, P510567, P510573, P5100574, P510582, P510584,
P510585, SEQ ID NO:52), PLT (P510337, SEQ ID NO:283), SQSDTFPLT
(P510170, SEQ ID NO:284), GQSDAFPLT (P510304, SEQ ID NO:285), LQGDLWPLT
(P510348, SEQ ID NO:286), and QQSLEFPLT (P510589, SEQ ID NO:287), n the
VH and VL CDR5 are ing to the Kabat numbering system.
Certain embodiments provide an ed binding molecule, e.g, an antibody, or
antigen-binding fragment thereof which specifically binds to Pseudomonas P51,
comprising an globulin VH and an immunoglobulin VL, each comprising a
complementarity determining region 1 (CDR1), CDR2, and CDR3, wherein the VH
CDR1 is PYYWT (SEQ ID NO:47), the VH CDR2 is YIHSSGYTDYNPSLKS (SEQ ID
NO: 48), the VL CDR1 is RASQSIRSHLN (SEQ ID NO:50), the VL CDR2 is
GASNLQS (SEQ ID N051), and the VH CDR3 and the VL CDR3 se,
tively, ADWDRLRALDI (P510096, SEQ ID NO:258) and WNW
(P510096, SEQ ID NO:280); AMDIEPHALDI (P510225, SEQ ID NO:267) and
QQDFFHGPN (P510225, SEQ ID NO:281); ADDPFPGYLDI (P510588, SEQ ID NO:268)
and QQSDTFPLK (P510588, SEQ ID NO:282); ADWNEGRKLDI (P510567, SEQ ID
NO:269) and the VL CDR3 is QQSYSFPLT (WapR0004, P510567, P510573, 74,
2, P510584, P510585, SEQ ID NO:52); ADWDHKHALDI (P510337, SEQ ID
NO:270) and QDSSSWPLT (P510337, SEQ ID NO:283); ATDEADHALDI (P510170,
SEQ ID NO:271) and SQSDTFPLT (P510170, SEQ ID NO:284); ADWSGTRALDI
(P510304, SEQ ID NO:272) and GQSDAFPLT (P510304, SEQ ID NO:285);
GLPEKPHALDI (P510348, SEQ ID NO:273) and 48, SEQ ID NO:286);
SLFTDDHALDI (Ps10573, SEQ ID NO:274) and SEQ ID NO:52; ASPGVVHALDI
(P510574, SEQ ID NO:275) and SEQ ID NO:52; AHIESHHALDI (P510582, SEQ ID
NO:276) and SEQ ID NO:52; ATQAPAHALDI (P510584, SEQ ID NO:277) and SEQ ID
NO:52; SQHDLEHALDI (P510585, SEQ ID ) and SEQ ID NO:52; or
AMPDMPHALDI (P510589, SEQ ID NO:279) and PLT (P510589, SEQ ID
NO:287).
Certain ments provide an isolated binding le, e.g., an antibody or
antigen-binding fragment thereof which specifically binds to Pseudomonas Psl,
comprising an immunoglobulin VH and an immunoglobulin VL, wherein the VH
comprises
QVQLQESGPGLVKPSETLSLTCTVSGGSISPYYWTWIRQPPGKX_1LELIGYIHSSGY
TDYNPSLKSRVTISGDTSKKQFSLKLSSVTAADTAVYYCARADWDRLRALDIWG
QGTMVTVSS, wherein X1 is G or C (P510096, SEQ ID NO:288), and the VL ses
DIQLTQSPSSLSASVGDRVTITCRASQSIRSHLNWYQQKPGKAPKLLIYGASNLQS
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTGAWNWFGX_2GTKVEIK,
wherein X2 is G or C (P510096, SEQ ID NO:289); wherein the VH comprises
SGPGLVKPSETLSLTCTVSGGSISPYYWTWIRQPPGKGLELIGYIHSSGY
TDYNPSLKSRVTISGDTSKKQFSLKLSSVTAADTAVYYCARAMDIEPHALDIWGQ
GTMVTVSS (P510225, SEQ ID NO:290), and the VL comprises
DIQLTQSPSSLSASVGDRVTITCRASQSIRSHLNWYQQKPGKAPKLLIYGASNLQS
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSDDGFPNFGGGTKVEIK
(P510225, SEQ ID NO:291); wherein the VH comprises
QVQLQESGPGLVKPSETLSLTCTVSGGSISPYYWTWIRQPPGKGLELIGYIHSSGY
TDYNPSLKSRVTISGDTSKKQFSLKLSSVTAADTAVYYCARADDPFPGYLDIWGQ
GTMVTVSS (P510588, SEQ ID NO:292), and the VL comprises
DIQLTQSPSSLSASVGDRVTITCRASQSIRSHLNWYQQKPGKAPKLLIYGASNLQS
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSDTFPLKFGGGTKVEIK
(P510588, SEQ ID NO:293); wherein the VH comprises
QVQLQESGPGLVKPSETLSLTCTVSGGSISPYYWTWIRQPPGKGLELIGYIHSSGY
TDYNPSLKSRVTISGDTSKKQFSLKLSSVTAADTAVYYCARADWNEGRKLDIWG
QGTMVTVSS (P510567, SEQ ID NO:294), and the VL comprises SEQ ID NO:11;
herein the VH comprises
SGPGLVKPSETLSLTCTVSGGSISPYYWTWIRQPPGKGLELIGYIHSSGY
TDYNPSLKSRVTISGDTSKKQFSLKLSSVTAADTAVYYCARADWDHKHALDIWG
QGTMVTVSS (Ps10337, SEQ ID NO:295), and the VL comprises
DIQLTQSPSSLSASVGDRVTITCRASQSIRSHLNWYQQKPGKAPKLLIYGASNLQS
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQDSSSWPLTFGGGTKVEIK
(Ps10337, SEQ ID ); wherein the VH comprises
EVQLLESGPGLVKPSETLSLTCNVAGGSISPYYWTWIRQPPGKGLELIGYIHSSGY
TDYNPSLKSRVTISGDTSKKQFSLHVSSVTAADTAVYFCARATDEADHALDIWG
QGTLVTVSS (Ps10170, SEQ ID NO:297), and the VL comprises
EIVLTQSPSSLSTSVGDRVTITCRASQSIRSHLNWYQQKPGKAPKLLIYGASNLQS
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCSQSDTFPLTFGGGTKLEIK (Ps10170,
SEQ ID NO:298); wherein the VH comprises
EVQLLESGPGLVKPSETLSLTCNVAGGSISPYYWTWIRQPPGKGLELIGYIHSSGY
TDYNPSLKSRVTISGDTSKKQFSLHVSSVTAADTAVYFCARADWSGTRALDIWG
QGTLVTVSS 04, SEQ ID NO:299), and the VL comprises
EIVLTQSPSSLSTSVGDRVTITCWASQSIRSHLNWYQQKPGKAPKLLIYGASNLQS
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGQSDAFPLTFGGGTKLEIK
(Ps10304, SEQ ID NO:300); wherein the VH comprises
EVQLLESGPGLVKPSETLSLTCNVAGGSISPYYWTWIRQPPGKGLELIGYIHSSGY
TDYNPSLKSRVTISGDTSKKQFSLHVSSVTAADTAVYFCARGLPEKPHALDIWGQ
GTLVTVSS (Ps10348, SEQ ID NO:301), and the VL ses
EIVLTQSPSSLSTSVGDRVTITCRASQSIRSHLNWYQQKPGKAPKLLIYGASNLQS
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQGDLWPLTFGGGTKLEIK
(Ps10348, SEQ ID NO:302); wherein the VH comprises
EVQLLESGPGLVKPSETLSLTCNVAGGSISPYYWTWIRQPPGKGLELIGYIHSSGY
TDYNPSLKSRVTISGDTSKKQFSLHVSSVTAADTAVYFCARSLFTDDHALDIWGQ
GTLVTVSS (Ps10573, SEQ ID NO:303), and the VL comprises SEQ ID NO:11; wherein
the VH comprises
EVQLLESGPGLVKPSETLSLTCNVAGGSISPYYWTWIRQPPGKGLELIGYIHSSGY
LKSRVTISGDTSKKQFSLHVSSVTAADTAVYFCARASPGVVHALDIWGQ
GTLVTVSS (Ps10574, SEQ ID NO:304), and the VL ses SEQ ID NO:11; wherein
the VH comprises
EVQLLESGPGLVKPSETLSLTCNVAGGSISPYYWTWIRQPPGKGLELIGYIHSSGY
TDYNPSLKSRVTISGDTSKKQFSLHVSSVTAADTAVYFCARAHIESHHALDIWGQ
SS (Ps10582, SEQ ID NO:305), and the VL ses SEQ ID NO: 1 1; wherein
the VH comprises
EVQLLESGPGLVKPSETLSLTCNVAGGSISPYYWTWIRQPPGKGLELIGYIHSSGY
TDYNPSLKSRVTISGDTSKKQFSLHVSSVTAADTAVYFCARATQAPAHALDIWG
QGTLVTVSS (Ps10584, SEQ ID NO:306), and the VL comprises SEQ ID NO:ll;
n the VH comprises
EVQLLESGPGLVKPSETLSLTCNVAGGSISPYYWTWIRQPPGKGLELIGYIHSSGY
TDYNPSLKSRVTISGDTSKKQFSLHVSSVTAADTAVYFCARSQHDLEHALDIWGQ
GTLVTVSS 85, SEQ ID NO:307), and the VL comprises SEQ ID NO:ll; or
wherein the VH ses
EVQLLESGPGLVKPSETLSLTCNVAGGSISPYYWTWIRQPPGKGLELIGYIHSSGY
TDYNPSLKSRVTISGDTSKKQFSLHVSSVTAADTAVYFCARAMPDMPHALDIWG
QGTLVTVSS (Ps10589, SEQ ID NO:308), and the VL comprises
EIVLTQSPSSLSTSVGDRVTITCRASQSIRSHLNWYQQKPGKAPKLLIYGASNLQS
SGSGSGTDFTLTISSLQPEDFATYYCQQSLEFPLTFGGGTKLEIK (Ps10589,
SEQ ID NO:325).
Also disclosed is an isolated antibody single chain FV (ScFV) fragment which
specifically binds to Pseudomonas Psl (an "anti-Psl ScFV"), comprising the formula VH-
L-VL or alternatively VL-L-VH, where L is a linker sequence. In n aspects the
linker can comprise (a) [GGGGS]n, wherein n is 0, l, 2, 3, 4, or 5, (b) [GGGG]n, wherein
n is 0, l, 2, 3, 4, or 5, or a combination of (a) and (b). For example, an exemplary linker
comprises: GGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID ). In certain
embodiments the linker further comprises the amino acids ala-leu at the C—terminus of the
linker. In n embodiments the anti—Psl ScFV comprises the amino acid sequence of
SEQ ID NO:240, SEQ ID NO:24l, SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:244,
SEQ ID NO:245, SEQ ID NO:246, SEQ ID NO:247, SEQ ID NO:248, SEQ ID NO:249,
SEQ ID NO:250, SEQ ID NO:251, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:254,
or SEQ ID NO:262.
2012/063722
Also disclosed is an ed antibody single chain Fv (ScFv) fragment which
specifically binds to Pseudomonas Pch (an "anti-Pch ScFv"), comprising the formula
VH-L-VL or alternatively H, where L is a linker sequence. In certain aspects the
linker can comprise (a) [GGGGS]n, wherein n is 0, 1, 2, 3, 4, or 5, (b) [GGGG]n, wherein
n is 0, 1, 2, 3, 4, or 5, or a combination of (a) and (b). For example, an exemplary linker
comprises: GGGGSGGGGSGGGGSGGGGSGGGGS (SEQ ID NO:326). In certain
embodiments the linker further comprises the amino acids ala-leu at the C—terminus of the
linker.
Also disclosed is an isolated g molecule, e.g., an antibody or antigenbinding
fragment thereof which specifically binds to monas Pch comprising an
immunoglobulin heavy chain variable region (VH) and/or light chain variable region
(VL) amino acid sequence at least 80%, 85%, 90% 95% or 100% identical to SEQ ID
NO: 216 or SEQ ID NO: 217.
Further disclosed is an isolated binding molecule, e.g., an antibody or antigen-
binding fragment thereof which specifically binds to Pseudomonas Pch comprising a
VH, where one or more of the VHCDRl, VHCDR2 or VHCDR3 regions of the VH are
cal to, or identical except for four, three, two, or one amino acid substitutions, to
one or more reference heavy chain VHCDRl, VHCDR2 and/or VHCDR3 amino acid
ces of one or more of: SEQ ID NOs: 218—220 as shown in Table 3. Thus,
according to this embodiment the VH comprises one or more of a VHCDRl, VHCDR2,
or VHCDR3 identical to or identical except for four, three, two, or one amino acid
substitutions, to one or more of the VHCDRl, VHCDR2, or VHCDR3 amino acid
sequences shown in Table 3.
Further provided is an isolated g molecule, e.g., an antibody or antigen-
binding fragment thereof which specifically binds to monas Pch sing a
VL, where one or more of the VLCDRl, VLCDR2 or VLCDR3 regions of the VL are
identical to, or cal except for four, three, two, or one amino acid substitutions, to
one or more reference heavy chain VLCDRl, VLCDR2 and/or VLCDR3 amino acid
sequences of one or more of: SEQ ID NOs: 221—223 as shown in Table 3. Thus,
according to this embodiment the VL comprises one or more of a VLCDRl, VLCDR2, or
VLCDR3 identical to or identical except for four, three, two, or one amino acid
substitutions, to one or more of the VLCDRl, VLCDR2, or VLCDR3 amino acid
sequences shown in Table 3.
Also provided is an isolated binding molecule, e. g., an antibody or n-
binding fragment thereof which specifically binds to Pseudomonas Pch comprising a
VH and a VL, wherein the VH comprises an amino acid sequence selected from the group
consisting of SEQ ID NO:255 and SEQ ID NO:257, and wherein the VL comprises the
amino acid sequence of SEQ ID NO:256.
Further provided is an isolated binding molecule, e.g., an antibody or antigen-
binding fragment thereof which specifically binds to Pseudomonas Pch comprising a
VH and a VL, each comprising a CDRl, CDR2, and CDR3, wherein the VH CDRl is (a)
SYAMS (SEQ ID NO:311), or a variant thereof sing 1, 2, 3, or 4 conservative
amino acid substitutions, the VH CDR2 is AISGSGYSTYYADSVKG (SEQ ID NO:
312), or a t f comprising 1, 2, 3, or 4 vative amino acid substitutions,
and the VHCDR3 is EYSISSNYYYGMDV (SEQ ID NO: 313), or a variant thereof
comprising 1, 2, 3, or 4 conservative amino acid substitutions; or (b) wherein the VL
CDRl is WASQGISSYLA (SEQ ID NO:314), or a variant thereof sing 1, 2, 3, or
4 conservative amino acid substitutions, the VL CDR2 is AASTLQS (SEQ ID NO:315),
or a variant f comprising 1, 2, 3, or 4 conservative amino acid substitutions, and the
VL CDR3 is QQLNSSPLT (SEQ ID NO:316), or a variant thereof comprising 1, 2, 3, or
4 conservative amino acid substitutions; or (c) a combination of (a) and (b); wherein the
VH and VL CDRs are according to the Kabat numbering . In certain aspects of
this embodiment, (a) the VH comprises an amino acid sequence at least 80%, 85%, 90%,
95%, 96%, 97%, 98% 99%, or 100% identical to SEQ ID NO:317, (b) the VL ses
an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% 99%, or 100%
identical to SEQ ID ; or (c) a combination of (a) and (b).
Also disclosed is an isolated bispeciflc binding molecule, e.g., a bispeciflc
antibody or antigen-binding fragment f which ically binds to both
Pseudomonas Psl and Pseudomonas Pch comprising an immunoglobulin heavy chain
variable region (VH) and/or light chain variable region (VL) amino acid sequence at least
80%, 85%, 90% 95% or 100% identical to SEQ ID NO: 228, SEQ ID NO:229, or SEQ ID
NO: 235.
In certain embodiments, a bispecific antibody as disclosed herein has the structure
of BSl, BS2, BS3, or BS4, all as shown in . In certain bispecific dies
disclosed herein the binding domain which specifically binds to Pseudomonas Psl
ses an anti-Psl ScFv molecule. In other aspects the binding domain which
specifically binds to Pseudomonas Psl comprises a tional heavy chain and light
chain. Similarly in certain bispecific antibodies disclosed herein the binding domain
which specifically binds to Pseudomonas Pch comprises an anti—Pch ScFv molecule.
In other aspects the binding domain which specifically binds to Pseudomonas Pch
comprises a conventional heavy chain and light chain.
In certain aspects a bispecific antibody as disclosed herein had the BS4 structure,
disclosed in detail in US. Provisional Appl. No. ,651filed on April 16, 2012 and
International Application No: PCT/US2012/ 63639, filed er 6, 2012 (attorney
docket no. AEMS—l lSWOl, entitled “MULTISPECIFIC AND ALENT
BINDING PROTEINS AND USES THEREOF”), which is incorporated herein by
reference in its entirety. For example, this disclosure provides a bispecific antibody in
which an anti-Psl ScFv molecule is inserted into the hinge region of each heavy chain of
an anti-Pch antibody or fragment thereof.
This disclosure provides an isolated binding molecule, e.g., a bispecfic antibody
comprising an antibody heavy chain and an antibody light chain, where the antibody
heavy chain ses the formula VH-CHl-Hl-Ll-S-L2-H2-CH2-CH3, wherein CHl is
a heavy chain constant region domain-l, H1 is a first heavy chain hinge region fragment,
L1 is a first linker, S is an anti-Pch ScFv molecule, L2 is a second linker, H2 is a second
heavy chain hinge region fragment, CH2 is a heavy chain constant region domain-2, and
CH3 is a heavy chain nt region domain-3. In certain aspects the VH comprises the
amino acid sequence of SEQ ID NO:255, SEQ ID NO:257, or SEQ ID NO:3l7. In
certain s L1 and L2 are the same or different, and independently comprise (a)
[GGGGS]n, wherein n is 0, l, 2, 3, 4, or 5, (b) [GGGG]n, wherein n is 0, l, 2, 3, 4, or 5,
or a combination of (a) and (b). In certain embodiments Hl comprises EPKSC (SEQ ID
), and H2 comprises DKTHTCPPCP (SEQ ID NO:32l).
In certain aspects, S comprises an anti-Psl ScFv molecule having the amino acid
ce of SEQ ID NO:240, SEQ ID , SEQ ID NO:242, SEQ ID NO:243, SEQ
ID NO:244, SEQ ID NO:245, SEQ ID NO:246, SEQ ID NO:247, SEQ ID NO:248, SEQ
—65—
ID NO:249, SEQ ID NO:250, SEQ ID NO:251, SEQ ID NO:252, SEQ ID NO:253, SEQ
ID NO:254, or SEQ ID NO:262, or any ation of two or more of these amino acid
sequences.
In further aspects, CH2-CH3 comprises (SEQ ID NO:322), wherein X1 is M or Y,
X2 is S or T, and X3 is T or E. In further aspects the antibody light chain comprises VL-
CL, wherein CL is an antibody light chain kappa constant region or am an antibody light
chain lambda constant region. In further aspects VL comprises the amino acid sequence
of SEQ ID NO:256 or SEQ ID NO:318. CL can comprise, e. g., the amino acid ce
of SEQ ID NO:323.
Further provided is an ed binding molecule, e. g., a bispeciflc antibody which
specifically binds to both Pseudomonas Psl and Pseudomonas Pch comprising a VH
comprising the amino acid sequence SEQ ID NO:264, and a VL comprising the amino
acid sequence SEQ ID NO:263.
In some embodiments, the bispecif1c antibodies of the invention can be a tandem
single chain (sc) Fv fragment, which contain two different scFv fragments (i.e., V2L2 and
W4) covalently tethered together by a linker (e.g., a polypeptide linker). (Ren-
Heidenreich et al. Cancer [00:1095—1103 (2004); Korn et al. J Gene Med 6:642—651
(2004)). In some embodiments, the linker can contain, or be, all or part of a heavy chain
polypeptide constant region such as a CH1 . In some embodiments, the two
antibody nts can be ntly tethered together by way of a polyglycine-serine or
polyserine—glycine linker as described in, e.g., US. Pat. Nos. 324 and 491,
respectively. Methods for generating bispeciflc tandem scFv antibodies are described in,
e. g., Maletz et al. Int J Cancer 93 :409—416 (2001); and Honemann et al. Leukemia
18:636—644 (2004). Alternatively, the antibodies can be "linear dies" as described
in, e.g., Zapata et al. Protein Eng. 8:1057—1062 . Briefly, these antibodies
comprise a pair of tandem Fd segments (VH-CHl-VH-CHl) that form a pair of antigen
binding s.
The disclosure also embraces variant forms of bispeciflc antibodies such as the
tetravalent dual variable domain immunoglobulin (DVD—Ig) molecules described in Wu
et al. (2007) Nat Biotechnol 25(1 1): 1290—1297. The DVD—Ig molecules are designed such
that two different light chain le s (VL) from two different parent antibodies
are linked in tandem directly or via a short linker by recombinant DNA techniques,
followed by the light chain constant domain. For example, the DVD-Ig light chain
polypeptide can contain in tandem: (a) the VL from V2L2; and (b) the VL from WapR-
004. rly, the heavy chain comprises the two different heavy chain variable
domains (VH) linked in tandem, ed by the constant domain CH1 and Fc region.
For example, the DVD-Ig heavy chain polypeptide can contain in tandem: (a) the VH
from V2L2; and (b) the VH from WapR-004. In this case, expression of the two chains in
a cell results in a heterotetramer containing four antigen combining sites, two that
specifically bind to V2L2 and two that ically bind to Psl. Methods for generating
DVD—Ig les from two parent antibodies are further described in, e.g., PCT
Publication Nos. and WO 24715.
In certain embodiments, an isolated binding le, e. g., an antibody or
n-binding fragment thereof as described herein specifically binds to Pseudomonas
Psl and/or Pch with an affinity characterized by a dissociation constant (KD) no r
than 5 x 10‘2 M, 10‘2 M, 5 x 10‘3 M, 10‘3 M, 5 x 10‘4 M, 10‘4 M, 5 x 10‘5 M, 10‘5 M, 5 x
‘6 M, 10‘6 M, 5 x10"7 M, 10‘7 M, 5 x10"8 M, 10‘8 M, 5 x10"9 M, 10-9 M, 5 x10"10 M,
'10 M, 5 x 10'11 M, 10'11 M, 5 x 10'12 M, 10'12 M, 5 x 10'13 M, 10'13 M, 5 x 10'14 M, 10'14
M, 5 x 10'15 M, or 10'15 M.
In specific embodiments, an isolated binding molecule, e. g., an antibody or
antigen-binding fragment thereof as described herein specifically binds to Pseudomonas
Psl and/or Pch, with an affinity characterized by a dissociation constant (KD) in a range
of about 1 x 10'10 to about 1 x 10'6 M. In one embodiment, an isolated binding molecule,
e.g., an dy or antigen-binding fragment f as described herein specifically
binds to Pseudomonas Psl and/or Pch, with an affinity characterized by a KD of about
1.18 x 10'7 M, as determined by the OCTET® binding assay described herein. In another
embodiment, an isolated binding le, e. g., an antibody or antigen-binding fragment
thereof as described herein specifically binds to Pseudomonas Psl and/or Pch, with an
affinity characterized by a KD of about 1.44 x 10'7 M, as determined by the OCTET®
g assay described herein.
Some embodiments include the isolated binding molecules e.g., an antibody or
nt thereof as described above, which (a) can inhibit attachment of Pseudomonas
aeruginosa to epithelial cells, (b) can promote OPK of P. aeruginosa, or (c) can inhibit
attachment of P. aeruginosa to epithelial cells and can promote OPK of P. aeruginosa.
—67—
In some embodiments the isolated binding le e.g., an antibody or fragment
thereof as described above, where maximum inhibition of P. aeruginosa attachment to
epithelial cells is achieved at an antibody concentration of about 50 ug/ml or less, 5.0
[Lg/ml or less, or about 0.5 [1ng or less, or at an antibody concentration ranging from
about 30 ug/ml to about 0.3 [Lg/ml, or at an antibody concentration of about 1 ug/ml, or at
an antibody tration of about 0.3 [Lg/ml.
Certain embodiments include the ed binding molecule e.g., an antibody or
fragment thereof as described above, where the OPK EC50 is less than about 0.5 [Lg/ml,
less than about 0.05 [Lg/ml, or less than about 0.005 [Lg/ml, or where the OPK EC50
ranges from about 0.001 ug/ml to about 0.5 ug/ml, or where the OPK EC50 ranges from
about 0.02 [1le to about 0.08 [Lg/ml, or where the OPK EC50 ranges from about 0.002
ug/ml to about 0.01 ug/ml or where the OPK EC50 is less than about 0.2 ug/ml, or
wherein the OPK EC50 is less than about 0.02 ug/ml. In certain embodiments, an anti-
Pseudomonas Psl binding molecule, e.g., antibody or fragment, variant or derivative
thereof described herein specifically binds to the same Ps1 e as monoclonal
antibody WapR—004, WapR-004RAD, 3, Cam—004, or Cam—005, or will
competitively inhibit such a monoclonal dy from binding to Pseudomonas Psl.
WapR-004RAD is identical to WapR-004 except for an amino acid substitution G98A of
the VH amino acid sequence of SEQ ID NO:11.
Some ments include 04 (W4) mutants comprising an scFv—Fc
molecule amino acid sequence identical to, or identical except for one, two, three, four,
five, or more amino acid substitutions to one or more of: SEQ ID NO: 78, SEQ ID NO:
79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84,
SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89,
SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94,
SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99,
SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO:
104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID
NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ
ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118,
SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO:
123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID
NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ
ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137,
SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO:
142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145; or SEQ ID NO: 146.
Other embodiments include WapR-004 (W4) mutants comprising an scFv-Fc
molecule amino acid sequence at least 80%, 85%, 90% 95% or 100% identical to one or
more of: SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID
NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID
NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID
NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID
NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID
NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ
ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111,
SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO:
116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID
NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ
ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130,
SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO:
135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID
NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ
ID NO: 145; or SEQ ID NO: 146.
In some embodiments, an anti—Pseudomonas Ps1 binding molecule, e.g., dy
or fragment, variant or derivative thereof described herein ically binds to the same
epitope as monoclonal antibody WapR—OOl, WapR-002, or WapR-003, or will
competitively inhibit such a onal dy from binding to Pseudomonas Psl.
In certain embodiments, an anti—Pseudomonas Ps1 binding molecule, e.g.,
antibody or fragment, variant or derivative thereof bed herein specifically binds to
the same epitope as monoclonal antibody WapR-016, or will competitively inhibit such a
monoclonal antibody from binding to Pseudomonas Psl.
TABLE 2: Reference VH and VL amino acid sequences*
Antibody VH VL
Name
Cam—003 QVRLQQSGPGLVKPSET SSELTQDPAVSVALGQTVRITCM
VSGGSTSM LRSYYASWYQQKPGQAPVLVIYGfl
fiWLRQPPGKGLEWIGfl NRPSGIPDRFSGS SSGNTASLTITGAQ
HSNGGTNYNPSLKSRL AEDEADYYCNSRDSSGNHVVFGGGT
TISGDTSKNQFSLNLSF KLTVL
ALYYCARM SEQ ID NO:2
DVYGPAFDIWGQGTM
SEQ ID NO:1
QVQLQQSGPGRVKPSE SSELTQDPAVSVALGQTVRITCM
TLSLTCTVSGYSVSSG_Y LRSYYASWYQQKPGQAPVLVIYGfl
YWGWIRQSPGTGLEWI PDRFSGS SSGNTASLTITGAQ
GSISHSGSTYYNPSLKS AEDEADYYCNSRDSSGNHVVFGGGT
RVTISGDASKNQFFLRL KLTVL
TSVTAADTAVYYCARQ SEQ ID NO:2
EATANFDSWGRGTLVT
SEQ ID NO:3
QVQLQQSGPGLVKPSET DPAVSVALGQTVRITCM
LSLTCTVSGGSVSM LRSYYASWYQQKPGQAPVLVIYGfl
MWIRQPPGKGLEWI NRPSGIPDRFSGSSSGNTASLTITGAQ
GSIYSSGSTYYSPSLKS AEDEADYYCNSRDSSGNHVVFGGGT
RVTISGDTSKNQFSLKL KLTVL
SSVTAADTAVYYCARL SEQ ID NO:2
NWGTVSAFDIWGRGTL
SEQ ID NO:4
Antibody VL
Name
WapR—OOl EVQLLESGGGLVQPGG QAGLTQPASVSGSPGQSITISCTGTSS
SLRLSCSASGFTFSM DIATYNYVSWYQQHPGKAPKLMIYE
MWVRQAPGKGLEYV GTKRPSGVSNRFSGSKSGNTASLTIS
SDIGTNGGSTNYADSV GLQAEDEADYYCSSYARSYTYVFGT
ERFTISRDNSKNTVYL GTELTVL
AEDTAVYHCV SEQ ID NO:6
AGIAAAYGFDVWGQG
TMVTVSS
SEQ ID NO:5
SGGGLVQPGG QTVVTQPASVSGSPGQSITISCTGTSS
SLRLSCSASGFTFSSY_P DVGGYNYVSWYQQHPGKAPKLMIY
MWVRQAPGKGLDYV EVSNRPSGVSNHFSGSKSGNTASLTIS
SDISPNGGSTNYADSV GLQAEDEADYYCSSYTTSSTYVFGT
K_GRFTISRDNSKNTLFL GTKVTVL
QMSSLRAEDTAVYYCV SEQ ID NO:8
MGLVPYGFDIWGQGTL
VTVSS
SEQ ID NO:7
QMQLVQSGGGLVQPGG QTVVTQPASVSASPGQSITISCAGTSG
SLRLSCSASGFTFSSY_P DVGNYNFVSWYQQHPGKAPKLLIYE
MWVRQAPGKGLDYV GSQRPSGVSNRFSGSRSGNTASLTIS
SDISPNGGATNYADSV EADYYCSSYARSYTYVFGT
ERFTISRDNSKNTVYL L
QMSSLRAEDTAVYYCV SEQ ID NO:10
MGLVPYGFDNWGQGT
MVTVSS
SEQ ID NO:9
dy VL
Name
WapR—004 EVQLLESGPGLVKPSET EIVLTQSPSSLSTSVGDRVTITCM
LSLTCNVAGGSISM SIRSHLNWYQQKPGKAPKLLIYw
IWIRQPPGKGLELIGE MGVPSRFSGSGSGTDFTLTISSLQ
HSSGYTDYNPSLKSRV PEDFATYYCQQSYSFPLTFGGGTKLE
TISGDTSKKQFSLHVSS 1K
VTAADTAVYFCARG_D SEQ ID N012
LDIWGQGTL
VTVSS
SEQ ID NO:11
EVQLVQSGADVKKPGA SSELTQDPAVSVALGQTVRITCM
KASGYTFTG_H LRSYYTNWFQQKPGQAPLLVVYA_K
wWVRQAPGQGLEW NKRPPGIPDRFSGSSSGNTASLTITGA
MGWINPDSGATSYAQ QAEDEADYYCHSRDSSGNHVVFGG
MRVTMTRDTSITT GTKLTVL
AYMDLSRLRSDDTAVY SEQ ID NO:14
YCATDTLLSNHWGQGT
LVTVSS
SEQ ID NO:13
EVQLVESGGGLVQPGGSL QSVLTQPASVSGSPGQSITISCTGTSSDVG
RLSCAASGYTFSMWV GYNYVSWYQQ
RQAPGKGLEWVAGISGSG GVSNRFSGSKSGNTASLTISGLQAEDEAD
DTTDYVDSVKGRFTVSRD YCSSYSSGTVVFGGGTELTVL
NSKNTLYLQMNSLRADDT SEQ ID NO: 16
AVYYCASRGGLGGYYRG
GFDFWGQGTMVTVSS
SEQ ID NO:15
Antibody VL
Name
WapR— EVQLLESGPGLVKPSET EIVLTQSPSSLSTSVGDRVTITCM
004RAD LSLTCNVAGGSISM SIRSHLNWYQQKPGKAPKLLIYw
IWIRQPPGKGLELIGE FSGSGSGTDFTLTISSLQ
HSSGYTDYNPSLKSRV PEDFATYYCQQSYSFPLTFGGGTKLE
SKKQFSLHVSS 1K
VTAADTAVYFCARA_D SEQ ID NO:12
WDLLHALDIWGQGTL
VTVSS
SEQ ID NO:74
V2L2 EMQLLESGGGLVQPGG AIQMTQSPSSLSASVGDRVTITCLAS
SLRLSCAASGFTFSfl g[GIRNDLGWYQQKPGKAPKLVIYE
MWVRQAPGEGLEWV STLQSGVPSRFSGSGSGTDFTLSISSL
SAITISGITAYYTDSVK QPDDFATYYCLQDYNYPWTFGQGT
QRFTISRDNSKNTLYLQ KVEIK
GDTAVYYCA SEQ ID NO:217
KEEFLPGTHYYYGMD
XWGQGTTVTVSS
SEQ ID NO:216
*VH and VL CDRl, CDR2, and CDR3 amino acid sequences are underlined
TABLE 3: Reference VH and VL CDRl, CDR2, and CDR3 amino acid sequences
Antibody VHCDRl VHCDR2 VHCDR3 VLCDRl VLCDR2 VLCDR3
Name
Cam—003 YI
TNYNPSL GPAFDI VV
KS SEQ ID SEQ ID NO:22
SEQ ID NO: 19
NO: 18
Antibody VHCDRl VHCDR2 VHCDR3 VLCDRl VLCDR2 VLCDR3
Name
Cam-004 SGYYW SISHSGST SEATAN QGDSLRSY NSRDSSGNH
G YYNPSLK FDS YAS VV
SEQ ID S SEQ ID SEQ ID SEQ ID N022
N023 SEQ ID NO:25 N020
N024
Cam—005 SSGYYW SIYSSGST LNWGTV QGDSLRSY GNH
YAS VV
T YYSPSLKS SAFDI
SEQ ID SEQ ID N022
N020
SEQ ID SEQ ID SEQ ID
N026 NO:27 NO:28
WapR-OO 1 RYPMH DIGTNG GIAAAY TGTSSDIAT EGTKRPS SSYARSYT
SEQ ID GSTNYA GFDV YNYVS SEQ ID YV
N029 DSVKG SEQ ID SEQ ID NO:33 SEQ ID NO:34
SEQ ID NO:3 1 NO:32
NO:30
WapR—OOZ SYPM
SEQ ID STNYAD GGYNYVS SEQ ID V
NO:35 SVKG SEQID NO:39 SEQ ID NO:40
SEQ ID N038
NO:36
WapR—003 SYPMH DISPNGG AGTSGDV EGSQRPS YT
SEQ ID ATNYAD GNYNFVS SEQ ID YV
NO:41 SVKG SEQ ID NO:45 SEQ ID NO:46
SEQ ID NO:44
NO:42
PCT/U82012/063722
Antibody VHCDRl VHCDR2 VHCDR3 VLCDRl VLCDR2 VLCDR3
Name
WapR-004 PYYWT YIHSSGY GDWDL RASQSIRS GASNLQS QQSYSFPLT
SEQID TDYNPSL LHALDI HLN SEQID SEQIDNO:52
NO:47 KS SEQID SEQID NO:51
SEQ ID NO:49 NO:50
NO:48
WapR-007 GHNIH WINPDS DTLLSN QGDSLRS AKNKRPP HSRDSSGN
SEQ ID GATSYA H YYTN SEQ ID HVV
NO:53 QKFQG SEQID SEQID NO:57 SEQIDNO:58
SEQ ID NO:55 NO:56
NO:54
WapR-016 SYATS GISGSGDT RGGLGG TGTSSDVG EVSNRPS SSYSSGTVV
SEQ ID TDYVDSV YYRGGF GYNYVS SEQ ID SEQ ID NO:64
NO:59 KG DF SEQ ID NO:63
SEQ ID SEQ ID NO:62
NO:60 NO:61
$2113- PYYWT YIHSSGY ADWDL RS GASNLQS QQSYSFPLT
SEQID TDYNPSL LHALDI HLN SEQID SEQIDNO:52
NO:47 KS SEQID SEQID NO:51
SEQ ID NO:75 NO:50
NO:48
V2L2 SYAMN AITISGIT EEFLPG RASQGIRN SASTLQS LQDYNYP
SEQ ID AYYTDS THYYY DLG SEQ ID SEQ ID
NO:218 VKG GMDV NO‘223
SEQ ID NO:222
SEQID SEQID NO:221
NO:219 NO:220
In n embodiments, an anti—Pseudomonas Pch g le, e.g.,
antibody or fragment, variant or derivative thereof described herein specifically binds to
the same Pch epitope as monoclonal antibody V2L2, and/or will competitively inhibit
such a monoclonal antibody from binding to monas Pch.
For example, in certain aspects the anti—Pseudomonas Pch binding molecule,
e.g., antibody or fragment, variant or derivative thereof comprises V2L2-GL and/or
V2L2—MD.
In certain embodiments, an anti—Pseudomonas Pch g molecule, e.g.,
antibody or fragment, variant or tive thereof described herein specifically binds to
the same Pch epitope as monoclonal antibody 29D2, and/or will competitively inhibit
such a monoclonal antibody from g to Pseudomonas Pch.
Any seudomonas Psl and/or Pch binding molecules, e.g., antibodies or
fragments, variants or derivatives thereof described herein can further include additional
ptides, e.g., a signal peptide to direct secretion of the d polypeptide,
antibody constant regions as described herein, or other heterologous polypeptides as
bed herein. Additionally, binding molecules or fragments thereof of the description
include polypeptide fragments as described elsewhere. Additionally anti—Pseudomonas
Psl and/or Pch binding molecules, e. g., antibodies or fragments, variants or derivatives
thereof bed herein can be fusion polypeptides, Fab fragments, scFvs, or other
derivatives, as bed herein.
Also, as described in more detail elsewhere herein, the disclosure includes
itions comprising anti—Pseudomonas Psl and/or Pch binding molecules, e.g.,
dies or fragments, variants or derivatives thereof described herein.
It will also be understood by one of ordinary skill in the art that seudomonas
Psl and/or Pch binding molecules, e. g., antibodies or fragments, variants or derivatives
thereof described herein can be modified such that they vary in amino acid sequence from
the naturally occurring binding polypeptide from which they were derived. For example,
a polypeptide or amino acid sequence derived from a designated protein can be similar,
e. g., have a certain percent identity to the starting sequence, e.g., it can be 60%, 70%,
75%, 80%, 85%, 90%, or 95% identical to the starting sequence.
As known in the art, "sequence identity" between two polypeptides is determined
by comparing the amino acid ce of one polypeptide to the sequence of a second
polypeptide. When discussed herein, whether any particular polypeptide is at least about
70%, 75%, 80%, 85%, 90% or 95% identical to r polypeptide can be determined
—76—
using methods and computer ms/software known in the art such as, but not limited
to, the BESTFIT program (Wisconsin Sequence Analysis Package, Version 8 for Unix,
Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI
53711). BESTFIT uses the local homology algorithm of Smith and Waterman, Advances
in Applied Mathematics 2:482—489 (1981), to find the best segment of homology between
two sequences. When using T or any other ce alignment program to
determine whether a particular sequence is, for example, 95% cal to a reference
sequence, the parameters are set, of course, such that the tage of identity is
ated over the full length of the reference polypeptide sequence and that gaps in
homology of up to 5% of the total number of amino acids in the nce sequence are
allowed.
Percentage of “sequence identity” can also be determined by comparing two
optimally aligned sequences over a comparison window. In order to optimally align
sequences for comparison, the portion of a polynucleotide or polypeptide sequence in the
comparison window can comprise additions or deletions termed gaps while the reference
sequence is kept constant. An optimal alignment is that alignment which, even with gaps,
produces the greatest possible number of “identical” ons between the reference and
comparator sequences. tage “sequence identity” between two sequences can be
determined using the version of the program “BLAST 2 Sequences” which was ble
from the National Center for Biotechnology Information as of September 1, 2004, which
program incorporates the programs BLASTN (for nucleotide sequence comparison) and
BLASTP (for polypeptide sequence ison), which programs are based on the
algorithm of Karlin and Altschul (Proc. Natl. Acad. Sci. USA 90(12):5873—5877, 1993).
When utilizing “BLAST 2 Sequences,” parameters that were default ters as of
September 1, 2004, can be used for word size (3), open gap penalty (11), extension gap
penalty (1), gap drop-off (50), expect value (10) and any other required parameter
including but not limited to matrix option.
rmore, nucleotide or amino acid substitutions, deletions, or insertions
leading to conservative substitutions or changes at "non-essential" amino acid regions can
be made. For example, a polypeptide or amino acid sequence derived from a designated
protein can be identical to the ng sequence except for one or more individual amino
acid substitutions, insertions, or deletions, e.g., one, two, three, four, five, six, seven,
eight, nine, ten, fifteen, twenty or more individual amino acid substitutions, insertions, or
deletions. In certain embodiments, a polypeptide or amino acid sequence derived from a
designated n has one to five, one to ten, one to fifteen, or one to twenty dual
amino acid substitutions, ions, or deletions relative to the ng sequence.
An anti—Pseudomonas Ps1 and/or Pch g molecule, e.g., an antibody or
fragment, variant or derivative thereof described herein can comprise, consist essentially
of, or consist of a fusion protein. Fusion proteins are chimeric molecules which
se, for example, an immunoglobulin antigen-binding domain with at least one
target binding site, and at least one heterologous portion, i.e., a n with which it is
not naturally linked in nature. The amino acid sequences can normally exist in te
proteins that are brought together in the fusion polypeptide or they can normally exist in
the same protein but are placed in a new arrangement in the fusion polypeptide. Fusion
proteins can be created, for example, by chemical synthesis, or by creating and translating
a cleotide in which the peptide s are encoded in the desired relationship.
The term "heterologous" as applied to a polynucleotide, polypeptide, or other
moiety means that the polynucleotide, polypeptide, or other moiety is derived from a
distinct entity from that of the rest of the entity to which it is being compared. In a non-
limiting example, a "heterologous ptide" to be fused to a binding molecule, e.g., an
antibody or an antigen-binding fragment, variant, or derivative thereof is derived from a
non-immunoglobulin polypeptide of the same species, or an immunoglobulin or nonimmunoglobulin
polypeptide of a different species.
IV. FUSION PROTEINS AND ANTIBODY CONIUGATES
In some embodiments, the seudomonas Ps1 and/or Pch binding molecules,
e. g., antibodies or fragments, variants or derivatives thereof can be administered multiple
times in conjugated form. In still another embodiment, the anti—Pseudomonas Psl and/or
Pch binding molecules, e. g., antibodies or fragments, variants or derivatives thereof can
be administered in unconjugated form, then in conjugated form, or vice versa.
In specific embodiments, the anti—Pseudomonas Psl and/or Pch binding
molecules, e.g., antibodies or nts, variants or derivatives thereof can be conjugated
to one or more antimicrobial , for e, Polymyxin B (PMB). PMB is a small
lipopeptide antibiotic approved for treatment of multidrug-resistant Gram-negative
WO 70615
—78—
infections. In addition to its icidal activity, PMB binds lipopolysaccharide (LPS)
and lizes its proinflammatory effects. (Dixon, R.A. & Chopra, I. J Antimicrob
Chemother 18, 557—563 (1986)). LPS is thought to significantly contribute to
inflammation and the onset of Gram-negative sepsis. (Guidet, B., et al., Chest 106, 1194—
1201 (1994)). Conjugates of PMB to carrier molecules have been shown to neutralize
LPS and mediate protection in animal models of endotoxemia and infection. (Drabick,
J.J., et a]. crob Agents Chemother 42, 583—588 (1998)). Also sed is a method
for attaching one or more PMB molecules to cysteine residues uced into the Fc
region of monoclonal antibodies (mAb) of the disclosure. For example, the Cam—003—
PMB conjugates retained specific, mAb—mediated binding to P. aeruginosa and also
retained OPK activity. Furthermore, mAb-PMB conjugates bound and neutralized LPS in
vitro. In specific embodiments, the anti—Pseudomonas Ps1 and/or Pch binding
molecules, e.g., antibodies or fragments, variants or derivatives thereof can be combined
with antibiotics (e.g., Ciprofloxacin, Meropenem, Tobramycin, Aztreonam).
In certain embodiments, an anti—Pseudomonas Ps1 and/or Pch binding molecule,
e. g., an antibody or fragment, variant or derivative f described herein can comprise
a heterologous amino acid sequence or one or more other moieties not ly
associated with an antibody (e. g., an antimicrobial agent, a therapeutic agent, a prodrug, a
peptide, a protein, an enzyme, a lipid, a biological response modifier, ceutical
agent, a lymphokine, a heterologous antibody or fragment thereof, a detectable label,
polyethylene glycol (PEG), and a ation of two or more of any said agents). In
further embodiments, an anti—Pseudomonas Ps1 and/or Pch binding molecule, e.g., an
antibody or fragment, variant or derivative thereof can comprise a detectable label
selected from the group consisting of an enzyme, a fluorescent label, a chemiluminescent
label, a bioluminescent label, a radioactive label, or a ation of two or more of any
said detectable labels.
V. POLYNUCLEOTIDES ENCODING BINDING MOLECULES
Also ed herein are c acid molecules encoding the anti—Pseudomonas
Ps1 and/or Pch binding molecules, e. g., antibodies or fragments, variants or tives
thereof described herein. .
One embodiment provides an isolated polynucleotide comprising, consisting
essentially of, or ting of a nucleic acid encoding an immunoglobulin heavy chain
variable region (VH) amino acid sequence at least 80%, 85%, 90% 95% or 100%
identical to one or more of: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO:
, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15,
SEQ IS NO: 74, or SEQ ID NO:216 as shown in Table 2.
One embodiment provides an isolated polynucleotide comprising, consisting
essentially of, or consisting of a nucleic acid encoding an immunoglobulin heavy chain
variable region (VH) amino acid sequence of SEQ ID NO:257 or SEQ ID NO:259. For
example the nucleic acid sequences of SEQ ID NO:261, and SEQ ID NO:: 259,
respectively.
Another embodiment provides an isolated polynucleotide comprising, ting
essentially of, or consisting of a nucleic acid encoding a VH amino acid ce
identical to, or identical except for one, two, three, four, five, or more amino acid
substitutions to one or more of: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID
NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO:
, SEQ ID NO: 74, or SEQ ID NO:216 as shown in Table 2.
Further embodiment provides an isolated polynucleotide comprising, consisting
essentially of, or consisting of a nucleic acid ng a VH, where one or more of the
, VHCDR2 or VHCDR3 regions of the VH are identical to, or identical except
for four, three, two, or one amino acid tutions, to one or more reference heavy chain
VHCDRl, VHCDR2 and/or VHCDR3 amino acid sequences of one or more of: SEQ ID
NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9,
SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 74, or SEQ ID NO:216
as shown in Table 2.
Another embodiment provides an ed polynucleotide comprising, consisting
essentially of, or consisting of a nucleic acid encoding an isolated binding molecule, e.g.,
an antibody or antigen-binding fragment thereof which specifically binds to Pseudomonas
Psl sing a VH, where one or more of the VHCDRl, VHCDR2 or VHCDR3
s of the VH are identical to, or identical except for four, three, two, or one amino
acid substitutions, to one or more reference heavy chain VHCDRl, VHCDR2 and/or
VHCDR3 amino acid sequences of one or more of: SEQ ID NO: 1, SEQ ID NO: 3, SEQ
2012/063722
ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 11, SEQ ID NO:
13, SEQ ID NO: 15, or SEQ ID NO: 74 as shown in Table 2.
A r embodiment provides an isolated binding molecule e.g., an antibody or
antigen—binding fragment comprising the VH encoded by the polynucleotide specifically
or entially binds to monas Ps1 and/or Pch.
Another embodiment provides an isolated polynucleotide comprising, consisting
essentially of, or consisting of a nucleic acid encoding an immunoglobulin light chain
variable region (VL) amino acid sequence at least 80%, 85%, 90% 95% or 100% identical
to one or more of: SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ
ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, or SEQ ID NO:217 as
shown in Table 2.
Another ment provides an isolated polynucleotide comprising, consisting
essentially of, or consisting of a nucleic acid ng the immunoglobulin light chain
variable region (VL) amino acid sequence of SEQ ID NO:256, e.g., the c acid
sequence SEQ ID NO:260..
A further embodiment provides an isolated polynucleotide comprising, consisting
essentially of, or consisting of a nucleic acid ng a VL amino acid sequence
identical to, or identical except for one, two, three, four, five, or more amino acid
substitutions to one or more of: SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID
NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, or SEQ ID
NO:217 as shown in Table 2.
Another embodiment provides an isolated polynucleotide comprising, consisting
essentially of, or consisting of a c acid encoding a VL, where one or more of the
VLCDRl, VLCDR2 or VLCDR3 regions of the VL are at least 80%, 85%, 90%, 95% or
100% identical to one or more reference light chain VLCDRl, VLCDR2 or VLCDR3
amino acid sequences of one or more of: SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6,
SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, or SEQ ID NO: 16, or
SEQ ID NO:217 as shown in Table 2.
A further embodiment provides an isolated polynucleotide comprising, consisting
essentially of, or consisting of a c acid encoding an isolated binding molecule, e.g.,
an antibody or antigen-binding fragment thereof which specifically binds to Pseudomonas
Ps1 comprising an VL, where one or more of the VLCDRl, VLCDR2 or VLCDR3
2012/063722
regions of the VL are identical to, or identical except for four, three, two, or one amino
acid substitutions, to one or more reference heavy chain VLCDRl, VLCDR2 and/or
VLCDR3 amino acid sequences of one or more of: SEQ ID NO: 2, SEQ ID NO: 4, SEQ
ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID
NO: 16, or SEQ ID NO:217 as shown in Table 2.
In another embodiment, isolated binding molecules e. g., an antibody or antigen-
binding fragment comprising the VL encoded by the polynucleotide ically or
entially bind to Pseudomonas Psl and/or Pch.
One embodiment provides an isolated polynucleotide comprising, consisting
essentially of, or consisting of a nucleic acid which encodes an scFV molecule including a
VH and a VL, where the scFV is at least 80%, 85%, 90% 95% or 100% identical to one or
more of SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID
NO:69, or SEQ ID NO:70 as shown in Table 4.
WO 70615
TABLE 4: Reference scFV nucleic acid sequences
dy scFV nucleotide sequences
Name
CAGCCGGCCATGGCCCAGGTACAGCTGCAGCAGTCAGGCCCAGG
ACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCT
GGTGGCTCCACCAGTCCTTACTTCTGGAGCTGGCTCCGGCAGCCC
CCAGGGAAGGGACTGGAGTGGATTGGTTATATCCATTCCAATGGG
GGCACCAACTACAACCCCTCCCTCAAGAGTCGACTCACCATATCA
GGAGACACGTCCAAGAACCAATTCTCCCTGAATCTGAGTTTTGTG
ACCGCTGCGGACACGGCCCTCTATTACTGTGCGAGAACGGACTAC
GATGTCTACGGCCCCGCTTTTGATATCTGGGGCCAGGGGACAATG
GTCACCGTCTCGAGTGGTGGAGGCGGTTCAGGCGGAGGTGGCAG
CGGCGGTGGCGGATCGTCTGAGCTGACTCAGGACCCTGCTGTGTC
TGTGGCCTTGGGACAGACAGTCAGGATCACATGCCAAGGAGACA
GCCTCAGAAGCTATTATGCAAGCTGGTACCAGCAGAAGCCAGGA
CAGGCCCCTGTACTTGTCATCTATGGTAAAAACAACCGGCCCTCA
GGGATCCCAGACCGATTCTCTGGCTCCAGCTCAGGAAACACAGCT
TCCTTGACCATCACTGGGGCTCAGGCGGAAGATGAGGCTGACTAT
TACTGTAACTCCCGGGACAGCAGTGGTAACCATGTGGTATTCGGC
GGAGGGACCAAGCTGACCGTCCTAGGTGCGGCCGCA
SEQ ID NO:65
WO 70615
Antibody scFV nucleotide sequences
Name
Cam—004 CAGCCGGCCATGGCCCAGGTACAGCTGCAGCAGTCAGGCCCAGG
ACGGGTGAAGCCTTCGGAGACGCTGTCCCTCACCTGCACTGTCTC
TGGTTACTCCGTCAGTAGTGGTTACTACTGGGGCTGGATCCGGCA
GTCCCCAGGGACGGGGCTGGAGTGGATTGGGAGTATCTCTCATAG
TGGGAGCACCTACTACAACCCGTCCCTCAAGAGTCGAGTCACCAT
ATCAGGAGACGCATCCAAGAACCAGTTTTTCCTGAGGCTGACTTC
CGCCGCGGACACGGCCGTTTATTACTGTGCGAGATCTGA
GGCTACCGCCAACTTTGATTCTTGGGGCAGGGGCACCCTGGTCAC
CGTCTCTTCAGGTGGAGGCGGTTCAGGCGGAGGTGGCAGCGGCG
GTGGCGGATCGTCTGAGCTGACTCAGGACCCTGCCGTGTCTGTGG
CCTTGGGACAGACAGTCAGGATCACATGCCAAGGAGACAGCCTC
AGAAGCTATTATGCAAGCTGGTACCAGCAGAAGCCAGGACAGGC
CCCTGTACTTGTCATCTATGGTAAAAACAACCGGCCCTCAGGGAT
CCCAGACCGATTCTCTGGCTCCAGCTCAGGAAACACAGCTTCCTT
GACCATCACTGGGGCTCAGGCGGAAGATGAGGCTGACTATTACTG
TAACTCCCGGGACAGCAGTGGTAACCATGTGGTATTCGGCGGAGG
GACCAAGCTGACCGTCCTAGGTGCGGCCGCA
SEQ ID NO:66
Antibody scFV nucleotide ces
Nmne
CmnflOS CAGCCGGCCATGGCCCAGGTACAGCTGCAGCAGTCAGGCCCAGG
ACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCTCT
GGTGGCTCCGTCAGCAGTAGTGGTTATTACTGGACCTGGATCCGC
CAGCCCCCAGGGAAGGGGCTGGAGTGGATTGGGAGTATCTATTCT
AGTGGGAGCACATATTACAGCCCGTCCCTCAAGAGTCGAGTCACC
ATATCCGGAGACACGTCCAAGAACCAGTTCTCCCTCAAGCTGAGC
TCTGTGACCGCCGCAGACACAGCCGTGTATTACTGTGCGAGACTT
AACTGGGGCACTGTGTCTGCCTTTGATATCTGGGGCAGAGGCACC
CTGGTCACCGTCTCGAGTGGTGGAGGCGGTTCAGGCGGAGGTGGC
AGCGGCGGTGGCGGATCGTCTGAGCTGACTCAGGACCCTGCTGTG
GCCTTGGGACAGACAGTCAGGATCACATGCCAAGGAGAC
AGCCTCAGAAGCTATTATGCAAGCTGGTACCAGCAGAAGCCAGG
ACAGGCCCCTGTACTTGTCATCTATGGTAAAAACAACCGGCCCTC
AGGGATCCCAGACCGATTCTCTGGCTCCAGCTCAGGAAACACAGC
TTCCTTGACCATCACTGGGGCTCAGGCGGAAGATGAGGCTGACTA
TTACTGTAACTCCCGGGACAGCAGTGGTAACCATGTGGTATTCGG
CGGAGGGACCAAGCTGACCGTCCTAGGTGCGGCCGCA
SEQ ID NO:67
—85—
Antibody scFV nucleotide sequences
Nmne
kaLmH TCTATGCGGCCCAGCCGGCCATGGCCGAGGTGCAGCTGTTGGAGT
CTGGGGGAGGTTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCT
CCTCTGGGTTCACCTTCAGTCGGTATCCTATGCATTGGGT
CCGCCAGGCTCCAGGGAAGGGACTGGAATATGTTTCAGATATTGG
TACTAATGGGGGTAGTACAAACTACGCAGACTCCGTGAAGGGCA
GATTCACCATCTCCAGAGACAATTCCAAGAACACGGTGTATCTTC
AAATGAGCAGTCTGAGAGCTGAGGACACGGCTGTGTATCATTGTG
TGGCGGGTATAGCAGCCGCCTATGGTTTTGATGTCTGGGGCCAAG
TGGTCACCGTCTCGAGTGGAGGCGGCGGTTCAGGCGGA
GGTGGCTCTGGCGGTGGCGGAAGTGCACAGGCAGGGCTGACTCA
GCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCC
TGCACTGGAACCAGCAGTGACATTGCTACTTATAACTATGTCTCCT
GGTACCAACAGCACCCAGGCAAAGCCCCCAAACTCATGATTTATG
AGGGCACTAAGCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCT
CCAAGTCTGGCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGG
CTGAGGACGAGGCTGATTATTACTGTTCCTCATATGCACGTAGTT
ACACTTATGTCTTCGGAACTGGGACCGAGCTGACCGTCCTAGCGG
CCGC
SEQ ID NO:68
Antibody scFV nucleotide sequences
Name
WapR—002 CTATGCGGCCCAGCCGGCCATGGCCCAGGTGCAGCTGGTGCAGTC
TGGGGGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTG
TTCAGCCTCTGGATTCACCTTCAGTAGCTATCCTATGCACTGGGTC
CGCCAGGCTCCAGGGAAGGGACTGGATTATGTTTCAGACATCAGT
CCAAATGGGGGTTCCACAAACTACGCAGACTCCGTGAAGGGCAG
CATCTCCAGAGACAATTCCAAGAACACACTGTTTCTTCA
AATGAGCAGTCTGAGAGCTGAGGACACGGCTGTGTATTATTGTGT
GATGGGGTTAGTACCCTATGGTTTTGATATCTGGGGCCAAGGCAC
CCTGGTCACCGTCTCGAGTGGAGGCGGCGGTTCAGGCGGAGGTGG
CTCTGGCGGTGGCGGAAGTGCACAGACTGTGGTGACCCAGCCTGC
CTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACT
GGAACCAGCAGTGACGTTGGTGGTTATAACTATGTCTCCTGGTAC
CAACAGCACCCAGGCAAAGCCCCCAAACTCATGATTTATGAGGTC
AGTAATCGGCCCTCAGGGGTTTCTAATCACTTCTCTGGCTCCAAGT
CTGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGAGG
CTGATTATTACTGCAGCTCATATACAACCAGCAGCACTT
ATGTCTTCGGAACTGGGACCAAGGTCACCGTCCTAGCGGCCG
SEQ ID NO:69
—87—
Antibody scFV nucleotide sequences
Name
WapR—003 AGCCGGCCATGGCCCAGATGCAGCTGGTGCAGTCGGGG
GGAGGCTTGGTCCAGCCTGGGGGGTCCCTGAGACTCTCCTGTTCA
GCCTCTGGATTCACCTTCAGTAGCTATCCTATGCACTGGGTCCGCC
AGGCTCCAGGGAAGGGACTGGATTATGTTTCAGACATCAGTCCAA
ATGGGGGTGCCACAAACTACGCAGACTCCGTGAAGGGCAGATTC
ACCATCTCCAGAGACAATTCCAAGAACACGGTGTATCTTCAAATG
AGCAGTCTGAGAGCTGAAGACACGGCTGTCTATTATTGTGTGATG
GGGTTAGTGCCCTATGGTTTTGATAACTGGGGCCAGGGGACAATG
GTCTCGAGTGGAGGCGGCGGTTCAGGCGGAGGTGGCTCT
GGCGGTGGCGGAAGTGCACAGACTGTGGTGACCCAGCCTGCCTCC
GTGTCTGCATCTCCTGGACAGTCGATCACCATCTCCTGCGCTGGA
ACCAGCGGTGATGTTGGGAATTATAATTTTGTCTCCTGGTACCAA
CAACACCCAGGCAAAGCCCCCAAACTCCTGATTTATGAGGGCAGT
CAGCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAGGTCTG
GCAACACGGCCTCCCTGACAATCTCTGGGCTCCAGGCTGAGGACG
AGGCTGATTATTACTGTTCCTCATATGCACGTAGTTACACTTATGT
CTTCGGAACTGGGACCAAGCTGACCGTCCTAGCGGCCGCA
SEQ ID NO:70
Antibody scFV nucleotide sequences
Name
WapR—004 TATGCGGCCCAGCCGGCCATGGCCGAGGTGCAGCTGTTGGAGTCG
GGCCCAGGACTGGTGAAGCCTTCGGAGACCCTGTCCCTCACCTGC
AATGTCGCTGGTGGCTCCATCAGTCCTTACTACTGGACCTGGATCC
GGCAGCCCCCAGGGAAGGGCCTGGAGTTGATTGGTTATATCCACT
GGTACACCGACTACAACCCCTCCCTCAAGAGTCGAGTCA
CCATATCAGGAGACACGTCCAAGAAGCAGTTCTCCCTGCACGTGA
TGACCGCTGCGGACACGGCCGTGTACTTCTGTGCGAGAG
GCGATTGGGACCTGCTTCATGCTCTTGATATCTGGGGCCAAGGGA
CCCTGGTCACCGTCTCGAGTGGAGGCGGCGGTTCAGGCGGAGGTG
GCTCTGGCGGTGGCGGAAGTGCACTCGAAATTGTGTTGACACAGT
CTCCATCCTCCCTGTCTACATCTGTAGGAGACAGAGTCACCATCA
CTTGCCGGGCAAGTCAGAGCATTAGGAGCCATTTAAATTGGTATC
AGCAGAAACCAGGGAAAGCCCCTAAACTCCTGATCTATGGTGCAT
CCAATTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGAT
CTGGGACAGATTTCACTCTCACCATTAGTAGTCTGCAACCTGAAG
ATTTTGCAACTTACTACTGTCAACAGAGTTACAGTTTCCCCCTCAC
TTTCGGCGGAGGGACCAAGCTGGAGATCAAAGCGGCCGC
SEQ ID NO:71
Antibody scFV nucleotide sequences
Nmne
WMpR£07 GCGGCCCAGCCGGCCATGGCCGAAGTGCAGCTGGTGCAGTCTGG
GGCTGACGTAAAGAAGCCTGGGGCCTCAGTGAGGGTCACCTGCA
AGGCTTCTGGATACACCTTCACCGGCCACAACATACACTGGGTGC
CCCCTGGACAAGGGCTTGAATGGATGGGATGGATCAAC
CCTGACAGTGGTGCCACAAGCTATGCACAGAAGTTTCAGGGCAGG
GTCACCATGACCAGGGACACGTCCATCACCACAGCCTACATGGAC
CTGAGCAGGCTGAGATCTGACGACACGGCCGTATATTACTGTGCG
ACCGATACATTACTGTCTAATCACTGGGGCCAAGGAACCCTGGTC
ACCGTCTCGAGTGGTGGAGGCGGTTCAGGCGGAGGTGGCAGCGG
CGGTGGCGGATCGTCTGAGCTGACTCAGGACCCTGCTGTGTCTGT
GGCCTTGGGACAGACAGTCAGGATCACTTGCCAAGGAGACAGTCT
CAGAAGCTATTACACAAACTGGTTCCAGCAGAAGCCAGGACAGG
CCCCTCTACTTGTCGTCTATGCTAAAAATAAGCGGCCCCCAGGGA
ACCGATTCTCTGGCTCCAGCTCAGGAAACACAGCTTCCT
TGACCATCACTGGGGCTCAGGCGGAAGATGAGGCTGACTATTACT
GTCATTCCCGGGACAGCAGTGGTAACCATGTGGTATTCGGCGGAG
GGACCAAGCTGACCGTCCTAGGTGCGGCCGCA
SEQ ID NO:72
Antibody scFVINKfleofidesequences
Nmne
VVapR:016 CAGCCGGCCATGGCCGAGGTGCAGCTGGTGGAGTCTGGGGGAGG
CTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTG
TGCAGCCTCTGGATACACCTTTAGCAGCTATGCCACGAGCTGGGT
CCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCG
CAGGTATTAGTGGTAGTGGTGATACCACAGACTACGTAGACTCCG
TGAAGGGCCGGTTCACCGTCTCCAGAGACAATTCC
AAGAACACCCTATATCTGCAAATGAACAGCCTGAGAGCCGACGA
CACGGCCGTGTATTACTGTGCGTCGAGAGGAGGTTT
AGGGGGTTATTACCGGGGCGGCTTTGACTTCTGGGGCCAGGGGAC
AATGGTCACCGTCTCGAGTGGAGGCGGCGGTTCAG
GCGGAGGTGGCTCTGGCGGTGGCGGAAGTGCACAGTCTGTGCTGA
CTGCCTCCGTGTCTGGGTCTCCTGGACAG
TCGATCACCATCTCCTGCACTGGAACCAGCAGTGACGTTGGTGGT
TATGTCTCCTGGTACCAACAGCACCCAGG
CAAAGCCCCCAAACTCATGATTTATGAGGTCAGTAATCGGCCCTC
AGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTG
GCAACACGGCCTCCCTGACCATCTCTGGGCTCCAGGCTGAGGACG
AGGCTGATTATTACTGCAGCTCATATACAAGCAGC
GGCACTGTGGTATTCGGCGGAGGGACCGAGCTGACCGTCCTAGCG
GCCGCA
SEQ ID NO:73
Antibody Name
V2L2 — VH GAGATGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGG
GGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTAGCA
GCTATGCCATGAACTGGGTCCGCCAGGCTCCAGGGGAGGGGCTGG
AGTGGGTCTCAGCTATTACTATTAGTGGTATTACCGCATACTACAC
CGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAA
GAACACGCTATATCTGCAAATGAACAGCCTGAGGGCCGGGGACAC
GGCCGTATATTACTGTGCGAAGGAAGAATTTTTACCTGGAACGCA
CTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCAC
CGTCTCCTCA
SEQ ID NO: 238
d Name
V2L2 — VL GCCATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAG
GAGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGAA
TAGGCTGGTATCAACAGAAGCCAGGGAAAGCCCCTAAAC
TCGTGATCTATTCTGCATCCACTTTACAAAGTGGGGTCCCATCAAG
GTTCAGCGGCAGTGGATCTGGCACAGATTTCACTCTCTCCATCAGC
AGCCTGCAGCCTGACGATTTTGCAACTTATTACTGTCTACAAGATT
ACAATTACCCGTGGACGTTCGGCCAAGGGACCAAGGTTGAAATCA
SEQ ID NO: 239
In some embodiments, an isolated antibody or antigen-binding fragment f
encoded by one or more of the polynucleotides bed above, which specifically binds
to Pseudomonas Ps1 and/or Pch, comprises, consists essentially of, or consists of VH
and VL amino acid ces at least 80%, 85%, 90%, 95% or 100% identical to:
(a) SEQ ID NO: 1 and SEQ ID NO: 2, respectively, (b) SEQ ID NO: 3 and SEQ
ID NO: 2, respectively, (c) SEQ ID NO: 4 and SEQ ID NO: 2
, respectively, (d)
SEQ ID NO: 5 and SEQ ID NO: 6 ID NO: 7 and SEQ ID
, respectively, (e) SEQ
NO: 8, respectively, (f) SEQ ID NO: 9 and SEQ ID NO: 10, respectively, (g) SEQ
ID NO: 11 and SEQ ID NO: 12 ID NO: 13 and SEQ ID
, respectively, (h) SEQ
NO: 14, respectively; (i) SEQ ID NO: 15 and SEQ ID NO: 16, respectively; or (j)
SEQ ID NO: 74 and SEQ ID NO: 12 , respectively.
In certain embodiments, an isolated binding molecule, e. g., an antibody or
antigen—binding fragment f encoded by one or more of the polynucleotides
described above, specifically binds to Pseudomonas Ps1 and/or Pch with an ty
characterized by a dissociation constant (KD) no greater than 5 x 10'2 M, 10'2 M, 5 x 10'3
M, 10‘3 M, 5 x104 M, 10‘4 M, 5 x10'5 M, 10‘5 M, 5 x106 M, 10‘6 M, 5 x10'7 M, 10‘7 M,
x 10‘8 M, 10‘8 M, 5 x109 M, 10‘9 M, 5 x1010 M, 10‘10 M, 5 x10'11M, 10'11M, 5 x10-
M, 10'12 M, 5 x 10'13 M, 10'13 M, 5 x 10'14 M, 10'14 M, 5 x 10'15 M, or 10'15 M.
In specific embodiments, an isolated binding molecule, e. g., an antibody or
antigen—binding fragment thereof encoded by one or more of the polynucleotides
described above, specifically binds to Pseudomonas Ps1 and/or Pch, with an affinity
characterized by a dissociation constant (KD) in a range of about 1 x 10'10 to about 1 x 10'
M. In one embodiment, an isolated binding molecule, e.g., an antibody or antigen-
binding fragment thereof encoded by one or more of the polynucleotides described above,
specifically binds to Pseudomonas Psl and/or Pch, with an affinity characterized by a KD
of about 1.18 x 10'7 M, as determined by the OCTET® binding assay described herein. In
another embodiment, an isolated binding molecule, e. g., an antibody or antigen-binding
fragment thereof encoded by one or more of the polynucleotides described above,
specifically binds to Pseudomonas Psl and/or Pch, with an affinity characterized by a KD
of about 1.44 x 10'7 M, as determined by the OCTET® binding assay described herein.
In certain ments, an anti—Pseudomonas Psl and/or Pch g molecule,
e. g., antibody or fragment, t or derivative thereof encoded by one or more of the
polynucleotides described above, specifically binds to the same Ps1 epitope as
monoclonal dy WapR—004, WapR—004RAD, Cam—003, Cam—004, or Cam—005, or
will competitively inhibit such a monoclonal antibody from binding to Pseudomonas Psl;
and/or specifically binds to the same Pch e as monoclonal antibody V2L2, or will
competitively inhibit such a monoclonal antibody from binding to Pseudomonas Pch.
WapR—004RAD is identical to 04 except for a nucleic acid substitution G293C of
the VH nucleic acid sequence encoding the VH amino acid sequence of SEQ ID NO:11 (a
tution of the nucleotide in the VH-encoding portion of SEQ ID NO:71 at position
317). The nucleic acid sequence encoding the WapR—004RAD VH is presented as SEQ
ID NO 76.
Some embodiments provide an isolated cleotide sing, consisting
essentially of, or consisting of a nucleic acid encoding a W4 mutant scFv—Fc molecule
amino acid sequence identical to, or identical except for one, two, three, four, five, or
more amino acid substitutions to one or more of: SEQ ID NO: 78, SEQ ID NO: 79, SEQ
ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID
NO: 85, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID
NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID
NO: 95, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID
NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ
ID NO: 105, SEQ ID NO: 106, SEQ ID NO: 107, SEQ ID NO: 108, SEQ ID NO: 109,
SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO:
114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID
NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ
ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128,
SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO:
133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID
NO: 138, SEQ ID NO: 139, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ
ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145; or SEQ ID NO: 146.
Other embodiments provide an isolated cleotide comprising, consisting
essentially of, or consisting of a nucleic acid encoding a W4 mutant scFV—Fc molecule
amino acid ce at least 80%, 85%, 90% 95% or 100% identical to one or more of:
SEQ ID NO: 78, SEQ ID NO: 79, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82,
SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 87,
SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92,
SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 97,
SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102,
SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, SEQ ID NO:
107, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID
NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ
ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121,
SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO:
126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID
NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ
ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, SEQ ID NO: 140,
SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO:
145; or SEQ ID .
One embodiment provides an isolated polynucleotide comprising, consisting
essentially of, or consisting of a nucleic acid which encodes a W4 mutant scFV—Fc
molecule, Where the nucleic acid is at least 80%, 85%, 90% 95% or 100% identical to one
or more of SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ
ID NO: 151, or SEQ ID NO: 152, SEQ IS NO: 153, SEQ ID NO: 154, SEQ ID NO: 155,
SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO:
160, SEQ ID NO: 161, SEQ ID NO: 162, SEQ ID NO: 163, SEQ ID NO: 164, SEQ ID
NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 169, SEQ
ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174,
SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178, SEQ ID NO:
179, SEQ ID NO: 180, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID
NO: 184, SEQ ID NO: 185, SEQ ID NO: 186, SEQ ID NO: 187, SEQ ID NO: 188, SEQ
ID NO: 189, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 192, SEQ ID NO: 193,
SEQ ID NO: 194, SEQ ID NO: 195, SEQ ID NO: 196, SEQ ID NO: 197, SEQ ID NO:
198, SEQ ID NO: 199, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 202, SEQ ID
NO: 203, SEQ ID NO: 204, SEQ ID NO: 205, SEQ ID NO: 206, SEQ ID NO: 207, SEQ
ID NO: 208, SEQ ID NO: 209, SEQ ID NO: 210, SEQ ID NO: 211, SEQ ID NO: 212,
SEQ ID NO: 213, SEQ ID NO: 214; or SEQ ID NO: 215.
One embodiment provides an isolated polynucleotide comprising, consisting
essentially of, or consisting of a nucleic acid which encodes a V2L2 polypeptide, where
the c acid is at least 80%, 85%, 90% 95% or 100% cal to one or more of SEQ
ID NO: 238 or SEQ ID NO: 239.
In other embodiments, an anti—Pseudomonas Psl and/or Pch binding molecule,
e. g., antibody or fragment, variant or derivative f encoded by one or more of the
polynucleotides described above, specifically binds to the same epitope as monoclonal
antibody WapR—001, WapR—002, or WapR—003, or will competitively inhibit such a
monoclonal antibody from binding to Pseudomonas Psl.
In certain embodiments, an anti—Pseudomonas Psl and/or Pch binding molecule,
e. g., antibody or fragment, variant or derivative f encoded by one or more of the
polynucleotides described above, specifically binds to the same epitope as onal
antibody WapR-016, or will competitively inhibit such a monoclonal antibody from
binding to Pseudomonas Psl.
The disclosure also includes fragments of the polynucleotides as described
elsewhere herein. Additionally polynucleotides which encode fusion polynucleotides,
Fab fragments, and other tives, as described herein, are also provided.
The polynucleotides can be produced or ctured by any method known in
the art. For example, if the nucleotide sequence of the antibody is known, a
polynucleotide encoding the antibody can be assembled from chemically synthesized
oligonucleotides (e.g., as described in Kutmeier et al., BioTechniques 17:242 (1994)),
which, briefly, es the synthesis of pping ucleotides containing portions
of the sequence encoding the antibody, annealing and ligating of those oligonucleotides,
and then amplification of the ligated oligonucleotides by PCR.
atively, a polynucleotide encoding an anti—Pseudomonas Psl and/or Pch
binding molecule, e. g., antibody or fragment, variant or tive f can be
generated from nucleic acid from a suitable source. If a clone containing a c acid
encoding a particular antibody is not available, but the sequence of the antibody le
is known, a nucleic acid encoding the antibody can be chemically synthesized or obtained
from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated
from, or nucleic acid, preferably poly A+RNA, isolated from, any tissue or cells
expressing the antibody or such as hybridoma cells selected to express an antibody) by
PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the
sequence or by cloning using an oligonucleotide probe specific for the particular gene
sequence to identify, e. g., a cDNA clone from a cDNA library that encodes the antibody.
Amplified nucleic acids generated by PCR can then be cloned into replicable cloning
vectors using any method well known in the art.
Once the tide sequence and corresponding amino acid sequence of an anti—
monas Psl and/or Pch binding molecule, e.g., antibody or fragment, variant or
derivative thereof is determined, its nucleotide ce can be manipulated using
methods well known in the art for the manipulation of nucleotide sequences, e.g.,
recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for e, the
techniques described in Sambrook et al., Molecular Cloning, A Laboratory Manual, 2d
Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. (1990) and Ausubel et al.,
eds., Current Protocols in lar Biology, John Wiley & Sons, NY , which are
both incorporated by reference herein in their entireties ), to generate antibodies having a
different amino acid ce, for example to create amino acid substitutions, deletions,
and/or insertions.
A polynucleotide encoding an anti—Pseudomonas Psl and/or Pch binding
molecule, e. g., antibody or fragment, variant or derivative thereof can be composed of
any polyribonucleotide or polydeoxribonucleotide, which can be unmodifled RNA or
DNA or modified RNA or DNA. For example, a polynucleotide encoding an anti-
Pseudomonas Psl and/or Pch binding molecule, e.g., dy or fragment, variant or
derivative thereof can be composed of — and double-stranded DNA, DNA that is a
mixture of single— and double—stranded regions, single— and double—stranded RNA, and
RNA that is mixture of — and double—stranded regions, hybrid molecules comprising
DNA and RNA that can be single-stranded or, more typically, double—stranded or a
mixture of single- and double-stranded s. In addition, a polynucleotide encoding an
anti—Pseudomonas Psl and/or Pch binding molecule, e. g., antibody or fragment, variant
or derivative thereof can be ed of triple—stranded regions comprising RNA or
DNA or both RNA and DNA. A polynucleotide encoding an anti—Pseudomonas Psl
and/or Pch binding molecule, e. g., antibody or fragment, variant or derivative thereof
can also n one or more modified bases or DNA or RNA backbones modified for
stability or for other reasons. "Modified" bases e, for e, tritylated bases and
unusual bases such as inosine. A variety of modifications can be made to DNA and
RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically
modifled forms.
An isolated polynucleotide encoding a non-natural variant of a ptide
derived from an immunoglobulin (e. g., an immunoglobulin heavy chain portion or light
chain portion) can be created by introducing one or more nucleotide substitutions,
additions or deletions into the tide sequence of the immunoglobulin such that one
or more amino acid substitutions, additions or deletions are introduced into the encoded
protein. ons can be introduced by standard techniques, such as site—directed
mutagenesis and PCR-mediated mutagenesis. Conservative amino acid tutions are
made at one or more non-essential amino acid es.
VI. EXPRESSION OF ANTIBODY POLYPEPTIDES
As is well known, RNA can be isolated from the original hybridoma cells or from
other transformed cells by standard techniques, such as guanidinium isothiocyanate
extraction and precipitation ed by centrifugation or chromatography. Where
desirable, mRNA can be isolated from total RNA by standard techniques such as
chromatography on oligo dT cellulose. le techniques are familiar in the art.
In one embodiment, cDNAs that encode the light and the heavy chains of the anti-
Pseudomonas Psl and/or Pch binding molecule, e.g., antibody or nt, variant or
derivative thereof can be made, either aneously or separately, using reverse
transcriptase and DNA polymerase in accordance with well-known methods. PCR can be
initiated by consensus constant region primers or by more specific primers based on the
published heavy and light chain DNA and amino acid sequences. As discussed above,
PCR also can be used to isolate DNA clones ng the antibody light and heavy
chains. In this case the libraries can be screened by consensus primers or larger
homologous probes, such as mouse constant region probes.
DNA, typically plasmid DNA, can be isolated from the cells using techniques
known in the art, restriction mapped and sequenced in accordance with standard, well
known techniques set forth in detail, e.g., in the foregoing references relating to
recombinant DNA techniques. Of course, the DNA can be synthetic according to the
present disclosure at any point during the isolation process or uent analysis.
Following manipulation of the isolated genetic al to provide an anti-
Pseudomonas Psl and/or Pch binding molecule, e.g., antibody or fragment, variant or
derivative thereof of the disclosure, the cleotides encoding anti—Pseudomonas Psl
and/or Pch binding molecules, are typically inserted in an expression vector for
introduction into host cells that can be used to produce the desired ty of anti-
Pseudomonas Psl and/or Pch binding molecules.
Recombinant expression of an antibody, or fragment, derivative or analog f,
e.g., a heavy or light chain of an antibody which binds to a target molecule described
herein, e. g., Psl and/or Pch, requires construction of an expression vector containing a
polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody
molecule or a heavy or light chain of an antibody, or n thereof (containing the
heavy or light chain variable domain), of the disclosure has been obtained, the vector for
the tion of the antibody molecule can be produced by recombinant DNA
logy using techniques well known in the art. Thus, methods for preparing a protein
by sing a polynucleotide containing an antibody encoding nucleotide sequence are
bed herein. Methods which are well known to those skilled in the art can be used to
construct expression vectors containing dy coding sequences and appropriate
transcriptional and translational control signals. These s include, for example, in
vitro recombinant DNA techniques, synthetic techniques, and in viva genetic
recombination. The sure, thus, provides replicable vectors comprising a nucleotide
sequence encoding an antibody molecule of the disclosure, or a heavy or light chain
thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such
vectors can include the nucleotide sequence encoding the constant region of the antibody
molecule (see, e.g., PCT ation WO 86/05807; PCT ation WO 89/01036; and
US. Pat. No. 5,122,464) and the variable domain of the antibody can be cloned into such
a vector for expression of the entire heavy or light chain.
The term “vector” or ssion ” is used herein to mean vectors used in
accordance with the present disclosure as a vehicle for introducing into and expressing a
desired gene in a host cell. As known to those skilled in the art, such s can easily
be selected from the group ting of plasmids, phages, viruses and retroviruses. In
general, vectors compatible with the instant disclosure will comprise a ion marker,
appropriate restriction sites to facilitate cloning of the desired gene and the ability to enter
and/or replicate in eukaryotic or prokaryotic cells.
For the purposes of this disclosure, numerous expression vector systems can be
employed. For example, one class of vector utilizes DNA elements which are derived
from animal viruses such as bovine papilloma virus, polyoma virus, adenovirus, vaccinia
virus, baculovirus, retroviruses (RSV, MMTV or MOMLV) or SV40 virus. Others
involve the use of polycistronic systems with internal ribosome binding sites.
onally, cells which have ated the DNA into their chromosomes can be
selected by introducing one or more markers which allow selection of ected host
cells. The marker can provide for prototrophy to an auxotrophic host, biocide resistance
(e.g., antibiotics) or resistance to heavy metals such as copper. The selectable marker
gene can either be ly linked to the DNA ces to be expressed, or introduced
into the same cell by cotransformation. Additional elements can also be needed for
optimal synthesis of mRNA. These elements can include signal sequences, splice s,
as well as transcriptional promoters, enhancers, and termination signals.
In some embodiments the cloned variable region genes are inserted into an
expression vector along with the heavy and light chain constant region genes (e.g.,
human) synthetic as discussed above. Of course, any expression vector which is capable
of eliciting expression in eukaryotic cells can be used in the present disclosure. Examples
of le vectors include, but are not limited to plasmids pcDNA3, pHCMV/Zeo,
pCR3.l, pEFl/His, pIND/GS, pRc/HCMV2, pSV40/Ze02, pTRACER-HCMV,
pUB6/V5-His, pVAXl, and pZeoSV2 (available from Invitrogen, San Diego, CA), and
plasmid pCI (available from Promega, Madison, WI). In l, screening large
numbers of transformed cells for those which s suitably high levels if
immunoglobulin heavy and light chains is routine experimentation which can be carried
out, for example, by robotic systems.
More generally, once the vector or DNA sequence encoding a monomeric subunit
of the anti—Pseudomonas Psl and/or Pch binding molecule, e.g., antibody or fragment,
variant or derivative thereof of the disclosure has been prepared, the sion vector
can be uced into an appropriate host cell. Introduction of the d into the host
cell can be accomplished by various techniques well known to those of skill in the art.
These include, but are not limited to, transfection ding electrophoresis and
electroporation), last fusion, calcium phosphate precipitation, cell fusion with
enveloped DNA, microinjection, and ion with intact Virus. See, Ridgway, A. A. G.
"Mammalian Expression Vectors" Vectors, uez and Denhardt, Eds., Butterworths,
Boston, Mass., Chapter 24.2, pp. 470-472 (1988). Typically, plasmid introduction into
the host is Via electroporation. The host cells ing the expression construct are
grown under conditions appropriate to the tion of the light chains and heavy
chains, and assayed for heavy and/or light chain protein synthesis. Exemplary assay
ques include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay
(RIA), or fluorescence—activated cell sorter analysis (FACS), immunohistochemistry and
the like.
The expression vector is transferred to a host cell by conventional techniques and
the transfected cells are then cultured by tional techniques to produce an antibody
for use in the methods described herein. Thus, the disclosure includes host cells
containing a polynucleotide encoding an anti—Pseudomonas Psl and/or Pch binding
molecule, e. g., antibody or fragment, variant or derivative f, or a heavy or light
chain thereof, operably linked to a heterologous promoter. In some embodiments for the
expression of double—chained antibodies, vectors encoding both the heavy and light
chains can be co—expressed in the host cell for expression of the entire immunoglobulin
molecule, as detailed below.
Certain embodiments include an ed polynucleotide sing a nucleic acid
which encodes the above—described VH and VL, wherein a binding molecule or antigen-
g fragment thereof expressed by the polynucleotide specifically binds
Pseudomonas Ps1 and/or Pch. In some embodiments the polynucleotide as described
encodes an scFV molecule including VH and VL, at least 80%, 85%, 90% 95% or 100%
—100—
identical to one or more of SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID
NO: 68, SEQ ID NO: 69, or SEQ ID NO: 70 as shown in Table 4.
Some embodiments include vectors sing the above—described
polynucleotides. In further embodiments, the polynucleotides are operably associated
with a er. In additional embodiments, the disclosure provides host cells
sing such vectors. In further embodiments, the disclosure provides vectors where
the polynucleotide is operably associated with a promoter, wherein vectors can s a
binding molecule which specifically binds Pseudomonas Psl and/or Pch in a suitable
host cell.
Also provided is a method of producing a binding molecule or fragment thereof
which specifically binds Pseudomonas Psl and/or Pch, comprising culturing a host cell
containing a vector comprising the above—described polynucleotides, and ring said
antibody, or fragment thereof. In further embodiments, the disclosure provides an
isolated binding molecule or fragment thereof produced by the above—described method.
As used , “host cells” refers to cells which harbor vectors constructed using
recombinant DNA techniques and encoding at least one heterologous gene. In
descriptions of processes for isolation of antibodies from recombinant hosts, the terms
"cell" and "cell culture" are used interchangeably to denote the source of antibody unless
it is y specified otherwise. In other words, recovery of polypeptide from the "cells"
can mean either from spun down whole cells, or from the cell culture containing both the
medium and the suspended cells.
A y of xpression vector systems can be utilized to express antibody
molecules for use in the methods described herein. Such host—expression systems
represent vehicles by which the coding ces of interest can be produced and
subsequently purified, but also ent cells which can, when transformed or transfected
with the appropriate nucleotide coding sequences, express an antibody molecule of the
disclosure in situ. These include but are not limited to microorganisms such as bacteria
(e.g., E. coli, B. is) transformed with recombinant bacteriophage DNA, plasmid
DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast
(e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors
containing antibody coding sequences; insect cell systems ed with recombinant
virus sion vectors (e.g., baculovirus) containing antibody coding sequences; plant
—101—
cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic
virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid
expression s (e. g., Ti plasmid) containing antibody coding sequences; or
mammalian cell systems (e. g., COS, CHO, BLK, 293, 3T3 cells) harboring recombinant
sion constructs containing ers derived from the genome of mammalian cells
(e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late
promoter; the vaccinia virus 7.5K promoter). Bacterial cells such as Escherichia coli, or
eukaryotic cells, especially for the expression of whole recombinant antibody molecule,
are used for the expression of a recombinant antibody molecule. For example,
mammalian cells such as e hamster ovary cells (CHO), in conjunction with a
vector such as the major ediate early gene promoter element from human
cytomegalovirus is an effective sion system for antibodies (Foecking et al., Gene
45:101 (1986); Cockett et al., Bio/Technology 8:2 (1990)).
The host cell line used for n expression is often of mammalian ; those
skilled in the art are credited with ability to determine particular host cell lines which are
best suited for the desired gene product to be expressed therein. Exemplary host cell lines
include, but are not limited to, CH0 (Chinese Hamster Ovary), DG44 and DUXBll
(Chinese r Ovary lines, DHFR minus), HELA (human cervical carcinoma), CV1
(monkey kidney line), COS (a derivative of CV1 with SV40 T antigen), VERY, BHK
(baby hamster kidney), MDCK, 293, W13 8, R1610 (Chinese hamster fibroblast)
BALBC/3T3 (mouse fibroblast), HAK (hamster kidney line), SP2/O (mouse myeloma),
P3x63—Ag3.653 (mouse myeloma), BFA—lclBPT (bovine endothelial cells), RAJI
(human cyte) and 293 (human kidney). Host cell lines are typically available
from commercial services, the American Tissue Culture Collection or from published
literature.
In on, a host cell strain can be chosen which modulates the sion of the
inserted sequences, or modif1es and processes the gene product in the specific fashion
desired. Such modifications (e.g., glycosylation) and processing (e. g., cleavage) of
protein products can be important for the function of the protein. Different host cells have
characteristic and specific mechanisms for the post-translational processing and
modification of proteins and gene products. Appropriate cell lines or host systems can be
chosen to ensure the t modification and processing of the foreign n expressed.
—102—
To this end, otic host cells which possess the ar machinery for proper
processing of the primary transcript, glycosylation, and phosphorylation of the gene
product can be used.
For long-term, high-yield production of recombinant proteins, stable expression is
preferred. For example, cell lines which stably express the dy molecule can be
engineered. Rather than using expression vectors which contain viral origins of
replication, host cells can be transformed with DNA controlled by appropriate expression
control elements (e. g., promoter, enhancer, sequences, transcription terminators,
polyadenylation sites, etc.), and a selectable marker. Following the introduction of the
foreign DNA, engineered cells can be allowed to grow for 1-2 days in an enriched media,
and then are switched to a selective media. The selectable marker in the recombinant
plasmid s resistance to the selection and allows cells to stably integrate the plasmid
into their chromosomes and grow to form foci which in turn can be cloned and expanded
into cell lines. This method can advantageously be used to engineer cell lines which
stably express the antibody molecule.
A number of selection systems can be used, ing but not limited to the herpes
simplex virus thymidine kinase (Wigler et al., Cell [1:223 (1977)), hypoxanthine-guanine
phosphoribosyltransferase lska & ski, Proc. Natl. Acad. Sci. USA 48202
(1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 1980) genes
can be employed in tk-, hgprt- or aprt-cells, tively. Also, tabolite resistance
can be used as the basis of selection for the following genes: dhfr, which confers
resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et
al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt, which confers resistance to
mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 782072 (1981)); neo,
which confers resistance to the aminoglycoside G—418 Clinical Pharmacy 12:488—505;
Wu and Wu, Biotherapy 3:87—95 (1991); Tolstoshev, Ann. Rev. Pharmacol. l.
32:573—596 (1993); Mulligan, Science 260:926—932 (1993); and Morgan and Anderson,
Ann. Rev. Biochem. 62:191—217 (1993);, T13 TECH II(5):155-215 (May, 1993); and
hygro, which confers resistance to hygromycin (Santerre et al., Gene 30:147 (1984).
Methods commonly known in the art of recombinant DNA technology which can be used
are described in Ausubel et al. , Current ols in Molecular Biology, John
Wiley & Sons, NY ; Kriegler, Gene Transfer and Expression, A Laboratory
—103—
Manual, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds),
Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colberre-Garapin
et al., J. Mol. Biol. 150:1 (1981), which are incorporated by nce herein in their
entireties.
The expression levels of an antibody molecule can be increased by vector
amplification (for a review, see Bebbington and Hentschel, The use of vectors based on
gene amplification for the expression of cloned genes in mammalian cells in DNA
cloning, Academic Press, New York, Vol. 3. (1987)). When a marker in the vector system
expressing antibody is amplif1able, increase in the level of inhibitor present in culture of
host cell will increase the number of copies of the marker gene. Since the amplified
region is associated with the antibody gene, production of the antibody will also increase
(Crouse et al., Mol. Cell. Biol. 3:257 (1983)).
In vitro production allows scale—up to give large amounts of the d
polypeptides. Techniques for ian cell cultivation under tissue culture ions
are known in the art and include homogeneous suspension culture, e.g. in an airlift reactor
or in a continuous stirrer reactor, or immobilized or entrapped cell culture, e. g. in hollow
fibers, microcapsules, on e microbeads or ceramic cartridges. If necessary and/or
desired, the solutions of polypeptides can be d by the customary chromatography
s, for example gel ion, ion-exchange chromatography, chromatography over
DEAE-cellulose or (immuno-)aff1nity chromatography, e. g., after ential
thesis of a synthetic hinge region polypeptide or prior to or subsequent to the HIC
chromatography step described herein.
Constructs encoding anti—Pseudomonas Psl and/or Pch binding molecules, e. g.,
antibodies or fragments, variants or derivatives f, as disclosed herein can also be
expressed non-mammalian cells such as bacteria or yeast or plant cells. ia which
y take up nucleic acids include members of the enterobacteriaceae, such as strains of
Escherichia coli or Salmonella; Bacillaceae, such as Bacillus subtilis; Pneumococcus;
Streptococcus, and Haemophilus influenzae. It will further be appreciated that, when
expressed in ia, the heterologous polypeptides lly become part of inclusion
bodies. The heterologouspolypeptides must be isolated, purified and then assembled into
functional molecules. Where tetravalent forms of antibodies are desired, the subunits will
then self-assemble into tetravalent antibodies (W002/096948A2).
—104—
In ial systems, a number of expression vectors can be advantageously
selected depending upon the use intended for the antibody molecule being expressed. For
example, when a large quantity of such a protein is to be produced, for the generation of
pharmaceutical compositions of an antibody molecule, vectors which direct the
expression of high levels of fusion protein products that are readily purified can be
desirable. Such s include, but are not d, to the E. coli expression vector
pUR278 (Ruther et al., EMBO J. 2:1791 (1983)), in which the antibody coding sequence
can be ligated individually into the vector in frame with the lacZ coding region so that a
fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13 :3101—
3109 (1985); Van Heeke & er, J. Biol. Chem. 24:5503—5509 (1989)); and the like.
pGEX vectors can also be used to express foreign polypeptides as fusion proteins with
glutathione S-transferase (GST). In general, such fusion proteins are soluble and can
easily be purified from lysed cells by adsorption and binding to a matrix glutathione-
agarose beads followed by elution in the presence of free glutathione. The pGEX vectors
are designed to include thrombin or factor Xa protease cleavage sites so that the cloned
target gene product can be released from the GST moiety.
In addition to prokaryotes, eukaryotic microbes can also be used. Saccharomyces
cerevisiae, or common baker's yeast, is the most commonly used among eukaryotic
microorganisms although a number of other strains are commonly available, e.g., Pichia
pastoris.
For expression in Saccharomyces, the plasmid YRp7, for e, (Stinchcomb et
al., Nature 282:39 (1979); Kingsman et al., Gene 7:141 (1979); Tschemper et al., Gene
:157 ) is commonly used. This d already contains the TRPl gene which
es a selection marker for a mutant strain of yeast lacking the ability to grow in
tryptophan, for e ATCC No. 44076 or PEP4—1 (Jones, Genetics 85:12 (1977)). The
presence of the trpl lesion as a characteristic of the yeast host cell genome then provides
an effective environment for detecting transformation by growth in the absence of
tryptophan.
In an insect system, apha californica r polyhedrosis virus (AcNPV)
is lly used as a vector to express foreign genes. The virus grows in Spodoptera
frugiperda cells. The antibody coding sequence can be cloned individually into non—
—105—
essential regions (for e the drin gene) of the virus and placed under control
of an AcNPV promoter (for example the polyhedrin promoter).
Once the anti—Pseudomonas Ps1 and/or Pch binding molecule, e.g., antibody or
fragment, variant or derivative thereof, as disclosed herein has been recombinantly
expressed, it can be purified by any method known in the art for cation of an
immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity,
ularly by affinity for the specific antigen after Protein A, and sizing column
chromatography), centrifugation, differential solubility, or by any other standard
technique for the purification of proteins. Another method for increasing the affinity of
antibodies of the disclosure is disclosed in US 2002 0123057 Al.
VII. IDENTIFICATION OF SEROTYPE—INDIFFERENT BINDING MOLECULES
The disclosure encompasses a target erent whole—cell approach to identify
pe independent therapeutic binding molecules e. g., antibodies or fragments thereof
with superior or desired therapeutic activities. The method can be utilized to identify
binding les which can antagonize, neutralize, clear, or block an undesired activity
of an infectious agent, e. g., a bacterial pathogen. As is known in the art, many ious
agents exhibit significant variation in their dominant surface antigens, allowing them to
evade immune surveillance. The identification method described herein can identify
binding molecules which target antigens which are shared among many different
Pseudomonas species or other Gram—negative pathogens, thus providing a therapeutic
agent which can target le pathogens from multiple s. For example, the
method was utilized to identify a series of binding molecules which bind to the surface of
P. aeruginosa in a serotype-independent manner, and when bound to bacterial pathogens,
mediate, promote, or enhance opsonophagocytic (OPK) activity against bacterial cells
such as bacterial pathogens, 6.g. opportunistic Pseudomonas species (e.g., Pseudomonas
aeruginosa, Pseudomonas fluorescens, monas putida, and Pseudomonas
alcaligenes) and/or inhibit the attachment of such bacterial cells to epithelial cells.
Certain embodiments disclose a method of identifying serotype-indifferent
binding molecules comprising: (a) ing na'ive and/or convalescent antibody libraries
in phage, (b) ng serotype-specific antibodies from the library by depletion
panning, (c) screening the library for dies that specifically bind to whole cells
—lO6—
independent of serotype, and (d) ing of the resulting antibodies for desired
functional properties.
Certain embodiments provide a whole—cell phenotypic screening approach as
disclosed herein with antibody phage libraries derived from either naive or P. aeruginosa
infected convalescing patients. Using a panning strategy that initially selected against
serotype-specific reactivity, different clones that bound P. aeruginosa whole cells were
isolated. Selected clones were converted to human IgG1 antibodies and were confirmed
to react with P. aeruginosa clinical isolates regardless of serotype classification or site of
tissue isolation (See Examples). Functional activity screens bed herein indicated
that the antibodies were effective in preventing P. aeruginosa attachment to mammalian
cells and mediated opsonophagocytic (OPK) killing in a concentration-dependent and
pe—independent manner.
In further embodiments, the above—described binding molecules or fragments
f, antibodies or fragments f, or compositions, bind to two or more, three or
more, four or more, or five or more different P. nosa serotypes, or to at least 80%,
at least 85%, at least 90% or at least 95% of P. aeruginosa strains isolated from infected
patients. In further embodiments, the P. aeruginosa strains are isolated from one or more
of lung, sputum, eye, pus, feces, urine, sinus, a wound, skin, blood, bone, or knee fluid.
VIII. PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI— PSEUDOMONAS PSL
AND/OR PCRV BINDING MOLECULES
The pharmaceutical compositions used in this disclosure comprise
pharmaceutically acceptable carriers well known to those of ordinary skill in the art.
Preparations for parenteral administration include sterile aqueous or non—aqueous
ons, suspensions, and emulsions. Certain ceutical compositions as disclosed
herein can be orally administered in an acceptable dosage form including, e.g., capsules,
tablets, aqueous sions or solutions. Certain pharmaceutical compositions also can
be administered by nasal aerosol or inhalation. Preservatives and other additives can also
be present such as for example, crobials, antioxidants, chelating , and inert
gases and the like. Suitable formulations for use in the therapeutic s sed
herein are described in Remington's Pharmaceutical Sciences, Mack Publishing Co., 16th
ed.(1980)
—lO7—
The amount of an anti—Pseudomonas Psl and/or Pch binding molecule, e.g.,
dy or fragment, variant or tive thereof, that can be combined with the carrier
materials to e a single dosage form will vary depending upon the host treated and
the particular mode of administration. Dosage regimens also can be ed to provide
the optimum d response (e.g., a therapeutic or prophylactic response). The
compositions can also comprise the anti—Pseudomonas Psl and/or Pch binding
molecules, e.g., antibodies or fragments, variants or derivatives thereof dispersed in a
biocompatible carrier material that functions as a suitable delivery or support system for
the compounds.
IX. TREATMENT METHODS USING THERAPEUTIC BINDING MOLECULES
Methods of preparing and administering anti-Pseudomonas Psl and/or Pch
binding molecules, e. g., an antibody or fragment, variant or derivative thereof, as
disclosed herein to a subject in need thereof are well known to or are readily determined
by those skilled in the art. The route of administration of the anti-Pseudomonas Psl
and/or Pch binding les, e. g., antibody or fragment, t or derivative thereof,
can be, for example, oral, parenteral, by inhalation or topical. The term eral as used
herein includes, e.g., intravenous, intraarterial, intraperitoneal, intramuscular, or
subcutaneous administration. A suitable form for administration would be a solution for
injection, in particular for intravenous or intraarterial injection or drip. However, in other
methods compatible with the teachings herein, an anti-Pseudomonas Psl and/or Pch
binding molecules, e. g., antibody or fragment, t or derivative thereof, as disclosed
herein can be delivered directly to the site of the adverse cellular population e.g.,
infection thereby increasing the exposure of the ed tissue to the therapeutic agent.
For example, an anti—Pseudomonas Psl and/or Pch g molecule can be directly
administered to ocular tissue, burn injury, or lung tissue.
Anti—Pseudomonas Psl and/or Pch g molecules, e.g., antibodies or
nts, variants or derivatives thereof, as disclosed herein can be administered in a
pharmaceutically ive amount for the in viva treatment domonas infection. In
this regard, it will be appreciated that the disclosed binding molecules will be formulated
so as to facilitate administration and promote stability of the active agent. For the
purposes of the instant application, a ceutically effective amount shall be held to
—108—
mean an amount sufficient to achieve effective binding to a target and to achieve a
benefit, e. g., treat, ameliorate, lessen, clear, or prevent Pseudomonas infection.
Some embodiments are directed to a method of preventing or treating a
Pseudomonas ion in a subject in need thereof, comprising stering to the
subject an effective amount of the binding molecule or fragment thereof, the antibody or
fragment thereof, the ition, the polynucleotide, the vector, or the host cell
described herein. In further embodiments, the Pseudomonas ion is a P. aeruginosa
infection. In some embodiments, the subject is a human. In certain embodiments, the
infection is an ocular infection, a lung infection, a burn infection, a wound infection, a
skin infection, a blood infection, a bone infection, or a combination of two or more of
said infections. In further embodiments, the t suffers from acute nia, burn
injury, corneal infection, cystic fibrosis, or a ation thereof
Certain embodiments are ed to a method of blocking or preventing
ment of P. aeruginosa to epithelial cells sing contacting a mixture of
epithelial cells and P. aeruginosa with the binding molecule or fragment thereof, the
antibody or fragment thereof, the composition, the polynucleotide, the vector, or the host
cell bed herein.
Also disclosed is a method of enhancing OPK of P. aeruginosa comprising
contacting a mixture of phagocytic cells and P. aeruginosa with the binding molecule or
fragment thereof, the antibody or fragment thereof, the composition, the polynucleotide,
the vector, or the host cell bed herein. In further embodiments, the phagocytic cells
are differentiated HL—60 cells or human polymorphonuclear leukocytes (PMNs).
In keeping with the scope of the disclosure, anti—Pseudomonas Psl and/or Pch
binding molecules, e. g., antibodies or fragments, variants or derivatives thereof, can be
administered to a human or other animal in accordance with the aforementioned methods
of treatment in an amount ient to produce a therapeutic effect. The anti-
monas Psl and/or Pch binding molecules, e.g., dies or fragments, variants
or derivatives thereof, disclosed herein can be administered to such human or other
animal in a conventional dosage form prepared by combining the antibody of the
disclosure with a conventional pharmaceutically able carrier or diluent according to
known techniques.
2012/063722
—lO9—
Effective doses of the compositions of the present disclosure, for treatment of
Pseudomonas infection vary depending upon many different factors, including means of
administration, target site, physiological state of the patient, whether the patient is human
or an animal, other medications administered, and whether treatment is prophylactic or
therapeutic. y, the patient is a human but non-human mammals including
transgenic mammals can also be treated. Treatment dosages can be titrated using routine
methods known to those of skill in the art to optimize safety and efficacy.
Anti—Pseudomonas Psl and/or Pch binding molecules, e.g., antibodies or
fragments, variants or tives thereof can be administered multiple occasions at
various frequencies depending on various factors known to those of skill in the art..
Alternatively, anti—Pseudomonas Psl and/or Pch binding molecules, e.g., antibodies or
fragments, variants or derivatives thereof can be administered as a sustained release
formulation, in which case less frequent administration is required. Dosage and
ncy vary depending on the half-life of the antibody in the patient.
The compositions of the disclosure can be stered by any suitable method,
e. g., parenterally, intraventricularly, orally, by inhalation spray, topically, rectally,
nasally, buccally, vaginally or via an implanted reservoir. The term “parenteral” as used
herein includes subcutaneous, intravenous, intramuscular, articular, intra-synovial,
intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion
techniques.
X. SYNERGY
Chou and Talalay (Adv. Enzyme Regal, 22:27—55 ) developed a
mathematical method to describe the experimental gs of combined drug effects in a
qualitative and quantitative manner. For ly ive drugs, they showed that the
generalized isobol on applies for any degree of effect (see page 52 in Chou and
y). An isobol or isobologram is the c representation of all dose combinations
of two drugs that have the same degree of effect. In isobolograms, a straight line
indicates additive effects, a e curve (curve below the straight line) represents
synergistic effects, and a convex curve (curve above the straight line) represents
antagonistic effects. These curves also show that a combination of two mutually
exclusive drugs will show the same type of effect over the whole concentration range,
—110—
either the combination is additive, synergistic, or antagonistic. Most drug combinations
show an additive effect. In some instances r, the combinations show less or more
than an additive effect. These combinations are called antagonistic or synergistic,
respectively. A combination manifests therapeutic synergy if it is therapeutically superior
to one or other of the constituents used at its m dose. See, T. H. Corbett et al.,
Cancer Treatment Reports, 66, 1187 . Tallarida R] (J Pharmacol Exp Ther. 2001
Sep; 298 (3):865—72) also notes "Two drugs that produce overtly similar effects will
sometimes produce exaggerated or shed effects when used concurrently. A
quantitative ment is necessary to distinguish these cases from simply additive
action."
A synergistic effect can be measured using the combination index (CI) method of
Chou and Talalay (see Chang et al., Cancer Res. 45: 2434—2439, (1985)) which is based
on the median-effect principle. This method calculates the degree of synergy, additivity,
or antagonism between two drugs at various levels of cytotoxicity. Where the CI value is
less than 1, there is synergy n the two drugs. Where the CI value is 1, there is an
additive effect, but no synergistic . CI values greater than 1 indicate antagonism.
The smaller the CI value, the greater the synergistic effect. In another embodiment, a
synergistic effect is ined by using the fractional inhibitory concentration (FIC).
This fractional value is determined by expressing the IC50 of a drug acting in
combination, as a function of the IC50 of the drug acting alone. For two interacting drugs,
the sum of the PIC value for each drug represents the measure of synergistic ction.
Where the PIC is less than 1, there is synergy between the two drugs. An FIC value of 1
indicates an additive effect. The smaller the PIC value, the greater the synergistic
interaction.
In some embodiments, a synergistic effect is obtained in Pseudomonas treatment
wherein one or more of the g agents are administered in a "low dose" (i.e., using a
dose or doses which would be considered non—therapeutic if administered alone), wherein
the administration of the low dose binding agent in combination with other g agents
(administered at either a low or eutic dose) results in a synergistic effect which
exceeds the additive effects that would ise result from individual administration of
the binding agent alone. In some embodiments, the synergistic effect is achieved via
—lll—
administration of one or more of the binding agents administered in a "low dose" wherein
the low dose is provided to reduce or avoid toxicity or other undesirable side effects.
XI. IMMUNOASSAYS
Anti—Pseudomonas Psl and/or Pch binding molecules, e.g., antibodies or
fragments, variants or tives thereof can be assayed for immunospecif1c binding by
any method known in the art. The assays which can be used include but are not
limited to competitive and non-competitive assay systems using techniques such as
western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay),
"sandwich" immunoassays, immunoprecipitation , precipitin reactions, gel
diffusion precipitin reactions, immunodiffusion , agglutination ,
complement-fixation assays, immunoradiometric assays, cent immunoassays,
protein A immunoassays, to name but a few. Such assays are e and well known in
the art (see, e.g., Ausubel et al., eds, Current Protocols in Molecular Biology, John Wiley
& Sons, Inc., New York, Vol. 1 (1994), which is incorporated by reference herein in its
entirety). Exemplary immunoassays are described briefly below (but are not intended by
way of limitation).
There are a variety of methods available for measuring the affinity of an antibody-
n interaction, but relatively few for determining rate constants. Most of the methods
rely on either labeling antibody or antigen, which inevitably complicates routine
measurements and introduces uncertainties in the measured ties. Antibody affinity
can be measured by a number of methods, including OCTET®, BIACORE®, ELISA, and
FACS.
The OCTET® system uses biosensors in a 96-well plate format to report kinetic
analysis. Protein binding and iation events can be monitored by ing the
binding of one protein in solution to a second protein immobilized on the ForteBio
biosensor. In the case of measuring binding of anti-Psl or Pch antibodies to Psl or Pch,
the Psl or Pch is immobilized onto OCTET® tips followed by analysis of binding of the
antibody, which is in solution. Association and disassociation of antibody to immobilized
Psl or Pch is then detected by the instrument sensor. The data is then collected and
exported to GraphPad Prism for affinity curve fitting.
—112—
Surface plasmon nce (SPR) as performed on BIACORE® offers a number
of advantages over conventional methods of measuring the affinity of antibody-antigen
interactions: (i) no requirement to label either antibody or antigen; (ii) antibodies do not
need to be purified in advance, cell culture supernatant can be used directly; (iii) real-time
measurements, allowing rapid semi-quantitative comparison of different monoclonal
antibody interactions, are enabled and are sufficient for many evaluation purposes; (iv)
ciflc e can be regenerated so that a series of different monoclonal antibodies
can easily be compared under identical conditions; (v) analytical procedures are fully
automated, and extensive series of measurements can be performed without user
intervention. BIAapplications Handbook, n AB (reprinted 1998), E® code
No. BR—lOOl—86; hnology Handbook, version AB (reprinted 1998), BIACORE®
code No. BR—1001—84.
SPR based binding studies require that one member of a binding pair be
immobilized on a sensor surface. The g r immobilized is referred to as the
ligand. The binding partner in solution is referred to as the analyte. In some cases, the
ligand is attached indirectly to the surface h binding to r immobilized
molecule, which is referred as the capturing molecule. SPR response reflects a change in
mass concentration at the or surface as analytes bind or dissociate.
Based on SPR, real-time BIACORE® measurements monitor interactions directly
as they . The technique is well suited to determination of kinetic parameters.
Comparative affinity ranking is extremely simple to perform, and both kinetic and affinity
constants can be derived from the sensorgram data.
When analyte is ed in a discrete pulse across a ligand surface, the resulting
gram can be divided into three essential phases: (i) Association of analyte with
ligand during sample injection; (ii) Equilibrium or steady state during sample injection,
where the rate of analyte binding is balanced by dissociation from the complex; (iii)
iation of analyte from the surface during buffer flow.
The association and dissociation phases provide information on the kinetics of
analyte-ligand interaction (ka and kd, the rates of complex formation and dissociation,
kd/ka = KD). The equilibrium phase provides information on the affinity of the analyte-
ligand interaction (KD).
—ll3—
BIAevaluation software provides comprehensive facilities for curve fitting using
both numerical integration and global fitting algorithms. With suitable analysis of the
data, separate rate and affinity nts for interaction can be obtained from simple
BIACORE® investigations. The range of affinities measurable by this technique is very
broad ranging from mM to pM.
Epitope specificity is an important characteristic of a monoclonal antibody.
Epitope mapping with E®, in contrast to conventional ques using
radioimmunoassay, ELISA or other surface adsorption s, does not require labeling
or purified antibodies, and allows site specificity tests using a sequence of several
monoclonal antibodies. Additionally, large numbers of es can be processed
automatically.
Pair-wise binding experiments test the ability of two MAbs to bind simultaneously
to the same n. MAbs directed against separate epitopes will bind independently,
whereas MAbs ed against identical or closely related epitopes will interfere with
each s binding. These binding ments with BIACORE® are straightforward to
carry out.
For example, one can use a capture molecule to bind the first Mab, followed by
addition of antigen and second MAb sequentially. The sensorgrams will reveal: 1. how
much of the antigen binds to first Mab, 2. to what extent the second MAb binds to the
surface—attached n, 3. if the second MAb does not bind, whether reversing the order
of the ise test alters the results.
Peptide inhibition is another technique used for epitope mapping. This method can
complement pair-wise antibody binding studies, and can relate functional es to
structural features when the primary sequence of the antigen is known. Peptides or
antigen fragments are tested for inhibition of binding of different MAbs to immobilized
antigen. Peptides which interfere with binding of a given MAb are assumed to be
structurally related to the epitope defined by that MAb.
XII. ADMINISTRATION
A composition comprising either an anti-Psl binding domain or anti-Pch binding
domain, or a composition comprising both an anti -Psl and anti-Pch binding domain are
administered in such a way that they provide a synergistic effect in the treatment of
—114—
Pseudomonas in a patient. stration can be by any suitable means provided that the
administration provides the desired therapeutic effect, i.e., synergism. In certain
ments, the antibodies are administered during the same cycle of therapy, e.g.,
during one cycle of therapy during a prescribed time period, both of the antibodies are
administered to the subject. In some embodiments, administration of the antibodies can
be during sequential administration in separate therapy cycles, e. g., the first therapy cycle
ing administration of an anti-Psl antibody and the second therapy cycle involving
administration of an anti-Pch antibody. The dosage of the binding domains
stered to a patient will also depend on frequency of administration and can be
readily determined by one of ry skill in the art.
In other embodiments the binding domains are administered more than once
during a treatment cycle. For example, in some embodiments, the binding domains are
stered weekly for three consecutive weeks in a three or four week treatment cycle.
Administration of the ition comprising one or more of the binding
domains can be on the same or different days provided that stration es the
desired therapeutic effect.
It will be readily apparent to those skilled in the art that other doses or frequencies
of administration that provide the desired therapeutic effect are suitable for use in the
present ion.
XII. KITS
In yet other embodiments, the present invention provides kits that can be used to
perform the methods described herein. In certain embodiments, a kit comprises a g
molecule disclosed herein in one or more containers. One d in the art will readily
ize that the disclosed binding domains, polypeptides and antibodies of the present
invention can be readily incorporated into one of the established kit formats which are
well known in the art.
* **
The practice of the disclosure will employ, unless otherwise indicated,
conventional techniques of cell biology, cell culture, molecular biology, transgenic
biology, microbiology, recombinant DNA, and immunology, which are within the skill of
the art. Such ques are explained fully in the literature. See, for example, Molecular
Cloning A Laboratory Manual, 2nd Ed., Sambrook et al., ed., Cold Spring Harbor
—115—
tory Press: (1989); Molecular Cloning: A Laboratory Manual, Sambrook et al.,
ed., Cold Springs Harbor Laboratory, New York (1992), DNA Cloning, D. N. Glover ed.,
Volumes I and 11 (1985); Oligonucleotide Synthesis, M. J. Gait ed., ; Mullis et al.
US. Pat. No: 4,683,195; Nucleic Acid Hybridization, B. D. Hames & S. J. Higgins eds.
(1984); Transcription And Translation, B. D. Hames & S. J. Higgins eds. ; Culture
Of Animal Cells, R. I. Freshney, Alan R. Liss, Inc., (1987); Immobilized Cells And
Enzymes, IRL Press, (1986); B. Perbal, A Practical Guide To Molecular Cloning ;
the treatise, Methods In Enzymology, Academic Press, Inc., N.Y.; Gene Transfer Vectors
For Mammalian Cells, J. H. Miller and M. P. Calos eds., Cold Spring Harbor Laboratory
(1987); s In logy, Vols. 154 and 155 (Wu et al. eds.); Immunochemical
Methods In Cell And Molecular Biology, Mayer and Walker, eds., Academic Press,
London (1987); Handbook 0fExperimental Immunology, Volumes l—IV, D. M. Weir and
C. C. Blackwell, eds., (1986); Manipulating the Mouse Embryo, Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, N.Y., (1986); and in Ausubel et al., Current
Protocols in lar y, John Wiley and Sons, Baltimore, Maryland (1989).
General principles of dy engineering are set forth in Antibody Engineering,
2nd n, C.A.K. Borrebaeck, Ed., Oxford Univ. Press (1995). General principles of
protein engineering are set forth in Protein Engineering, A Practical Approach,
Rickwood, D., et al., Eds., IRL Press at Oxford Univ. Press, Oxford, Eng. (1995).
General ples of antibodies and antibody-hapten binding are set forth in: Nisonoff,
A., Molecular Immunology, 2nd ed., Sinauer Associates, Sunderland, MA (1984); and
Steward, M.W., Antibodies, Their Structure and Function, Chapman and Hall, New York,
NY (1984). Additionally, standard s in immunology known in the art and not
specifically described are generally followed as in Current ols in Immunology,
John Wiley & Sons, New York; Stites et al. (eds) Basic and Clinical -Immunology (8th
ed.), Appleton & Lange, Norwalk, CT (1994) and Mishell and Shiigi (eds), Selected
Methods in Cellular Immunology, W.H. Freeman and Co., New York (1980).
Standard reference works setting forth general principles of immunology include
t Protocols in Immunology, John Wiley & Sons, New York; Klein, J
Immunology: The Science ofSelf-NonselfDiscrimination, John Wiley & Sons, New York
(1982); Kennett, R., et al., eds., Monoclonal Antibodies, Hybridoma.‘ A New ion in
Biological Analyses, Plenum Press, New York (1980); Campbell, A., “Monoclonal
2012/063722
—116—
Antibody Technology” in Burden, R., et al., eds., Laboratory Techniques in Biochemistry
and Molecular Biology, Vol. 13, Elsevere, Amsterdam (1984), Kuby Immunnology 4th ed.
Ed. Richard A. Goldsby, Thomas J. Kindt and Barbara A. Osborne, H. nd & Co.
(2000); Roitt, 1., Brostoff, J. and Male D., Immunology 6th ed. London: Mosby (2001);
Abbas A., Abul, A. and Lichtman, A., Cellular and Molecular Immunology Ed. 5,
Elsevier Health es Division (2005); mann and Dubel, Antibody Engineering,
Springer Verlan ; Sambrook and Russell, Molecular Cloning: A Laboratory
Manual. Cold Spring Harbor Press (2001); Lewin, Genes VIII, Prentice Hall (2003);
Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Press (1988);
Dieffenbach and Dveksler, PCR Primer Cold Spring Harbor Press (2003).
EXAMPLES
Example 1: Construction and screening of human antibody phage display libraries
This e describes a target indifferent whole cell panning approach with
human antibody phage ies derived from both naive and P. aeruginosa infected
convalescing patients to identify novel protective antigens against Pseudomonas infection
(Figure 1A). Assays included in the in vitro functional screens included
phagocytosis (OPK) killing assays and cell attachment assays using the epithelial
cell line A549. The lead candidates, based on superior in vitro activity, were tested in P.
aeruginosa acute pneumonia, keratitis, and burn infection models.
Figure 1B shows construction of patient antibody phage display library. Whole
blood was pooled from 6 recovering patients 7—10 days post diagnosis followed by RNA
extraction and phage library construction as previously bed (Vaughan, T.J., et al.,
Nat Biotechnol 14, 309—314 (1996); Wrammert, J., et al., Nature 453, 1 (2008)).
Figure 1C shows that the final cloned scFv library contained 5.4 X 108 transformants and
cing revealed that 79% of scFv genes were full—length and in frame. The VH
CDR3 loops, often important for determining epitope icity, were 84% diverse at the
amino acid level prior to library selection.
In on to the t library, a naive human scFv phage display library
containing up to 1x1011 binding members (Lloyd, C., et al., Protein Eng Des Sel 22, 159—
168 (2009)) was used for antibody isolation (Vaughan, T.J., et al., Nat Biotechnol I 4,
309—314 ). Heat killed P.aeruginosa (1X109) was immobilized in IMMUNOTM
2012/063722
—117—
Tubes (Nunc; MAXISORPTM) followed for phage display selections as described
(Vaughan, T.J., et al., Nat Biotechnol 14, 309—314 (1996)) with the exception of
triethanolamine (100nM) being used as the elution buffer. For selection on P. aeruginosa
in suspension, heat killed cells were blocked followed by addition of blocked phage to
cells. After g, eluted phage was used to infect E. coli cells as described (Vaughan,
1996). Rescue of phage from E. coli and binding to heat—killed P. aeruginosa by ELISA
was performed as described (Vaughan, 1996).
Following development and validation of the cell affinity ion
methodology, both the new convalescing patient library and a previously constructed
naive y (Vaughan, T.J., et al., Nat Biotechnol 14, 309—314 (1996)) underwent
affinity selection on suspensions of P. nosa strain 3064 possessing a complete 0—
antigen as well as an isogenic wapR mutant strain which lacked surface expression of 0—
antigen. Figure 1D shows that output titers from successive patient library selections
were found to increase at a greater rate for the patient library than for the naive library
(1x107 vs 3x105 at round 3, respectively). In on, duplication of VH CDR3 loop
sequences in the ies (a measure of clonal enrichment during ion), was also
found to be higher in the patient y, reaching 88-92%, compared to 15-25% in the
naive library at round 3 (Figure 1D). Individual scFv phage from affinity selections were
next screened by ELISA for reactivity to P. aeruginosa heterologous serotype strains
(Figure 1E). ELISA plates (Nunc; MAXISORPTM) were coated with P. aeruginosa
strains from overnight cultures as described (DiGiandomenico, A., et al., Infect Immun
72, 7012—7021 ). d antibodies were added to d plates for 1 hour,
, and treated with HRP-conjugated anti-human secondary antibodies for 1 hour
followed by development and analysis as described (Ulbrandt, N.D., et al., J Virol 80,
7799—7806 (2006)). The dominant species of phage obtained from whole cell selections
with both libraries yielded serotype specific reactivity (data not shown). Clones
exhibiting serotype independent binding in the absence of nonspecific binding to E. coli
or bovine serum albumin were selected for further evaluation.
For IgG expression, the VH and VL chains of selected antibodies were cloned into
human IgG1 expression vectors, co—expressed in HEK293 cells, and purified by protein A
affinity chromatography as described (Persic, L., et al., Gene 187, 9—18 ). Human
IgG1 antibodies made with the variable regions from these selected serotype independent
—118—
phage were ed for P. aeruginosa specificity and prioritized for subsequent
analysis by whole cell binding to dominant clinically relevant serotypes by FACS
analysis (Figure 1F), since this method is more stringent than ELISA. For the flow
cytometry based binding assays mid—log phase P. aeruginosa s were concentrated in
PBS to an OD650 of 2.0. After incubation of antibody (10 ug/mL) and bacteria (~l x 107
cells) for 1 hr at 4°C with shaking, washed cells were ted with an ALEXA FLUOR
647® goat anti- human IgG antibody (Invitrogen, ad, CA) for 0.5 hr at 4°C.
Washed cells were stained with BACLIGHTTM green bacterial stain as recommended
(Invitrogen, Carlsbad, CA). Samples were run on a LSR II flow cytometer (BD
Biosciences) and analyzed using BD FacsDiva (V. 6.1.3) and FlowJo (V. 9.2; TreeStar).
Antibodies exhibiting binding by FACS were further prioritized for functional activity
testing in an opsonophagocytosis killing (OPK) assay.
Example 2: Evaluation of mAbs ing OPK of P. aeruginosa
This example describes the evaluation of prioritized human IgG1 antibodies to
promote OPK of P. aeruginosa. Figure 2A shows that with the exception of WapR—007
and the ve control antibody R347, all antibodies mediated concentration dependent
killing of luminescent P. aeruginosa serogroup 05 strain (PAOl.lux). WapR—004 and
Cam—003 exhibited superior OPK activity. OPK assays were performed as described in
(DiGiandomenico, A., et al., Infect Immun 72, 7012—7021 (2004)), with modifications.
Briefly, assays were performed in 96-well plates using 0.025 ml of each OPK component;
P. aeruginosa strains; diluted baby rabbit serum; differentiated HL-60 cells; and
monoclonal antibody. In some OPK , luminescent P. nosa strains, which
were constructed as described (Choi, KH., et al., Nat Methods 2, 443—448 (2005))., were
used. Luminescent OPK assays were performed as bed above but with
determination of relative luciferase units (RLUs) using a Perkin Elmer ENVISION
Multilabel plate reader (Perkin Elmer).
The ability of the WapR-004 and Cam-003 antibodies to mediate OPK activity
against r clinically relevant O-antigen pe strain, 9882—80.lux, was evaluated.
Figure 2B shows that enhanced WapR-004 and Cam-003 OPK activity extends to strain
9882—80 (01 l).
—ll9—
In addition, this example describes the evaluation of WapR-004 (W4) mutants in
scFv—Fc format to promote OPK of P. aeruginosa. One mutant, Wap—004RAD (W4—
RAD), was specifically created through site-directed mutagenesis to remove an RGD
motif in VH. Other W4 mutants were prepared as follows. Nested PCR was performed
as described (Roux, K.H., PCR Methods App] 4, 8185—194 (1995)), to amplify W4
variants (derived from somatic hypermutation) from the scFv library d from the
escing P. aeruginosa ed patients for analysis. This is the library from which
WapR—004 was derived. W4 variant fragments were subcloned and sequenced using
standard procedures known in the art. W4 mutant light chains (LC) were recombined
with the WapR-004 heavy chain (HC) to produce W4 s in scFv-Fc format. In
addition WapR-004 RAD heavy chain (HC) mutants were recombined with parent LCs of
M7 and M8 in the c format. Constructs were prepared using standard procedures
known in the art. Figures 11 (A-M) show that with the exception of the negative control
antibody R347, all WapR-004 (W4) mutants mediated concentration dependent killing of
luminescent P. aeruginosa serogroup 05 strain (PAOl.lux).
The WapRRAD variable region was germ-lined to reduce potential
immunogenicity, producing WapRgermline ("WapRGL"), and was lead
optimized via site-directed mutagenesis. Clones with improved affinity for Psl were
selected in competition—based s. Top clones were ranked by affinity improvement
and analyzed in an in vitro functional assay. The 14 lead optimized clones are: 6,
Plel70, Ps10225, Ple304, , Psl348, Ps10567, Ps10573, 4, Ps10582,
Ps10584, 5, Ps10588 and Ps10589.
Example 3: Serotype independent anti—P.aerugin0sa antibodies target the Psl exopolysaccharide
This example describes fication of the target of anti—P. nosa
antibodies derived from phenotypic screening. Target analysis was performed to test
whether the serotype independent antibodies ed protein or carbohydrate antigens.
No loss of g was observed in ELISA toPAOl whole cell extracts exhaustively
digested with proteinase K, suggesting that vity targeted surface accessible
carbohydrate residues (data not shown). Isogenic mutants were constructed in genes
responsible for O-antigen, alginate, and LPS core biosynthesis; wpr igendeficient
); wpr/aZgD (O-antigen and alginate deficient); rmZC (O-antigen-deficient and
truncated outer core); and gaZU (O—antigen—deficient and truncated inner core). P.
WO 70615
—120—
aeruginosa mutants were constructed based on the allele replacement strategy described
by Schweizer (Schweizer, H.P., M01 Microbiol 6, 204 (1992); Schweizer, H.D.,
Biotechniques 15, 831—834 (1993)). s were mobilized from E. coli strain Sl7.1
into P. aeruginosa strain PAOl; inants were isolated as described (Hoang, T.T., et
al., Gene 212, 77—86 (1998)). Gene deletion was confirmed by PCR. P. aeruginosa
mutants were complemented with pUCP30T—based constructs harboring wild type genes.
Reactivity of antibodies was determined by indirect ELISA on plates coated with above
indicated P. nosa strains: Figure 3A shows that Cam—003 binding to the wpr or
the wpr/algD double mutant was unaffected, however binding to the rmlC and gaZU
mutants were abolished. While these results were consistent with binding to LPS core,
vity to LPS purified from PAOl was not observed. The rmZC and galU genes were
recently shown to be required for thesis of the Psl exopolysaccharide, a repeating
pentasaccharide polymer consisting of D-mannose, nose, and D—glucose. Cam—
003 binding to an isogenic pslA knockout PAOlApsZA, was tested, as psZA is required for
Psl biosynthesis (Byrd, M.S., et al., M01 Microbiol 73, 622—638 ). g of
Cam—003 to PAOlApsZA was abolished when tested by ELISA (Figure 3B) and FACS
(Figure 3C), while the LPS molecule in this mutant was cted (Figure 3D). Binding
of Cam—003 was restored in a PAOlAwpr/aZgD/pslA triple mutant complemented with
pslA (Figure 3E) as was the ability of 3 to mediate opsonic killing to
complemented SlA in contrast to the mutant (Figure 3F and 3G). Binding of
Cam-003 antibody to a Pel ysaccharide mutant was also unaffected further
confirming Psl as our antibody target (Figure 3E). Binding assays confirmed that the
remaining antibodies also bound Psl (Figure 3H and 31).
Example 4: Anti—Ps1 mAbs block attachment of P. aeruginosa to cultured epithelial cells.
This example shows that anti—Ps1 antibodies blocked P. aeruginosa association
with epithelial cells. Anti—Ps1 antibodies were added to a confluent monolayer of A549
cells (an adenocarcinoma human alveolar basal epithelial cell line) grown in opaque 96-
well plates (Nunc Nunclon Delta). Log—phase luminescent P. aeruginosa PAOl strain
(PAOl.lux) was added at an MOI of 10. After incubation of PAOl.lux with A549 cells at
37°C for 1 hour, the A549 cells were washed, followed by addition of LB+0.5% glucose.
Bacteria were quantified following a brief incubation at 37°C as performed in the OPK
assay described in Example 2. ements from wells without A549 cells were used
—l2l—
to correct for non-specific binding. Figure 4 shows that with the exception of Cam-005
and WapR—007, all antibodies reduced association of PAOl.lux to A549 cells in a dose—
dependent manner. The mAbs which performed best in OPK assays, WapR-004 and
Cam—003 (see Figures 2A-B, and Example 2), were also most active at inhibiting P.
nosa cell attachment to A549 lung lial cells, providing up to ~80% reduction
compared to the negative control. WapR-016 was the third most active antibody,
showing similar inhibitory activity as WapR-004 and Cam-003 but at 10-fold higher
dy concentration.
e 5: In vivo passaged P. aeruginosa strains maintain/increase expression of Psl
To test if Psl expression in vivo is maintained, mice were injected intraperitoneally
with P. aeruginosa isolates followed by harvesting of bacteria by peritoneal lavage four
hours post—infection. The presence of Psl was analyzed with a control antibody and Cam-
003 by flow cytometry as conditions for antibody binding are more stringent and allow
for fication of cells that are positive or negative for Psl expression. For ex vivo
binding, bacterial inocula (0.1ml) was prepared from an ght TSA plate and
delivered intraperitoneally to BALB/c mice. At 4 hr. ing challenge, bacteria were
ted, RBCs lysed, sonicated and resuspended in PBS supplemented with 0.1%
Tween—20 and 1% BSA. Samples were stained and analyzed as previously described in
Example 1. Figure 5 shows that ia harvested after peritoneal lavage with three wild
type P. aeruginosa strains showed strong 3 staining, which was comparable to log
phase cultured bacteria (compare Figures 5A and 5C). In vivo passaged wild type
bacteria ted enhanced staining when compared to the inoculum (compare Figures
5B and 5C). Within the inocula, Psl was not detected for strain 6077 and was minimally
detected for strains PAOl (05) and 6206 (Oll—cytotoxic). The binding of Cam—003 to
ia increased in on to the a indicating that Psl expression is maintained or
increased in vivo. Wild type strains 6077, PAOl, and 6206 express Psl after in vivo
passage, however strain PAOl harboring a deletion of pslA (PAOlApsZA) is unable to
react with Cam-003. These results further emphasize Psl as the target of the monoclonal
antibodies.
—l22—
Example 6: Survival rates for animals treated with anti-Psl monoclonal antibodies Cam-003 and
WapR—004 in a P. aeruginosa acute pneumonia model
Antibodies or PBS were administered 24 hours before infection in each model. P.
aeruginosa acute pneumonia, keratitis, and thermal injury infection models were
performed as described (DiGiandomenico, A., et al., Proc Natl Acad Sci U S A 104,
4624-4629 (2007)), with cations. In the acute pneumonia model, BALB/c mice
(The Jackson Laboratory) were infected with P. aeruginosa strains suspended in a 0.05
ml inoculum. In the thermal injury model, CF—l mice (Charles River) received a 10%
total body surface area burn with a metal brand heated to 92°C for 10 seconds. Animals
were infected subcutaneously with P. aeruginosa strain 6077 at the indicated dose. For
organ burden experiments, acute pneumonia was induced in mice followed by harvesting
of lungs, spleens, and kidneys 24 hours post-infection for determination of CFU.
Monoclonal antibodies Cam—003 and WapR—004 were evaluated in an acute lethal
pneumonia model against P. aeruginosa strains representing the most frequent serotypes
associated with clinical disease. Figures 6A and 6C show significant concentration-
dependent survival in Cam—003—treated mice infected with strains PAOl and 6294 when
compared to controls. Figures 6B and 6D show that complete tion from challenge
with 33356 and cytotoxic strain 6077 was afforded by Cam—003 at 45 and 15 mg/kg while
80 and 90% survival was ed at 5mg/kg for 33356 and 6077, respectively. Figures
6E and 6F show significant tration-dependent survival in WapRtreated mice
in the acute pneumonia model with strain 6077 (01 l) (8 x 105 CFU) e 6E), or 6077
(01U(6x105CFU)Gfigne6F)
Cam-003 and 04 were next examined for their ability to reduce P.
aeruginosa organ burden in the lung and spread to distal , and later the animals
were treated with various concentrations of WapR-004, Cam-003, or control antibodies at
l different concentrations. Cam—003 was effective at ng P. aeruginosa lung
burden against all four strains tested. Cam-003 was most effective against the highly
pathogenic cytotoxic strain, 6077, where the low dose was as effective as the higher dose
(Figures 7D). Cam-003 also had a marked effect in reducing dissemination to the spleen
and kidneys in mice infected with PAOl (Figure 7A), 6294 e 7C), and 6077 (Figure
7D), while dissemination to these organs was not observed in 33356 infected mice
e 7B). Figures 7E and 7F show that similarly, WapR—004 reduced organ burden
after induction of acute nia with 6294 (O6) and 6206 (01 1). Specifically, WapR-
—123—
004 was effective at reducing P. nosa dissemination to the spleen and s in
mice infected.
Example 7: Construction of anti-Pch monoclonal antibody V2L2
VelocImmune® mice (Regeneron Pharmaceuticals) were immunized by Ultra-
Short immunization method with r-Pch and serum titers were followed for binding to
Pch and neutralizing the hemolytic activity of live Raeruginosa. Mice showing anti—
hemolytic activity in the serum were sacrificed and the spleen and lymph nodes (axial,
inguinal and popliteal) were harvested. The cell populations from these organs were
panned with biotinylated r—Pcrv to select for anti-Pch specif1c B—cells. The selected cells
were then fused with mouse myeloma partner P3X63—Ag8 and seeded at 25Kcells/well in
hybridoma selection . After 10 days the medium from the hybridoma wells were
completely changed with fresh medium and after r 3-4 days the hybridoma
supematants were assayed for anti-hemolytic ty. Colonies showing emolytic
activity were d dilution cloned at 0.2 cells/well of 96-well plates and the anti-
hemolytic activity assay was repeated. Clones showing anti-hemolytic activity were
d to Ultra-low IgG containing hybridoma culture medium. The IgG from the
ioned media were purified and d for in vitro anti—hemolytic activity and in
vivo for protection t infection by P.aerugin0sa. The antibodies were also
categorized by competition assay into different groups. The variable (V) domains from
the antibodies of interest were subcloned from the cDNA derived from their different
respective clones. The subcloned V—segments were fused in frame with the cDNA for the
corresponding constant domain in a mammalian expression plasmid. Recombinant IgG
were expressed and purified from HEK293 cells. In instances where more than one
cDNA V— sequence was obtained from a particular clone, all combinations of variable
heavy and light chains were expressed and characterized to identify the onal IgG.
Example 8: Survival rates for animals treated with anti-Psl monoclonal antibodies Cam-003,
WapR—004 and anti-Pch monoclonal antibody V2L2 in a P. aeruginosa corneal infection model
Cam—003 and WapR—004 efficacy was next ted in a P. nosa corneal
infection model which emphasizes the pathogens ability to attach and ze damaged
tissue. Figures 8 A—D and 8 F—G show that mice receiving Cam-003 and WapR-004 had
significantly less pathology and reduced bacterial counts in total eye homogenates than
—124—
was observed in ve control—treated animals. Figure 8E shows that Cam—003 was
also effective when tested in a thermal injury model, providing significant protection at
and 5mg/kg when compared to the dy-treated control. Figure 8 (H): The activity
of anti-Psl and anti-Pch monoclonal antibodies V2L2 was tested in a P. aeruginosa
mouse ocular keratitis model. C3H/HeN mice were injected intraperitoneally (IP) with
PBS or a control IgGl antibody (R347) at 45mg/kg or WapR—004 (ct-Ps1) at 5mg/kg or
V2L2 (oc-Pch) at 5mg/kg, 16 hours prior to infection with 6077 (01 1-cytotoxic — 1x106
CFU). Immediately before infection, mice were anesthetized followed by initiation of
three 1 mm scratches on the cornea and superficial stroma of one eye of each mouse using
a 27—gauge needle under a dissection microscope, followed by topical application of P.
aeruginosa 6077 strain in a 5 pl um. Eyes were photographed at 48 hours post
infection followed by corneal grading by visualization of eyes under a dissection
cope. Grading of corneal infection was performed as previously described by
Preston et a]. (Preston, MJ., 1995, Infect. Immun. 7). Briefly, infected eyes were
graded 48 h after infection with strain 6077 by an investigator who was unaware of the
animal treatments. The following grading scheme was used: grade 0, eye macroscopically
identical to an uninfected eye; grade 1, faint opacity partially covering the pupil; grade 2,
dense opacity covering the pupil; grade 3, dense y covering the entire pupil; grade
4, perforation of the cornea kage of the eyeball). Mice receiving systemically dosed
(1P) 3 or WapR—004RAD showed significantly less pathology and reduced
bacterial colony g units (CFU) in total eye homogenates than was observed in the
R347 control mAb-treated animals. Similar results were observed in V2L2—treated
animals when ed to R3 47—treated controls.
Example 9: A Cam-003 Fc mutant dy, CamTM, has diminished OPK and in viva
efficacy but ins anti-cell attachment activity.
Given the potential for dual mechanisms of action, a Cam-003 Fc mutant, Cam-
003 —TM, was created which harbors mutations in the Fc domain that reduces its
interaction with Fcy ors (Oganesyan, V., et al., Acta Crystallogr D Biol Crystallogr
64, 700—704 (2008)), to identify if protection was more correlative to anti—cell attachment
or OPK activity. P. nosa s were constructed based on the allele replacement
strategy described by Schweizer (Schweizer, H.P., M01 Microbiol 6, 1195—1204 (1992);
Schweizer, H.D., Biotechniques 15, 831—834 (1993)). Vectors were mobilized from E.
2012/063722
—l25—
coli strain S17.1 into P. aeruginosa strain PAOl; recombinants were isolated as described
(Hoang, T.T., et al., Gene 212, 77—86 (1998)). Gene deletion was confirmed by PCR. P.
aeruginosa mutants were complemented with pUCP30T—based constructs harboring wild
type genes. Figures 9A shows that Cam—003—TM ted a 4—fold drop in OPK activity
compared to Cam—003 (EC50 of 0.24 and 0.06, respectively) but was as effective in the
cell ment assay (Figure 9B). Figure 9C shows that Cam—003—TM was also less
effective against nia suggesting that optimal OPK activity is necessary for
optimal protection. OPK and cell attachment assays were performed as previously
described in Examples 2 and 4, respectively.
Example 10: Epitope mapping and relative affinity for anti-Psl antibodies
Epitope mapping was performed by competition ELISA and confirmed using an
OCTET® flow system with Psl derived from the supernatant of an overnight e of P.
aeruginosa strain PAOl. For competition ELISA, antibodies were biotinylated using the
EZ-Link NHS-Biotin and Biotinylation Kit (Thermo Scientific). Antigen coated
plates were treated with the EC50 of biotinylated antibodies bated with unlabeled
antibodies. After incubation with HRP-conjugated streptavidin (Thermo Scientific),
plates were developed as bed above. Competition experiments between anti—Psl
mAbs determined that dies targeted at least three unique epitopes, referred to as
class 1, 2, and 3 antibodies (Figure 10A). Class 1 and 2 antibodies do not compete for
binding, r the class 3 antibody, 16, partially inhibits binding of the Class
1 and 2 antibodies.
Antibody affinity was determined by the OCTET® binding assays using Psl
derived from the supernatant of overnight PAOl cultures. Antibody KD was determined
by averaging the binding kinetics of seven concentrations for each dy. Affinity
measurements were taken with a FORTEBIO® OCTET® 384 instrument using 384
slanted well plates. The supernatant from overnight PAOl es :: the psZA gene were
used as the Psl source. Samples were loaded onto OCTET® AminoPropylSilane
(hydrated in PBS) sensors and blocked, followed by measurement of anti-Psl mAb
binding at several concentrations, and disassociation into PBS + 1% BSA. All procedures
were performed as described (Wang, X., et al., J Immunol s 362, 151—160).
Association and disassociation raw AnM data were curve-fitted with GraphPad Prism.
Figure 10A shows the relative binding affinities of anti-Psl antibodies characterized
—l26—
above. Class 2 antibodies had the highest affinities of all the anti-Psl antibodies. Figure
10A also shows a summary of cell attachment and OPK data experiments. Figure 10B
shows the relative binding affinities and OPK EC50 values of the Wap-004RAD
) mutant as well as other W4 mutants lead optimized via site—directed
mutagenesis as bed in Example 2. Figure 10C shows the relative binding affinities
of the Wap-004RAD (W4RAD), Wap-004RAD-Germline (W4RAD-GL) as well as lead
optimized anti-Psl monoclonal antibodies (Ps10096, Plel70, Ple225, Ple304, Ple337,
Psl348, Ps10567, Ps10573, 4, Ps10582, Ps10584, Ps10585, Ps10588 and Ps10589).
Highlighted clones Ps10096, Ps10225, Ps10337, Ps10567 and Ps10588 were selected based
on their enhanced OPK activity, as shown in Example 10 below.
Example 11: Evaluation of lead zed WapR-004 (W4) mutant clones and lead optimized
anti-Psl monoclonal antibodies in the P. aeruginosa opsonophagocytic killing (OPK) assay
This example describes the tion of lead optimized WapR-004 (W4) mutant
clones and lead optimized anti-Psl monoclonal antibodies to promote OPK of P.
aeruginosa using the method described in Example 2. Figures llA—Q show that with the
exception of the negative control antibody R347, all antibodies mediated concentration
dependent killing of luminescent P. aeruginosa serogroup 05 strain (PAOl.lux).
Example 12: Anti-Pch monoclonal antibody V2L2 reduces lethality from acute pneumonia from
multiple strains
The Pch epitope diversity was analyzed using three approaches: bead based flow
try method, ition ELISA and western blotting of nted rPch.
Competition experiments between anti-Pch mAbs determined that antibodies targeted at
least six unique epitopes, referred to as class 1, 2, 3, 4, 5 and 6 dies (Figure 12A).
Class 2 and 3 antibodies partially compete for binding. mAbs representing additional
epitope classes: class 1 (V2L7, 3G5, 4C3 and llA6), class 2 (IE6 and 1F3), class 3
(29D2, 4A8 and 2H3), class 4 (V2L2) and class 5 (2lFl, LElO and SH3) were tested for
in viva protection as below described.
Novel anti—Pch mAbs were isolated using oma technology and the most
potent T3 SS inhibitors were selected using a rabbit red blood cell lysis tion assay.
Percent inhibition of xicity analysis was analysed for the parental V2L2 mAb,
mAbl66 (positive control) and R347 (negative l), where the antibodies were
administered to cultured broncho-epithelial cell line A549 ed with log-phase P.
—l27—
nosa strain 6077 (exoU+) at a MOI of imately 10. A549 lysis was d
by measuring released lactate dehydrogenase (LDH) activity and lysis in the presence of
mAbs was compared to wells without mAb to determine percent inhibition. The V2L2
mAb, mAbl66 (positive control) and R347 (negative control) were evaluated for their
ability to prevent lysis of RBCs, where the antibodies were mixed with log—phase P.
aeruginosa 6077 (exoU+) and washed rabbit red blood cells (RBCs) and incubated for 2
hours at 37°. Intact RBCs were ed and the extent of lysis determined by measuring
the OD405 of the cell-free supernatant. Lysis in the presence of anti-Pch mAbs was
compared to wells without mAb to determine percent inhibition. The positive control
antibody, mAbl66, is a previously characterized ch antibody (J Infect Dis. 186:
64—73 , Crit Care Med. 40: 2320-2326 (2012)).(B) The parental V2L2 mAb
demonstrated inhibition of cytotoxicity with an IC50 of 0. 10 ug/ml and exhibited an IC50
tration 28-fold lower than mAbl66 (IC50 of 2.8 ug/ml). (C) V2L2 also
demonstrated prevention of RBC lysis with an IC50 of 0.37 ug/ml and exhibited an IC50
concentration 10-fold lower than mAbl66 (IC50 of 3.7 ug/ml).
The V2L2 variable region was fully germlined to reduce potential
genicity. V2L2 was affinity matured using the parsimonious mutagenesis
approach to randomize each position with 20 amino acids for all six CDRs, identifying
affinity-improved single mutations. A combinatorial library was then used, encoding all
possible combinations of affinity-improved single mutations. Clones with improved
affinity to Pch were selected using g ELISA in IgG format. Top clones were
ranked by affinity ement and analyzed in an in vitro functional assay.V2L2 CDRs
were systematically mutagenized and clones with improved affinity to Pch were selected
in competition—based screens. Clones were ranked by ses in affinity and analyzed in
a functional assay. As shown in Figure 12D, RBC lysis was analyzed for V2L2-germlined
MAb (V2L2—GL), V2L2—GL optimized mAbs (V2L2—P4M, V2L2—MFS, D and
V2L2-MR), and a negative control antibody R347 using Pseudomonas strain 6077
infected A549 cells. V2L2—GL, V2L2—P4M, V2L2—MFS, V2L2—MD and V2L2—MR
demonstrated prevention of RBC lysis.. As shown in Figure 12E, mAbs 1E6, lF3, llA6,
29D2, PCRV02 and V2L7 trated prevention of RBC lysis. As shown in Figure
l2F, V2L2 was more potent in prevention of RBC lysis than the 29D2.
—l28—
Binding kinetics of L and V2L2-MD were measured using a Bio-Rad
ProteOnTM XPR36 instrument. dies were ed on a GLC bisensor chip using
anti-human IgG reagents. rPch protein was injected at multiple concentrations and the
dissociation phase followed for 600 seconds. Data was captured and ed using
ProteOn r software. Figure 12 (G-H) shows the relative binding affinities of (G)
V2L2—GL and (H) V2L2—MD antibodies. The clone V2L2—MD had increased Kd by 2—3
folds over V2L2—GL.
The in vivo effect of administration of an anti-Pch antibodies was studied in mice
using an acute pneumonia model. Groups of mice were treated with either sing
concentrations of the V2L2 antibody, a positive control anti-Pch antibody (mAbl66), or
a negative control (R347), as shown in Figure 13 (A—B). Groups of mice were also
treated with either increasing concentrations of the V2L2 antibody, the Pch antibody
Pch-02, or a negative control (R347), as shown in Figure 13 (C-D). Twenty—four hours
after treatment, all mice were infected with 5 X 107 CFU (C) Pseudomonas aeruginosa
6294 (06) or (D) PA103A (011). As shown in Figure 13, nearly all control treated
animals succumbed to infection by 48 hours post infection. However, V2L2 showed a
dose—dependent effect on ed survival even out to 168 hours nfection.
Further, V2L2 provided icantly more potent protection than mAbl66 at similar
doses (P=0.025, 5 mg/kg for strain 6077; P < 0.0001, 1 mg/kg for strain 6294).
Groups of mice were d with either increasing concentrations of the 11A6,
3G5 or V2L7, the same concentrations of 29D2, 1F3, 1E6, V2L2, LE10, SH3, 4A8, 2H3,
or 21F1, increasing concentrations of the 29D2, increasing concentrations of the V2L2,
the Pch antibody Pch-02, or a negative control (R347), as shown in Figure 13 (E-H).
Mice were injected intraperitoneally (IP) with mAbs 24 hours prior to to intranasal
infection with Pseudomonas strain 6077 (1 X 106 CFU/animal). As shown in Figure 13E
mAbs 11A6, 3G5 and V2L7 did not provide protection in vivo. As shown in Figure 13F,
mAb 29D2 provides protection in vivo. As shown in Figure 13G, mAb V2L2 also
provides protection in vivo. Figure 13H shows in vivo comparison of 29D2 and V2L2.
Figure 131 shows that mAb V2L2 protects against additional Pseudomonas s
(i.e.,6294 and PA103A).
—129—
Organ burden of Pseudomonas—infected mice was also studied in response to
administration of V2L2. Figure 14 (A) Mice were treated with either 1 mg/kg R347
(control), or 1 mg/kg, 0.2 mg/kg, or 0.07 mg/kg of V2L2 and then were infected
intranasally with 1.2 x 106 cfu of monas 6206. Figure 14 (B) Mice were also
treated with either 15 mg/kg R347 (negative l); 15.0 mg/kg, 5.0 mg/kg, or 1.0
mg/kg mAb166 (positive control); or 5.0 mg/kg, 1.0 mg/kg, or 0.2 mg/kg V2L2 and then
were infected intranasally with 5.5 x 106 cfu of Pseudomonas 6206. As shown in Figure
14 (A-B), while V2L2 had little effect on clearance in the kidney, it y reduced
dissemination to both the lung and spleen in a dose-dependent manner. In addition, V2L2
provided significantly greater reduction in organ CFU than mAb166 at similar doses (P <
0.0001, 1 mg/kg, lung).
Example 13: In vivo activity of combination y using 04 (anti-Ps1) and V2L2 (anti-
Pch) antibodies
The in vivo effect of combination administration of anti-Ps1 and anti-Pch binding
domains was further studied in mice using the dies V2L2 and WapR-004 (RAD).
Groups of mice were treated with R347 (2.1 mg/kg - negative control), V2L2 (0.1mg/kg),
W4—RAD (0.5 mg/kg), or V2L2/W4 combination (either 0.1, 0.5, 1.0 or 2.0 mg/kg each).
Twenty-four hours post-administration of antibody, all mice were infected with an
inoculum containing 5.25 x 105 cfu 6206 (01 1—ExoU+). Twenty—four hours post
infection, lungs, spleens, and kidneys were harvested, homogenized, and plated for
colony forming unit (CFU) identification per gram of . As shown in Figure 15, at
the concentrations tested, both V2L2 and W4 were effective in lowering organ burden,
the V2L2/W4 ation showed an additive effect in tissue clearance. Histological
examination of lung tissue revealed less hemorrhaging, less edema, and less inflammatory
infiltrate compared to mice receiving V2L2 or WapR-004 alone (Table 5).
Similarly immunized animals were also assessed for survival from acute
pneumonia infections.
EOREER=£ BREE:
HOE/STQDmHmm gusto—:0:
.EQ 33:5 EoEfic 0:0:05 0:0:05 0E2
9:... Afimb Afimmv 8:09:00 $009 cozwwmcoo gm: .Afiovv m_
602025 £53
- R24. R_:0E:0:0 R_:0E:0:0 E8838 09:9: 09:9: 0:0 R_:0E:0:0 5:08:08 98V EEE
o2 0% 0cm
- 55029:. $8838:
REESE REESE SE REESE EEE REESE R__SE00 REESE cozwwmcoo 0:0:0:m_ £8838:
0:255
_R:0>O 0:0:0:m_ 0:0:0:m_ R__SE.0 0:0:0:m_ R__SE00 0:0:0:m_ 0:0:05 0:0:0:m_ SR:000_>_ EREE 5:59: 9:2
$925 + -mgmi + + +
ESERS... Nvmm A9:9: N|_N> A9:9: voofiqm; A9:9: $925
+ 9:9: .:.E + 9:9: 3:.E + 9:9: 3?: -mfii+ v8 9:9: 3?:
ENV Tov m9 N._N> rfo N._N> m o
8 <8 o N._N> <8 r N._N> :8 om
—l3l—
Example 14: Survival rates for animals treated with anti-Pch monoclonal antibody V2L2
in a P. aeruginosa acute pneumonia model
Monoclonal antibodies V2L2-GL, V2L2-MD, V2L2-A, V2L2-C, V2L2-PM4 and
V2L2-MFS were evaluated in an acute lethal nia model t P. aeruginosa
6077 strain as previously described in Example 11. s 16 (A—F) show al in all
V2L2 treated mice infected with strain 6077 when compared to control. However, no
significant difference in survival is observed between V2L2 antibodies at either dose:
0.5mg/kg and lmg/kg (A—C) or 0.5mg/kg and kg (D—F). Figures 16 (G—I) show
survival in all V2L2 d mice infected with strain 6077 when compared to control. No
significant difference in survival is observed between V2L2 antibodies at either dose:
0.5mg/kg and lmg/kg (G-I). (A-H)
All of the control mice succumbed to infection by approximately 48 hours post—
infection.
Example 15: Construction of WapR—004/V2L2 bispeciflc antibodies
Figure 17A shows TNFOL bispeciflc model constructs. For le—TNFoc/W4, the W4
scFv is fused to the amino-terminus of TNFoc VL through a (G4S)2 linker. For Bs2-
TNFOL/W4, the W4 scFv is fused to the amino-terminus of TNFoc VH through a (G4S)2
linker. For BS3—TNFOL/W4, the W4 scFv is fused to the carboxy—terminus of CH3
through a (G4S)2 linker.
Since the combination of WapR—004 + V2L2 provide protection against
Pseudomonas challenge, bispeciflc constructs were generated comprising a WapR—004
scFv D) and V2L2 IgG (Figure 17B). To generate Bs2-V2L2—2C, the W4-RAD
scFv is fused to N—terminal of V2L2 VH through (G4S)2 linker. To generate L2-
2C, W4—RAD scFv was fused to C—terminal of CH3 through (G4S)2 linker. To generate
L2-2C, the W4-RAD scFv was inserted in hinge , linked by (G4S)2 linker
on N—terminal and C—terminal of scFv. To generate Bs2-W4-RAD-2C, the V2L2 scFv
was fused to the amino-terminus of W4-RAD VH through a (G4S)2 linker.
To generate the W4-RAD scFv for the Bs3 construct, the W4-RAD VH and VL
were amplified by PCR. The primers used to amplify the W4-RAD VH were: W4-RAD
VH forward primer: includes (G4S)2 linker and 22bp of VH N—terminal sequence
(GTAAAGGCGGAGGGGGATCCGGCGGAGGGGGCTCTGAGGTGCAGCTGTTGG
2012/063722
—l32—
AGTCGG (SEQ ID NO:224)); and W4-RAD VH reverse primer: includes part of (G4S)4
linker and 22 bp of VH C—terminal sequence
(GATCCTCCGCCGCCGCTGCCCCCTCCCCCAGAGCCCCCTCCGCCACTCGAGA
CGGTGACCAGGGTC (SEQ ID NO:225). Similarly, the W4-RAD VL was amplified
by PCR using the primers: W4-RAD VL forward primer: includes part of (G4S)2 linker
and 22 bp of VL N—terminal sequence
(AGGGGGCAGCGGCGGCGGAGGATCTGGGGGAGGGGGCAGCGAAATTGTGTT
GACACAGTCTC (SEQ ID )); and W4-RAD VL reverse primer: includes part of
vector sequence and 22 bp of VL C—terminal sequence
(CAATGAATTCGCGGCCGCTCATTTGATCTCCAGCTTGGTCCCAC SEQ ID
NO:227)). The overlapping fragments were then fused together to form the W4-RAD
scFv.
W4—RAD scFv sequence in BS3 vector: underlined ces are G4S linker
GGGGSGGGGSEVQLLESGPGLVKPSETLSLTCNVAGGSISPYYWTWIRQPPGKCLELIGY
TDYNPSLKSRVTISGDTSKKQFSLHVSSVTAADTAVYFCARADWDLLHALDIW
GQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEIVLTQSPSSLSTSVGDRVTITCRASQSIRS
HLNWYQQKPGKAPKLLIYGASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQS
YSFPLTFGCGTKLEIK (SEQ ID NO:228)
After the W4-RAD scFv nt was amplified, it was then gel purified and
ligated into the Bs3 vector which had been digested with BamHI/NotI. The ligation was
done using the In-Fusion system, followed by transformation in Stellar competent cells.
Colonies were sequenced to confirm the correct W4—RAD scFv insert.
To generate the L2—2C, the IgG portion in the Bs3 vector was replaced
with V2L2 IgG. Briefly, the Bs3 vector which contains W4—RAD scFv was digested with
BssHII / SalI and the resultant vector band was gel purified. Similarly, the vector
containing V2L2 vector was digested with BssHII / SalI and the V2L2 insert was gel
ed. The V2L2 insert was then ligated with the Bs3-W4-RAD scFv vector and
colonies were sequenced to confirm the correct V2L2 IgG insert.
A r approach was used to generate Bs2-V2L2-2C.
W4—RAD scFv-V2L2 VH sequences in Bs2 : underlined sequences are G4S linker
EVQLLESGPGLVKPSETLSLTCNVAGGSISPYYWTWIRQPPGKCLELIGYIHSSGYTDYNP
SLKSRVTISGDTSKKQFSLHVSSVTAADTAVYFCARADWDLLHALDIWGQGTLVTVSSQ
GGGSGGGGSGGGGSGGGGSEIVLTQSPSSLSTSVGDRVTITCRASQSIRSHLNWYQQKPG
—l33—
KAPKLLIYGASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSFPLTFGCGT
KLEIKGGGGSGGGGSEMQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMNWVRQAPGE
GLEWVSAITISGITAYYTDSVKGRFTISRDNSKNTLYLQMNSLRAGDTAVYYCAKEEFLP
GTHYYYGMDVWGQGTTVTVSS (SEQ ID NO:229)
The following primers were used to amplify W4—RAD scFv. VH rd
) and VL (reverse primer): W4-RAD VH forward primer for Bs2 vector which
includes some intron, 3' signal e and 22bp of W4-RAD VH inal sequence
(TTCTCTCCACAGGTGTACACTCCGAGGTGCAGCTGTTGGAGTCGG (SEQ ID
NO:230)) and W4—RAD VL reverse primer for Bs2 vector: include (G4S)2 linker and 32
bp of VL C—terminal sequence
(CCCCCTCCGCCGGATCCCCCTCCGCCTTTGATCTCCAGCTTGGTCCCACAGCC
GAAAG (SEQ ID NO:23 l))
To amplify the V2L2 VH region the ing primers were used: V2L2 VH
forward primer: includes (G4S)2 linker and 22 bp of V2L2 VH N—terminal sequence
(GGCGGAGGGGGATCCGGCGGAGGGGGCTCTGAGATGCAGCTGTTGGAGTCT
GG (SEQ ID NO:232)), and V2L2 VH reverse primer: includes some of CH1 N—terminal
sequence and 22 bp of V2L2 VH C—terminal sequence
(ATGGGCCCTTGGTCGACGCTGAGGAGACGGTGACCGTGGTC (SEQ ID NO:
233)).
These primers were then used to amplify V2L2 VH, which was then joined by
overlap with W4-RAD scFv and V2L2 VH to get W4-RAD scFv-V2L2-VH. The W4-
RAD scFv-V2L2 VH was then ligated into Bs2 vector by gel purifying W4-RAD scFv —
V2L2 VH (from overlap PCR); digesting Bs2 vector with BerI/SalI, and gel purifying
vector band. The W4—RAD scFv-V2L2—VH was then ligated with Bs2 vector by In—
Fusion system and ormed into r competent cells and the colonies were
confirmed for the correct W4-RAD scFv-V2L2 VH insert. To e VL in Bs2 vector
with V2L2 VL, the Bs2 vector which contains W4-RAD scFv—V2L2—VH was digested
with BssHII / BsiWI and the vector band was gel purified. The pOE—V2L2 vector was
then digested with BssHII / BsiWI and the V2L2 VL insert was gel purified. The V2L2
VL insert was then d with Bs2—W4—RAD scFv-V2L2—VH vector and the colonies
were sequenced for correct V2L2 IgG insert.
Finally, a similar PCR-based approach was used to generate the Bs4-V2L2-2C
construct. The hinge region with linker sequence is shown below:
—134—
Hinge region with linker sequence:
GGSGGGGS — N-terminus ofscFv (SEQ ID NO:329)
CHl hinge linker
C-terminus ofscFv — GGGGSGGGGSDKTHTCPPC (SEQ ID NO:330)
linker hinge CH2
W4-RAD scFv sequences in BS4 vector: W4-RAD scFv is in bolded italics with the G4S
linkers underlined in bolded s; hinge regions are dmibleddemed
KVDKRV]EPKSCGGGGSGGGGSEVQLLESGPGLVKPSETLSLTCNVAGGSISPYYWTWIR
QPPGKCLELIGYIHSSGYTDYNPSLKSRVTISGDTSKKQFSLHVSSVTAADTA VYFCARAD
WDLLHALDIWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEIVLTQSPSSLSTSVGDRV
TITCRASQSIRSHLNWYQQKPGKAPKLLIYGASNLQSGVPSRFSGSGSGTDFTLTISSLQP
EDFATYYCQQSYSFPLTFGCGTKLEIKGGGGSGGGGS DKTHTCPPCPAPELMSEQ ID
W4-RAD scFv is presented in bolded italics with the G4S linkers underlined in bolded
italics
EVQLLESGPGLVKPSETLSLTCNVAGGSISPYYWTWIRQPPGKCLELIGYIHSSGYTDYNP
SLKSRVTISGDTSKKQFSLHVSSVTAADTA VYFCARADWDLLHALDIWGQGTLVTVSSfl
GGSGGGGSGGGGSGGGGSEIVLTQSPSSLSTSVGDRVTITCRASQSIRSHLNWYQQKPGK
APKLLIYGASNLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSFPLTFGCGTK
LEIK
W4—RAD scFv was generated using PCR and the following primers: W4-RAD
VH forward primer for BS4 vector: includes some of linker sequences and 24 bp of W4—
RAD VH N—terminal sequence (GAGGTGCAGCTGTTGGAGTCGGGC (SEQ ID
NO:236)); and W4—RAD VL e primer for BS4 vector: includes some hinge
sequence, linker and 21 bp of W4-RAD VL C-terminal sequence
(GTGTGAGTTTTGTngatccCCCTCCGCCAGAGCCACCTCCGCCTTTGATCTCCA
GCTTGGTCCC (SEQ ID NO: 237)).
W4—RAD scFv was then ligated into BS4 vector to get Bs4—V2L2—2C by gel
purifying W4-RAD scFv (from PCR); the Bs4-V2L2 vector was digested with BamHI
and the vector band was gel purified. The W4—RAD scFv was ligated with BS4 vector by
ion system and the vector transform Stellar competent cells. Colonies were
ced for the correct W4—RAD scFv insert.
—l35—
The sequences for the light chain and heavy chain of the Bs4-V2L2-2C construct
are provided in SEQ ID NOS: 327 and 328, respectively.
Example 16: A Psl/Pch bispecif1c dy promotes survival in pneumonia models
As an initial matter, the Bs2 and Bs3 bispecific antibodies were tested to e
whether they retained their W4 or V2L2 activity in a bispecif1c format. For the parental
W4 scFV, a bispeciflc antibody was generated having W4 and a pha binding arm.
A cell attachment assay was performed as described above using the luminescent P.
aeruginosa strain PAOl.lux. As shown in Figure 18, all bispecific ucts performed
similarly to the parent W4—IgGl construct.
As shown in Figure 19 (A-C), percent inhibition of cytotoxicity was analyzed for
both Bs2—V2L2 and Bs3—V2L2 using both (A) 6206 and (B) 6206ApslA infected cells,
and (C) percent inhibition of RBC lysis was analyzed for Bs2-V2L2-2C, Bs3-V2L2-2C
and Bs4-V2L2-2C using 6206 infected cells. As shown in Figure 19 (A-C), all ific
antibodies retained anti-cytotoxicity actiVity and inhibited RBC lysis at levels similar to
the parental V2L2 antibody using 6206 and slA infected cells.
The ability of the Bs2 and Bs3 bispecif1c antibodies to mediate OPK of P.
aeruginosa was assessed using the method bed in Example 2. While the Bs2—V2L2
antibody showed similar killing compared to the parental W4-RAD antibody, the killing
for the Bs3-V2L2 dy was decreased (Figure 20A). While the Bs2-V2L2-2C and
L2-2C antibodies showed similar killing compared to the parental W4-RAD
antibody, the killing for the L2—2C antibody was decreased (Figure 20B). Figure
20C shows that different preparations of Bs4 antibodies (old lot vs. new lot) showed
similar killing compared to the parental W4-RAD dy, however the Bs4-V2L2-2C—
YTE dies had a 3-fold drop in OPK actiVity when compared to Bs4-V2L2-2C. A
YTE mutant comprises a combination of three "YTE mutations": M252Y, S254T, and
T256E, wherein the numbering is according to the EU index as set forth in Kabat,
introduced into the heavy chain of an IgG. See U.S. Patent No. 7,658,921, which is
incorporated by reference herein. The YTE mutant has been shown to increase the serum
half-life of antibodies approximately four-times as compared to wild—type versions of the
same antibody. See, e.g., Dall'Acqua et al., J. Biol. Chem. 281:23514—24 (2006) and U.S.
Patent No. 7,083,784, which are hereby incorporated by reference in their entireties.
—l36—
Following confirmation that both W4 and V2L2 retained ty in a ific
format, the Bs2-V2L2, Bs3—V2L2 and Bs4—V2L2 constructs were assessed for survival
from acute pneumonia infections. As shown in Figure 2lA, all of the control mice
succumbed to infection by approximately 30 hours post—infection. All of the Bs3—V2L2
animals survived, along with those which received the V2L2 control. Approximately
90% of the W4-RAD immunized animals survived. In contrast, Figures B-F show that
approximately 50% of the Bs2-V2L2 animals bed to infection by 120 hours. All
of the control mice succumbed to infection by approximately 48 hours post—infection.
Figures G—H do not show difference in survival between Bs4-V2L2—2C and Bs4—V2L2—
2C—YTE treated mice at either dose. These s suggest that both antibodies on
equivalently in the 6206 acute nia model. Figure 21 I shows that Bs2-V2L2, Bs4-
V2L2-2C, and W4-RAD + V2L2 antibody mixture are the most ive in protection
against lethal pneumonia in mice challenged with P. aeruginosa strain 6206 (ExoU+).
Organ burden was also assessed for similar immunized mice as described above.
ing immunization as above, mice were challenged with 2.75 x 105 CFU 6206. As
shown in Figure 22, at the concentration tested, both Bs2-V2L2 and Bs3-V2L2
significantly sed organ burden in lung. However, neither of the bispeciflc
constructs was able to icantly affect organ burden in spleen or kidney compared to
the parental antibodies due to the use of suboptimal concentrations of the bispeciflc
constructs. Suboptimal concentrations were used to enable the y to decipher
antibody activity.
Survival and organ burden effects of the bispeciflc antibodies were also addressed
using the 6294 strain. Using the 6294 model system, both the BS2-V2L2 and BS3-V2L2
significantly decreased organ burden in all of the tissues to a level comparable to that of
the V2L2 al antibody. The W4-RAD parental antibody had no effect on decreasing
organ burden (Figure 23A). As shown in Figure 23B, Bs2-V2L2, Bs3-V2L2, and W4-
RAD+V2L2 combination significantly decreased organ burden in all of the tissues to a
level comparable to that of the V2L2 parental antibody.
The survival data for immunized mice was similar in the 6294 nged mice as
before. As shown in Figure 24, BS3-V2L2 showed similar survival activity to V2L2
alone-treated mice, while L2 treated mice showed a slightly lower level of
protection from challenge.
—l37—
Organ burden was also assessed in bispecif1c antibodies treated in comparison
with combination—treated animals as described above. As shown in Figures 25 (A—C),
both the BS2-V2L2 and BS3-V2L2 decreased organ burden in the lung, spleen and
s to a level comparable to that of the W4 + V2L2 combination. In the lung, the
combination icantly reduced bacterial CFUs Bs2- and Bs3-V2L2 and V2L2 using
the Kruskal-Wallis with Dunn’s post test. Significant differences in bacterial burden in
the spleen and kidney were not observed, although a trend towards reduction was noted.
An organ burden study was also performed with Bs4-GLO using 6206 in the pneumonia
model. As shown in Figure 25 (D), when higher concentrations of antibody are used in
prophylaxis of mice, a significant al-Wallis with Dunn’s post test) level of
reduction in bacterial burden from the lung was observed. Significant reductions in
bacterial dissemination to the spleen and kidneys were also observed when using higher
concentrations of Bs4-GLO in this model.
These results were med by histological examination of lung tissue of
immunized BALB/c mice challenged with 1.3 3x107 CFU using P. aeruginosa strain 6294
awnomuijCFUmngaW%mmammnmauTwm6mamy25xmfimU
using P. aeruginosa strain 6206 (Table 7).
Example 17: Therapeutic adjunctive therapy: Bs4-V2L2-2C + antibiotic
Survival effect of the Bs4 bispecif1c antibody and antibiotic adjunctive therapy
was evaluated in an acute lethal pneumonia model against P. aeruginosa 6206 strain as
previously described in Example 6 (Figure 26 (A—J)). (A—B) Mice were treated 24 hours
prior to infection with 6206 with R347 ive control) or Bs4-V2L2-2C or
loxacin (CIP) 1 hour post infection, or a combination of the L2-2C 24 hours
prior to infection and Cipro 1 hour post infection. (C) Mice were treated 1 hour post
infection with 6206 with R347 or CIP or Bs4-V2L2-2C, or a combination of the Bs4-
V2L2-2C and CIP. (D) Mice were treated 2 hours post infection with 6206 with R347 or
CIP or L2-2C, or a combination of the Bs4-V2L2-2C and CIP. (E) Mice were
treated 2 hours post infection with 6206 with R347or Bs4-V2L2-2C or CIP 1 hour post
ion, or a combination of the Bs4-V2L2-2C 2 hours post infection and CIP 1 hour
post infection. (F) Mice were d 1 hour post infection with 6206 with R347 or
Meropenem (MEM) or Bs4-V2L2-2C, or a combination of the Bs4-V2L2-2C and MEM.
2012/063722
—l38—
(G) Mice were d 2 hours post infection with 6206 with R347 or Bs4—V2L2—2C or
MEM 1 hour post infection, or a combination of the Bs4-V2L2-2C 2 hours post infection
and MEM 1 hour post infection. (H) Mice were treated 2 hours post infection with 6206
with R347 or Bs4-V2L2-2C or MEM, or a combination of the Bs4-V2L2-2C 2 and MEM.
(I) Mice were treated 4 hour post infection with 6206 with R347 or Cipro or Bs4-V2L2-
2C or a combination of the Bs4—V2L2—2C and Cipro. All of the control mice succumbed
to infection by approximately 24 hours post-infection. As shown in Figures 26 (A-I) Bs4
antibody combined with either CIP or MEM increases efficacy of antibiotic therapy,
indicating synergistic protection when the molecules are combined. Further studies
focused on the level of bacterial burden in mice treated with Bs4 or CIP alone or in
combination (Bs4+CIP). As shown in Figure 26 (J), the level of bacterial burden in all
organs (lung, spleen and kidneys) were similar in R347+CIP and Bs4+CIP, however only
mice where Bs4 was included in the combination with CIP survive the infection (Figures
26 (A-E, 1)). Altogether, these data indicate the otics are important for reducing the
bacterial burden in this animal model setting, however the specific antibody is required to
reduce bacterial pathogenicity, thus protecting normal host immunity.
Survival effect of the Bs4 bispecif1c antibody and Tobramycin antibiotic
adjunctive therapy will be evaluated in an acute lethal nia model against P.
aeruginosa 6206 strain as previously described in Example 6. Mice will be d 24
hours prior to infection with 6206 with R347 ive control) or Bs4-V2L2-2C or
Tobramycin 1 hour post infection, or a combination of the Bs4-V2L2-2C 24 hours prior
to infection and Tobramycin 1 hour post infection. Mice will also be treated 1 hour post
infection with 6206 with R347 or Tobramycin or L2-2C, or a combination of the
L2-2C and Tobramycin. In on, mice will be treated 2 hours post infection
with 6206 with R347 or Tobramycin or Bs4-V2L2-2C, or a combination of the Bs4-
V2L2-2C and Tobramycin. Furthermore, mice will be treated 2 hours post infection with
6206 with R347 or Bs4-V2L2-2C or Tobramycin 1 hour post infection, or a combination
of the Bs4-V2L2-2C 2 hours post infection and Tobramycin 1 hour post infection. Mice
will be d 4 hour post infection with 6206 with R347 or ycin or Bs4-V2L2-
2C or a combination of the Bs4-V2L2-2C and Tobramycin.
Survival effect of the Bs4 bispecific antibody and nam antibiotic adjunctive
therapy will be evaluated in an acute lethal pneumonia model against P. aeruginosa 6206
2012/063722
—l39—
strain as previously described in Example 6. Mice will be treated 24 hours prior to
infection with 6206 with R347 (negative l) or Bs4-V2L2-2C or Aztreonam 1 hour
post infection, or a combination of the Bs4-V2L2-2C 24 hours prior to ion and
Aztreonam 1 hour post ion. Mice will also be treated 1 hour post infection with
6206 with R347 or Aztreonam or L2-2C, or a combination of the Bs4-V2L2-2C
and Aztreonam. In addition, mice will be treated 2 hours post infection with 6206 with
R347 or Aztreonam or Bs4-V2L2-2C, or a combination of the Bs4-V2L2-2C and
Aztreonam. Furthermore, mice will be treated 2 hours post infection with 6206 with
R347 or L2-2C or Aztreonam 1 hour post infection, or a combination of the Bs4-
V2L2-2C 2 hours post infection and Aztreonam 1 hour post infection. Mice will be
treated 4 hour post infection with 6206 with R347 or Aztreonam or Bs4-V2L2-2C or a
combination of the Bs4-V2L2-2C and Aztreonam.
Example 18: Construction of the BS4-GLO bispecific antibody
The BS4—GLO (Germlined Lead thimized) bispecific construct was generated
comprising anti-Psl scFv (Ps10096 scfv) and V2L2-MD (VH+VL) as shown in Figure
35A. The BS4-GLO light chain comprises ined lead optimized anti-Pch antibody
light chain variable region (i.e., V2L2-MD). The BS4-GLO heavy chain comprises the
formula VH-CHl-Hl-Ll-S-L2-H2-CH2-CH3, n CH1 is a heavy chain nt
region domain-l, H1 is a first heavy chain hinge region fragment, L1 is a first linker, S is
an anti-Pch ScFv molecule, L2 is a second linker, H2 is a second heavy chain hinge
region fragment, CH2 is a heavy chain constant region domain-2, and CH3 is a heavy
chain constant region domain-3.
Bs4—GLO light chain:
AIS 2MT§ QSPSSLSASVGDRVTITCRASS QGIRNDLGWYS 2g QKPGKAPKLLIYSASTLS QS
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDYNYPWTFGQGTKVEIKRTVA
APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQ
DSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID
GLO (germlined lead optimized) V2L2 (i.e., V2L2-MD) light chain variable region is
underlined
Bs4—GLO heavy chain:
—140—
EM LLESGGGLV PGGSLRLSCAASGFTFSSYAMNWVR APGEGLEWVSAITIS
GITAYYTDSVKGRFTISRDNSKNTLYLS zMNSLRAGDTAVYYCAKEEFLPGTHYY
YGMDVWGS [GTTVTVSS[ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK
VDKRV]MGGGGSGGGGSEVQLLESGPGLVKPSETLSLTCNVAGGSISPYYW
TWIRQPPGKCLELIGYIHSSGYTDYNPSLKSRVTISGDTSKKQFSLHVSSVTAADTA
VYFCARADWDLLHALDIWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSEIVLTQ
SPSSLSTSVGDRVTITCRASQSIRSHLNWYQQKPGKAPKLLIYGASNLQSGVPSRFS
GSGSGTDFTLTISSLQPEDFATYYCQQSYSFPLTFGCGTKLEIKGGGGSGGGGSD
KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIfiRIPEVTCVVVDVSHEDPEVKFNW
YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG
QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ
KSLSLSPGK GLO ined -lead optimized) V2L2 (i.e., V2L2—MD) heavy chain
variable region is underlined; CH1 is bracketed []; GLO (germlined-lead optimized) W4-
RAD (i.e., Ps10096) scFv is in bolded italics with the G48 linkers underlined in bolded
italics; hinge regions are doubled underlined.
An alternative Bs4-GLO bispecif1c construct comprising an anti-Pch ScFv and
an anti-Psl (VH+VL) is shown in Figure 35B, and is generated similarly.
Example 19: Evaluation of the functional activity and efficacy of the Bs4—GLO bispecific
Bispeciflc antibodies Bs4—WT (also referred to herein as Bs4—V2L2—2C), Bs4—GL
ising germlined anti-Pch and anti-Ps1 variable regions) and O produced
as described in Example 18 were tested for differences in functional activity in an
opsonophagocytic killing assay (Figure 27A), as usly bed in Example 2, anti-
cell attachment assay (Figure 27B), as previously bed in Example 4 and a RBC
lysis anti-cytotoxicity assay (Figure 27C), as previously described in Example 12. No in
vitro difference in functional activities between the antibodies was ed.
In vivo efficacy of Bs4—GLO was ed as follows. For prophylactic
evaluation, mice were prophylactically d with several trations of the Bs4-
GLO (i.e., 0.007mg/kg, 0.02mg/kg, 0.07mg/kg, 0.2mg/kg, 0.5mg/kg, 1mg/kg, 3mg/kg,
—141—
5mg/kg, 10mg/kg or 15mg/kg) (Figure 28A), 24 hours before ion with the following
P. aeruginosa strains (6206 (1.0 x 106), 6077 (1.0 x 106), 6294 (2.0 x 107) or PA103 (1.0
x 106)). For therapeutic evaluation, mice were eutically treated with several
concentrations of the Bs4—GLO (i.e., 0.03mg/kg, 0.3mg/kg, 0.5mg/kg, 1mg/kg, 2mg/kg,
5mg/kg, 10mg/kg, g, or 45mg/kg) (Figure 28B), at one hour after infection with
the following P. nosa strains (6206 (1.0 x 106), 6077 (1.0 x 106), 6294 (2.0 x 107)
or PA103 (1.0 x106».
Survival effect of the Bs4—GLO bispecific antibody was evaluated in an acute
lethal pneumonia model against different P. aeruginosa strains as usly described in
Example 6. Figure 29 shows survival rates for animals treated with the Bs4-GLO in a P.
aeruginosa lethal bacteremia model. Aspects of the emia model are disclosed in
detail in US. Provisional Appl. No. 61/723,128, filed November 6, 2012 (attorney docket
no. ATOX—500P1, entitled “METHODS OF TREATING S. AUREUS ASSOCIATED
DISEASES”), which is incorporated herein by reference in its entirety.
Animals were d with Bs4-GLO or R347, 24 hours prior to intraperitoneal
infection with (A) 6294 (O6) or (B) 6206. The BS4-GLO is effective at all tested
concentrations in protection against lethal pneumonia in mice challenged with P.
aeruginosa strains (A) 6294 and (B) 6206.
Survival effect of the Bs4—GLO bispeciflc antibody was evaluated in a P.
aeruginosa thermal injury model against different P. aeruginosa strains. Figure 30 shows
al rates for animals lactically treated with the Bs4-GLO in a P. aeruginosa
thermal injury model. Animals were treated with Bs4-GLO or R347 hours prior to
induction of thermal injury and subcutaneous infection with P. aeruginosa strain (A)
6077 (01 1—ExoU+) or (B) 6206 (01 1—ExoU+) or (C) 6294 (06) directly under the wound.
The BS4-GLO is effective at all tested concentrations in prevention in a P. nosa
thermal injury model in mice challenged with P. aeruginosa strains (A) 6077, (B) 6206
and (C) 6294.
Figure 31 shows survival rates for animals therapeutically treated with bispecif1c
antibody Bs4-GLO in a P. nosa l injury model. (A) Animals were treated
with Bs4-GLO or R347 (A) 4h hours or (B) 12 hours after induction of thermal injury and
subcutaneous infection with P. aeruginosa strain 6077 (Oll—ExoU+) directly under the
wound. The Bs4—GLO is effective at all tested concentrations in treatment in a P.
—142—
nosa thermal injury model in mice treated with Bs4-GLO (B) 4h hours or (B) 12
hours after induction of thermal injury and subcutaneous ion with P. nosa
strain 6077.
Example 20: Therapeutic adjunctive y: Bs4-GLO + antibiotic
Survival effect of the Bs4—GLO bispecif1c antibody and antibiotic adjunctive
therapy was evaluated in an acute lethal pneumonia model against P. aeruginosa 6206
strain as previously described in Example 6.
Figure 32 shows therapeutic adjunctive y with ciprofloxacin (CIP). (A)
Mice were treated 4 hour post infection with P. aeruginosa strain 6206 with R347 + CIP
or Bs4-WT or a combination of the Bs4-WT and CIP. (B) Mice were treated 4 hour post
ion with P. aeruginosa strain 6206 with R347 + CIP or Bs4-GLO or a combination
of the Bs4-GLO and CIP. (A-B) Bs4-WT or BS4-GLO antibody combined with CIP
increased efficacy of antibiotic therapy.
Figure 33 shows therapeutic adjunctive therapy with meropenem (MEM): (A)
Mice were treated 4 hour post infection with P. aeruginosa strain 6206 with R347 +
MEM or Bs4-WT or a combination of the BS4-WT and MEM. (B) Mice were treated 4
hour post infection with P. aeruginosa strain 6206 with R347 + MEM or BS4 or a
combination of the Bs4-GLO and MEM. (A-B) Bs4-WT or Bs4-GLO antibody
combined with MEM increases efficacy of antibiotic therapy.
Figure 34 shows therapeutic adjunctive therapy: Bs4—GLO plus antibiotic in a
lethal bacteremia model. Mice were treated 24 hours prior to intraperitoneal infection
with P. aeruginosa strain 6294 with Bs4-GLO at the indicated concentrations, which
were previously determine to be sub—therapeutic protective doses in this model and R347
ive control). One hour post infection, mice were treated subcutaneously with
antibiotics at the indicated trations, which were previously determined to be sub—
therapeutic protective doses (A) oxacin (CIP), (B) Meropenem (MEM) or (C)
ycin (TOB). Animals were carefully red for survival up to 72 hours post—
infection. Bs4-GLO antibody combined with either CIP, MEM or TOB, at sub-protective
doses, increases efficacy of antibiotic therapy.
—143—
The sure is not to be limited in scope by the specific embodiments described
which are intended as single illustrations of individual aspects of the sure, and any
compositions or methods which are functionally equivalent are within the scope of this
sure. Indeed, various modifications of the disclosure in addition to those shown and
described herein will become nt to those d in the art from the foregoing
description and accompanying drawings. Such cations are intended to fall within
the scope of the appended .
All publications and patent applications mentioned in this specification are herein
incorporated by reference to the same extent as if each individual publication or patent
application was specifically and individually indicated to be incorporated by reference.
In addition, US. Provisional Application Nos.: 61/556,645 filed November 7, 2011;
61/624,651 filed April 16, 2012; 61/625,299 filed April 17, 2012; 61/697,585 filed
September 6, 2012 and International Application No: , filed
November 6, 2012 (attorney docket no. AEMS—115W01, entitled “MULTISPECIFIC
AND MULTIVALENT BINDING PROTEINS AND USES THEREOF”) are
incorporated by reference in their entirety for all purposes.
I H H -mmz
Ila+Nst. +m-+m+m +Ni +N-+F
st z_>_n_
+N I
+m 22
. .
55. 55.
mEoEsmca 525 55.
525 E85595 525 mEoEsmca 525
REESE 56:58 cozmméoo 56:58 REESE 56:58 cozmméoo ococohm 56:58
55. 55. 55. 55.
ococohm cozmm 9: 20252 ococohm 3003 @5659: o >EmE:n_ 3°03 .,:0
.05% axBENQ 28
9:9:
F.ov
oExH
82 82 82
325:5 255 +I H
+N I H
mom—2:058: +N +5
602025 mEoEsmcq 525 mEoEsmca 525
IIEE
ca mEoEsmca
:ofiwwEE. €24. 56:58 56:58 525
oomtsm _m_Em$E_ 55. REESE 55. cozmmmcoo REESE mEoEsmcq
>57: ococohm
56:58
=2o>0 95.. ococohm 250$ m 388 2:: ococohm 05955 _m__m£_am >EmE:n_ 55.
E2532... N._N>-Nmm_ am
. +.w..m__w\w>> 3555.9
mo Evgsohwm 8:“ 8: 85 @N Ame Amvm
oExH nnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
2012/063722
OHNEEmr—C— 32%...
8:898
@00er
SN> 9:9:
flash
Claims (17)
1. A bispecific dy comprising a binding domain that binds to Pseudomonas Psl and a binding domain that binds to Pseudomonas PcrV.
2. The bispecific antibody of claim 1, wherein (a) the Psl binding domain ses a scFv fragment and the PcrV g domain comprises an intact immunoglobulin, or (b) the Psl binding domain comprises an intact immunoglobulin and the PcrV binding domain comprises a scFv fragment.
3. The bispecific antibody of claim 2, n (a) the scFv is fused to the amino-terminus of the VH region of the intact immunoglobulin; (b) the scFv is fused to the carboxy-terminus of the CH3 region of the intact immunoglobulin, or (c) the scFv is inserted in the hinge region of the intact globulin.
4. The ific antibody of claim 1, wherein the anti-Psl binding domain (a) binds to the same Pseudomonas Psl epitope as an antibody or antigenbinding fragment thereof comprising a VH comprising the amino acid sequence SEQ ID NO: 11 and a VL region comprising the amino acid sequence SEQ ID NO: 12; (b) can competitively inhibit Pseudomonas Psl binding by an antibody or antigen-binding fragment thereof comprising a VH comprising the amino acid sequence SEQ ID NO: 11 and a VL region comprising the amino acid sequence SEQ ID NO: 12; or (c) a combination of (a) and (b).
5. The bispecific antibody of any one of claims 1 to 4, wherein the anti-PcrV binding domain (a) binds to the same Pseudomonas PcrV epitope as an antibody or antigen-binding fragment thereof comprising a VH comprising the amino acid sequence SEQ ID NO: 216 and a VL comprising the amino acid sequence SEQ ID NO: 217; (b) itively inhibits Pseudomonas PcrV binding by an antibody or antigen-binding fragment thereof comprising a VH comprising the amino acid sequence SEQ ID NO: 216 and a VL sing the amino acid ce SEQ ID NO: 217, or (c) a combination of (a) and (b).
6. The bispecific antibody of claim 5, wherein the crV binding domain comprises a VH comprising the amino acid sequence SEQ ID NO: 216 and a VL comprising the amino acid sequence SEQ ID NO: 217.
7. The bispecific antibody of any one of claims 1 to 6, wherein the anti-Psl binding domain comprises a VH comprising the amino acid sequence SEQ ID NO: 11, and a VL comprising the amino acid sequence SEQ ID NO: 12, and wherein the anti-PcrV binding domain comprises a VH comprising the amino acid sequence SEQ ID NO: 216, and a VL comprising the amino acid sequence SEQ ID NO: 217.
8. An isolated polynucleotide molecule comprising a nucleic acid sequence that encodes the bispecific antibody or nt thereof of any one of claims 1 to
9. A composition comprising the ific antibody or fragment thereof of any one of claims 1 to 7, and a pharmaceutically acceptable r.
10. The composition of claim 9, comprising a binding domain that binds to Pseudomonas Psl and a binding domain that binds to Pseudomonas PcrV.
11. The use of a ific antibody ing to any one of claims 1 to 7, or a composition of claim 9 or 10 in the manufacture of a medicament for preventing or treating a Pseudomonas infection in a subject in need thereof.
12. A kit comprising the composition of claim 9 or 10.
13. A bispecific antibody according to claim 1, substantially as herein bed ore exemplified.
14. An isolated polynucleotide molecule according to claim 8, substantially as herein described or exemplified.
15. A ition according to claim 9, substantially as herein described or exemplified.
16. A use according to claim 11, substantially as herein described or exemplified.
17. A kit according to claim 12, substantially as herein described or exemplified. 1193 (a 30353, mam cw 33% “mmco “Sag, Emum “mkmgatmu fimwummou wmfimbxm mmcmm moaghm 3:06 mmcmm 50mmm £75 mmEEmm mman 5 an .5 mafia ficmwma mmogmfimm wxwmm “phenom?“ www.cgmw dim 303 EM wcm mega HEP”. :3, m: E3: vmwfiEm mum 1} 3:388?“ @Ea cowuawwcam so mmmga wmummfl mcmccma mmmggfimm 39% Eb $er mmcowwugé mummfl wvmfl mahEmm $ch B. 93> E 3MB: mmmna $338 cofimhmymou EMS i mafia?” 3 E £3“QO wmmmmmmm .63. SUBSTITUTE SHEET (RULE 26) 2193 Dupficated Va EDI-Z3 (W53 33 an 8 aw am S. ‘ 4mm Ma. we. . Q mad“ andmad mafia EKG Nb 9 Q 36 mam: mfimfifi «e e ,9 Iaéfiwo @352 3.353 . OWEN» :9% Parkman, mam 3m mud mad Ed $0.0 ham“ SS xaaaa EEEQ meEE a aoWOW¢ a waa 4...:avmow, mmmgmflmm mmmmm ““““““““““““““““““““ aowawnw . “, 86 «:mmwwn. 3553 a a, go ,zaj an? ,mmofimfimm @3me 0%.Wbsw. .D ngw 33% Sat; Sovxm m P Im.W12 Hmm% $933ng F 3% \NN w , .QE m, \m \‘ \w.3, 1«S mm: x x. X tam: «39¢va w £8 E ma Wm m; m «am m ww. Nmmmfim mmmxvmm w w m m xxd\\\ mmocmmnbfim \\\\ \\ mmmm mNé \M. Snow .Q \ § $3 “mmocmnvmw $5: mewm Hmwmm 6wa mEmcém mmmuvfi 5..me Pmum \fwuw bmum >uom ywuw pmum >wom 33m ”mam MQQEQU fl megawafiu @0323“an Ravage/“‘0 manufifixw megawaqu a EMS: Emma: “SEE Egg \Cmfim Emfim 8:330 Emufimm‘tm z) v.5. ,3» gum mg”. mfigcn .Uv .mw SUBSTITUTE SHEET (RULE 26) 3193 fiflwm 7 $me m,“a qgwm 3%. Sqémma. m S v xEW w 0m E; .9. .GE Eeiamg 92, «33% NE {AWE ”a”. 3&3 ............................................... mgwwq Ba..m%§ Q: mm S ,9“ mm a xBw m. %. ngmammw “E *8 :..§:E.:....:.§ EU {$me m8 qfim GE 35R1é§ SeéwQ e NS . Ema vagmamg :mfifii mi: 2 mwa .9 ,u u m § n m N ,9. m2. aw ..Q,@ 3 mm cg ow cm mm mm .3 n. m: iM:N my % v8EW m. {m SUBSTITUTE SHEET (RULE 26) 4193 Buému, Eefimmfi «wax .fi. L? 1Q. «GM flmekmav wmm 9&5 Q c: an‘UB'ZSSS $0 502W 3113933351 £9.58 Salaam maoému Eoimmg mmmlmamg wcoimawg Sagmmmfi wéxmamfi NEE .0. in. 1v. .I. .m. LT I} hm. in. : , 5:. gamma“. 54m 8%: E: mm 8 :3 am am, .63.... m mW»d 0 Ruwwm SUBSTITUTE SHEET (RULE 26) 5193 RANK moa..EwO ”M; m: W", “mam w00 0x maslfimm ‘wamafimu U w. A», 5&3».ch o urn L.” 1px x “w? .@ a, £0 \rvmm $0 @ % .nu ““0, ,0 AV». >9 SEKme‘nmv nu, «,9 8/ $0 3,0, é? on”. m i. m. A)! #1 my Ga 1 w...” “N.“ 0r 1 my my, fix m: A? mun», . Q» «I? a,FM‘QR 07 was «S GU. «I? 0? N mm, A" mm Muo kw $3305 3 :Efimw ads: ”w ‘ mw 5.0 mu QM u59 fi md 0.0 .0 NAMDO an . .mm arm 5% Sufisflofi v9 QEfiSfi QamfiOE ”9 ¢.$w + $ .l m. 333.0% .................................... 1? "a Emma e2, am am av am wmwim‘rzwfi, 3% ENEE m N Uat:m m . 6m ow .0». 58 S aw «a am x9W M.0 SUBSTITUTE SHEET (RULE 26)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ722379A NZ722379B2 (en) | 2011-11-07 | 2012-11-06 | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161556645P | 2011-11-07 | 2011-11-07 | |
US61/556,645 | 2011-11-07 | ||
US201261625299P | 2012-04-17 | 2012-04-17 | |
US61/625,299 | 2012-04-17 | ||
US201261697585P | 2012-09-06 | 2012-09-06 | |
US61/697,585 | 2012-09-06 | ||
PCT/US2012/063722 WO2013070615A1 (en) | 2011-11-07 | 2012-11-06 | Combination therapies using anti- pseudomonas psl and pcrv binding molecules |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ624072A NZ624072A (en) | 2016-09-30 |
NZ624072B2 true NZ624072B2 (en) | 2017-01-05 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11203633B2 (en) | Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas perv | |
US10844114B2 (en) | Anti-Pseudomonas Psl binding molecules and uses thereof | |
US20150284450A1 (en) | Combination therapies using anti-pseudomonas psl and pcrv binding molecules | |
US20170183397A1 (en) | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof | |
NZ624072B2 (en) | Combination therapies using anti- pseudomonas psl and pcrv binding molecules | |
NZ722379B2 (en) | Combination therapies using anti-pseudomonas psl and pcrv binding molecules | |
NZ618266B2 (en) | Anti-pseudomonas psl binding molecules and uses thereof |